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Abstract  
 
 
 
Breast cancer is the most common type of cancer among females with a high 
incidence and mortality rate. It is essential to classify the breast cancer into their 
subtypes so patients do not need to undergo any unnecessary therapy and the 
appropriate treatment can be applied to improve patient survival rates.  
 The high throughput technologies such as the microarray technology based 
gene expression profiling is effectively used in diagnosis, prognosis, or treatment 
outcome prediction of breast cancer, and has brought substantial advances to our 
understanding of the biology of breast cancers at the molecular level. Microarray 
data analysis is a critical task because of the following characterisitics: thousands 
of gene expressions are measured for very few samples, the measurements are 
noisy, and they are highly correlated due to gene co-expressions providing 
irrelevant biological facts. As a result, computational experiments are needed in 
order to perform the tasks of diagnosis, prognosis, or treatment outcome prediction 
among breast cancer patients, which can make these discoveries useful by 
providing satisfactory results. The machine learning methods were chosen as good 
candidates to perform the above tasks. However, the machine learning methods for 
performing microrarray data analysis involves numerous steps and the results are 
prone to overfitting.       
 Although a number of algorithms have been developed in the recent past 
that identified molecular signatures to perform the above tasks, the results from 
existing algorithms have not been satisfactory and have several limitations, 
including dependency on the training sets, low performance, limited biological 
roles associated with the gene signature of an algorithm, and worse, lack of 
generalization. As a result, the questions concerning how to effectively diagnose, 
prognose, or to predict the treatment outcome among breast cancer patients remain 
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unanswered, and the methods able to identify robust molecular signatures to 
perform the above tasks have been lacking. Novel molecular signatures with 
improved performance are therefore highly needed.     
 To fill this significant gap, the research presented here develops a robust 
reliability algorithm for the identification of reliable interactions from the protein 
interaction network that can be incorporated with a gene expression dataset to 
improve the algorithm performance, and novel breast cancer based diagnostic, 
prognostic and treatment prediction algorithms, respectively, which take into 
account the above mentioned issues in order to provide a fair estimation of their 
performance. The experimental results of our proposed approaches demonstrate 
they are highly effective in assessing the reliability of interactions, or in diagnosing, 
prognosing, and predicting the treatment outcome among breast cancer patients. 
Also, the experimental comparisons of the proposed approaches with other existing 
related approaches demonstrate that the proposed approaches significantly increase 
the classification performance. Further, in addition to the statistical evaluations, 
thorough biological evaluations were also conducted to demonstrate the 
effectiveness and stability of the proposed algorithms.   
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Chapter 1  
 
Introduction 
 
In this chapter, we begin by introducing the background and basic concepts relevant 
to this thesis. We then describe the research objectives and highlight the major 
contributions of the research in our study. Finally, we outline the organization of 
this thesis.        
 
1.1 Background and Motivation  
Cancer based research is considered one of the most significant research areas in 
the medical community. Breast cancer is one of the most complex and 
heterogeneous forms of cancer which arises from different cell types, and is 
believed to be the leading cause of death among women in the western world. In 
patients with breast cancer, cancerous cells are found in the tissues of the breast. 
The breast has 15 to 20 partitions called lobes, and lobes have various tiny partitions 
known as lobules. The cancer which originates in the lobes is known as lobular 
carcinoma. Each lobe and lobule is connected by a very slim tube known as a duct 
and in the cells of the duct the most common type of breast cancer originates, which 
is known as ductal carcinoma [152]. Figure 1.1 illustrates the lobe, lobules, ducts, 
and other parts of the female breast.    
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Figure 1.1: Essential parts of the female breast.                                                     
[Source: http://lombardi.georgetown.edu/breastcancer/]) 
 
The malignant behaviour of breast cancer makes it complex from other diseases, 
which means the spreading of cancerous cells (which originate from breast tissue) 
to other parts of the body (like bone, liver, lymph) results in distant metastasis 
[100]. It is believed that each particular subtype of breast cancer responds 
differently to different therapies and has variable impacts on the outcome of the 
disease. The accurate classification of breast cancer or prediction of the behaviour 
of cancer subtype or therapy effectiveness is therefore essential in providing better 
treatment (personalized treatment) and lessens the mortality rate among women. 
High throughput technologies, such as microarray gene expression profiling (see 
Section 2.1 for more details), enable researchers to study cancers at the molecular 
level and develop new tools for better diagnosis (to detect a particular type of cancer 
from others), prognosis (to predict how a cancer will behave in future, such as 
prediction of metastasis or recurrence of a sample after 5 years of initial diagnosis), 
and treatment outcome prediction (such as prediction of a good outcome or poor 
outcome from a particular type of treatment) of breast cancer [82].  
 The use of mammograms will detect breast cancer at an early stage and help 
physicians treat the disease with proper medication or therapy. However, in many 
cases, women develop breast cancer that becomes distantly metastasized, which is 
common in the late stages, and as a result, has a poor survival rate. The essentiality 
of research for breast cancer is therefore important for preserving public health. 
The microarrays consistently enable us to diagnose, prognose or to predict the 
treatment response of this disease to some extent by incorporating the clinical 
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covariates or factors. The clinical covariates determine the characteristics of the 
breast cancer patient samples and help in making decisions for an effective breast 
cancer treatment plan by uncovering the right type of diagnostic or prognostic 
subtypes. These clinical covariates are discussed in the following section.    
1.1.1 Clinical Covariates of Breast Cancer 
The basic purpose of classification is to derive an accurate subtype of breast cancer 
or to predict the survival rate for a patient sample. This helps to select a treatment 
approach that is most appropriate in order to achieve a good outcome by 
incorporating the clinical covariates of breast cancer. The most widely used clinical 
covariates for breast cancer diagnosis, prognosis, or treatment prediction approach, 
are shown in Table 1.1. 
Table 1.1: Clinical covariates used for the diagnosis, prognosis, or treatment prediction of 
breast cancer. 
Clinical 
Covariate 
Variable 
Type Description Factor Levels 
Age continuous Age of patient             - 
Size continuous Size of tumor ( in cm)             - 
Grade factor Grade of disease (1, 2, 3) Grade 1, Grade 2, Grade 3 
Lymph 
Node factor Lymph node assessment 1 = positive, 0 = negative 
Histological 
Type factor Tumor histology 
IDC (Invasive Ductal Carcinoma),                   
ILC (Invasive Lobular Carcinoma),                 
IDC+ILC, IDC-TUB (Tubular Carcinoma), 
IDC-MUC (Mucinous Carcinoma), 
INVASIVE TUMOR, OTHER 
ER factor Estrogen Receptor (ER) status 1= positive, 0 = negative, null 
PR factor Progesterone Receptor (PR) status 1= positive, 0 = negative, null 
HER factor 
Human Epidermal growth 
factor Receptor (HER) 
status 
1= positive, 0 = negative, null 
Subtype factor Molecular subtypes of breast cancer 
Luminal A, Luminal B, Her2, Normal, 
Basal 
Treatment factor Treatment available or received   
HT = Hormone Therapy, 
RT = Radiation Therapy, 
CT = Chemo Therapy,  
HT/RT, CT/HT/RT, CT/HT,  
NONE =  No Therapy 
DMFS factor Distant metastasis-free survival 0 = No metastasis, 1= metastasis 
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RFS factor Recurrence-free survival (local, regional, or distal) 0 = No recurrence, 1=  recurrence 
DFS factor Disease-free survival 0 = No disease, 1= disease 
OS factor Overall survival 0 = Surviving, 1=  dead 
 
All of the above clinical covariates must be considered and tested cautiously in 
order to minimize their associated batch effect error, thus making them either  
genuine diagnostic factors (evaluates the classification of breast cancer to its 
subtype), or genuine prognostic factors (evaluates the consequence of disease in the 
absence of therapy (such as good prognosis or low risk to metastasis, recurrence, 
or poor prognosis or high risk to metastasis, recurrence)), or genuine treatment 
prediction factors (evaluates the probability of response to a particular treatment). 
 It is highly desired that the accurate subtype of breast cancer needs to be 
diagnosed in order to get the most effective prognosis or to select the appropriate 
treatment. Therefore, we discuss some of the essential subtypes of breast cancer in 
the following section.     
1.1.2 Subtypes of Breast Cancer 
Breast cancer is arising from many different cells and each different cell type has 
its own clinical property. Currently, breast cancer is diagnosed by testing the 
expression level of the Estrogen Receptor, Progesterone Receptor, and Human 
Epidermal Growth Factor Receptor 2. Each of the three receptors is explained 
below:  
x Estrogen Receptor (ER)   
The Estrogen Receptor is a protein molecule which can be seen inside of 
those cells that are the targets of estrogens. By binding to various cell parts, 
estrogens can act on tissues like the breast. The Estrogen Receptor is 
activated by the hormone estrogens and once activated, it will adhere to 
DNA and modulate the activity levels of various genes. When the ER is 
overexpressed, it is then called ER Positive (ER+), and if underexpressed, 
it is then called an ER Negative (ER-) subtype of breast cancer. In 
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approximately 70% of breast cancer cases, ERs are overexpressed which 
are known as ER positive (ER+) tumors [54].   
x Progesterone Receptor (PR): 
The Progesterone Receptor is an intracellular steroid receptor that adheres 
to progesterone. Steroid receptors form an essential group of proteins which 
are involved in various physiological functions, such as cell differentiation. 
In reproductive tissue, the PR is expressed which has essential roles in 
ovulation and pregnancy. Around 65% of ER+ breast cancers are also 
observed as PR+ breast cancers, and around 5% of breast cancers are 
observed as ER- and PR+ [54, 72, 128]. 
x Human Epidermal Growth Factor Receptor 2 (HER2): 
The HER2 (also known as Neu, ErbB-2, ERBB2) is a protein which is 
encoded by the ERBB2 gene in humans and causes relatively broad 
aggressiveness in breast cancers in addition to other types of cancers. HER2 
belongs to a family of four transmembrane receptor tyrosine kinases 
(HER1/EGFR, HER2, HER3, and HER4) which regulates cell growth and 
proliferation. Around 30% of breast cancers have an over expression of the 
HER2 gene (HER2+) or its protein product. Increased disease recurrence is 
associated with the over expression of the HER2 in breast cancer [162, 231]. 
As discussed in Section 1.1, breast cancers are one of the most complex and 
heterogeneous forms of the disease and have different clinical outcomes. Therefore, 
more precise identification of subtypes is vital to understand the etiology of breast 
cancer.          
 Traditionally, the receptor status was considered for diagnosing or 
prognosing breast cancer by analysing each receptor cautiously, i.e., ER, PR, 
HER2. However, newer approaches, along with the receptor status, also consider 
the tumor grade in order to best categorise the breast cancer into various concrete 
molecular classes, and all of these classes have different prognoses and responses 
to various therapies [154, 161]. The various forms of breast cancer molecular 
subtypes are shown in Table 1.2.        
  
6 
 
Table 1.2: Molecular subtypes of breast cancer. 
 
Subtypes Description 
 
 
 
 
 
 
Luminal 
Subtypes 
 
 
Luminal A Luminal B Luminal ER-/AR+ 
When the receptors are 
ER+, and/or PR+, and 
the tumor grade is low, 
it is denoted as 
Luminal A breast 
cancer. Compared to 
all other, Luminal A 
shows best prognosis 
results, with high 
survival rates and low 
recurrence rates [149]. 
When the receptors are 
ER+, and/or PR+, and the 
tumor grade is usually 
high, it is denoted as 
Luminal B breast cancer. 
Compared to Luminal A, 
patients with Luminal B 
leads to poor prognosis. 
Luminal B tumors 
generally have high 
survival rates, though 
lesser than Luminal A 
[149]. 
This molecular subtype 
is identified as an 
androgen responsive 
subtype that corresponds 
to antihormonal 
treatment with 
bicalutamide. This 
subtype overlaps with 
apocrine and therefore, is 
called molecular 
apocrine [125].  
It is believed most breast cancers are luminal tumors. Each of these luminal 
subtypes has a different prognosis, and therefore, a varied therapy effectiveness 
rate. 
ERBB2/H
ER2+ 
 
 
When the receptors are ER-, and PR-, and the tumor grade is often poor, it is then 
denoted as HER2+ breast cancer. HER2+ usually has a poor prognosis and is also 
sensitive to frequent recurrence and metastases. Patients with HER2+ are generally 
diagnosed at a younger age in contrast to other molecular subtypes. 
Basal-like When the receptors are ER-, PR-, and HER2-, it is then denoted as Basal-like breast 
cancer. It is also called a Triple negative breast cancer (TNBC), and it is believed 
that most basal-like are triple negative, and vice-versa. This subtype usually occurs 
in younger women and African American women. TNBC/Basal-like tumors are 
aggressive and also have poorer prognosis than Luminal A and B subtypes [34]. 
Normal 
Breast-like 
This molecular subtype is a less common subtype of breast cancer compared to 
others, though it is given the name normal-like. Usually these tumors are small and 
also have a good prognosis. This molecular subtype is often common among 
postmenopausal women compared to premenopausal women [32]. 
    
 
Although a lot of research has been done in the recent, this area still lacks a more 
robust breast cancer diagnosis, prognosis, and treatment prediction approach that 
can improve the survival rate of patients or which can help alleviate the high costs 
involved with unnecessary treatments by enabling the choice of personalised 
treatments. 
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1.2 Research Objectives 
The medical context of this thesis has influenced the need for improving diagnostic, 
prognostic and treatment prediction methods in order to spare breast cancer patients 
from unnecessary anti-cancer treatments (and their adverse side effects), or to 
predict the response or resistance to such treatments that can improve the survival 
rate of patients. The objective of this thesis is to investigate the microarray gene 
expression data and protein interaction data in order to develop a highly effective 
series of computational algorithms to:   
(1) Detect potential false-positive interactions (unreliable interactions) from the 
protein interaction dataset and to demonstrate that once these false-positives 
are removed from the dataset, the resulting interaction between proteins in 
the network will be strongly related to each other semantically. Comparison 
with the other existing reliability algorithm will also be undertaken to 
demonstrate that the proposed reliability approach is efficient in detecting 
unreliable interactions from the protein interaction dataset.    
(2) Diagnose the breast cancer into its subtypes, such as ER+ or ER-, using a 
new innovative approach and to demonstrate that the proposed breast cancer 
diagnosis approach is more effective in diagnose breast cancer than the 
existing approaches. 
(3) Prognose the breast cancer into its subclasses, such as good prognosis (low 
risk to death) or poor prognosis (high risk to death), by proposing an 
effective and robust approach. Also, demonstrate that the proposed 
approach is more effective in performing breast cancer prognosis than 
existing approaches.  
(4) Predict the treatment outcome of a therapy, such as predicting the good or 
poor response to chemotherapy, by proposing an innovative approach and 
to demonstrate that the proposed approach is more effective in predicting 
the treatment outcome than existing approaches. 
These objectives will bring new insights into breast cancer biology. 
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1.3 Main Contribution 
x Propose two new semantic interaction reliability metrics, R1 and R2, which 
consider every possible external and internal interaction of an interacting 
protein pair in order to assign the combined reliability score to each 
interaction in the protein interaction dataset. 
x Propose a new semantic reliability algorithm that detects an unreliable 
interaction (false-positive interactions) from the protein interaction 
network. The proposed algorithm demonstrates that after removing the 
unreliable interaction from the protein interaction network, the remaining 
reliable interactions are functionally-related to each other and show better 
results than existing reliability-based approaches.  
x Propose a statistical model to determine the reliability weights, which are 
then incorporated with the gene expressions to form reliable gene 
expressions.  
x Propose a novel subnetwork based breast cancer classification approach to 
distinguish two subtypes of breast cancer, i.e., ER+ and ER-. The evaluation 
of the proposed approach and the experimental comparisons with other 
existing approaches demonstrated that the proposed approach significantly 
increased the classification performance. Further, in addition to the 
statistical evaluations, thorough biological evaluations were also conducted 
to show the effectiveness and stability of the proposed algorithm.  
x Propose a breast cancer prognosis based classification algorithm to 
distinguish two prognosis groups as good prognosis, which corresponds to 
the breast cancer-free state for at least 5 years, and the poor prognosis state, 
which corresponds to the recurrence of breast cancer within 5 years. The 
proposed algorithm showed better results in distinguishing two prognosis 
groups when compared to other existing prognosis based algorithms. 
x Propose a novel computational chemotherapy responsiveness prediction 
algorithm to predict the samples as either pCR (pathologic complete 
response or good response to therapy) or npCR (non-pathologic complete 
response or poor response to therapy) in their neoadjuvant (preoperative) 
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settings. The evaluation of the proposed algorithm demonstrated the robust 
performance and how it outperformed existing related algorithms.  
x Propose a novel computational algorithm that can distinguish ER+ and ER- 
breast cancer subtypes and also predict the samples as either pCR or npCR.  
 
1.4 Thesis Organisation  
This section provides the overall organization of this thesis. As the objective of this 
thesis is to tackle the reliability of protein interactions, breast cancer diagnosis, 
breast cancer prognosis, and breast cancer treatment prediction, the content of each 
chapter is organized as follows.   
x Chapter 2 provides a comprehensive survey on the microarray technology 
based gene expression data, existing approaches related to breast cancer 
diagnosis, prognosis, and treatment prediction, along with existing 
evaluation methods. Efforts have been given to identify the current issues 
and any new and important research features/issues. This chapter will also 
explore challenges that remain open. 
x Chapter 3 introduces a novel reliability algorithm that detects the false-
positive interactions in the protein interaction dataset and repurifies the 
highly erroneous protein interaction network by using semantic 
methodology.   
x Chapter 4 proposes a novel breast cancer diagnosis based algorithm that can 
accurately classify the patient samples as ER+ or ER- by incorporating the 
protein interaction network with gene expression data. 
x Chapter 5 proposes a novel breast cancer prognosis based algorithm that 
can accurately distinguish the patient samples as a good prognosis or a poor 
prognosis by using a multivariate logistic regression model constructed with 
microarray data along with clinical variables. 
x Chapter 6 proposes a novel breast cancer treatment prediction algorithm 
that can accurately predict the patient samples as a good response to 
chemotherapy or pCR, or a poor response to chemotherapy or npCR in their 
  
10 
 
neoadjuvant (preoperative) settings by using scoring metrics with 
incorporated multiple classification techniques. 
x Chapter 7 proposes a novel algorithm for performing multiple tasks, 
including classifying an estrogen receptor based binary subclass (ER+ or 
ER-) and predicting a chemotherapy response (neoadjuvantly) based binary 
subclass (pCR or npCR) by using scoring metrics with considered multiple 
classification techniques. This chapter also considers network-based 
information in performing the binary prediction task.   . 
x Chapter 8 is the conclusion of this thesis, with any recommendations to 
improve the proposed algorithms and any possibilities for further work in 
the future discussed. 
To maintain the readability, each chapter is organized in a self-contained format, 
and some essential contents, e.g. definition, are briefly recounted in related 
chapters. 
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Chapter 2  
 
Preliminaries 
 
This chapter aims to provide an extensive literature review of related techniques 
and issues by tracing the trends and directions of this research. Specifically, this 
chapter details the data, state-of-the art methods, and the evaluation methods used 
in this thesis. Section 2.1 provides the introduction to microarray technology and 
includes the issues associated with microarray data, the need to pre-process 
microarray data, and also includes microarray data analysis. Section 2.2 reviews 
and thoroughly explains the various cancer classification techniques, the related 
breast cancer classifier based studies with the issues associated with them, and also 
reviews the need to develop novel algorithms that accurately diagnose, prognose or 
predict the treatment outcome of breast cancer by using the microarray gene 
expression data. Finally, we review existing evaluation methods and emphasize the 
significance of evaluating the breast cancer classifiers using statistical evaluation 
and biological validation in Section 2.3.     
2.1 Microarray Technology 
Microarray technology is a novel and high throughput technology that is used to 
identify genes. In recent years, this technology has been used for various biological 
purposes, such as diagnosing, prognosing, or treatment outcome prediction for 
breast cancer and other various diseases. Microarray expression profiling is used to 
concurrently access the gene expression profile of the thousands of genes to 
measure the changes in expression levels or for other biological purposes. 
 A microarray is a glass slide, into which the molecules of a single strand of 
DNA are adhered at fixed spots. Usually there are tens of thousands of spots on an 
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array and each are related to a single gene. The raw microarray data are the 
monochrome images, which are then converted into the gene expression matrices 
in which the rows define the genes, the columns define the various samples based 
on different conditions or tissues, and the numbers in each cell of the matrix 
represent the expression level of the specific gene in the specific sample. 
Conversion of these images into the gene expression matrix is a non-trivial process, 
such as spots that correspond to the genes on the microarray should be recognised, 
their boundaries should be determined, and from each spot the fluorescence 
intensity should be analysed and compared to their background intensity [27]. It is 
believed the formation of the database of the gene expression matrix will help us to 
understand the gene regulation, signalling pathways, treatments for drug response, 
and the genetic mechanisms of the disease. For instance, if the overexpression of 
some specific genes is related to a particular cancer, then which other conditions 
can affect the expression of these genes and which other genes have similar 
expression profiles can be examined. It can also be investigated which potential 
drugs can reduce the expression levels of these genes [27].   
 The probes are adhered to a solid surface constituting either glass or silicon 
by a covalent bond to a chemical matrix. Photolithographic technology is used by 
affymetrix technology to blend 25-mer oligonucleotides on a silica wafer [3]. There 
are other microarray platforms that exist, such as Agilent which uses single channel 
arrays, and Illumina, which uses microscopic beads rather than the large solid 
support [229]. These are discussed below in detail. Microarrays also differ in the 
workings, efficiency, accuracy, and cost. 
x Affymetrix microarrays [142]: The probes of affymetrix are designed using 
the publicly available information. The probes are derived from the sequences 
and were selected from the GenBank, RefSeq, and dbEST. From the UniGene 
database [218], the sequencing clusters were generated from Build 133 (April 
20, 2001) and amended by analysing and comparing the variety of other 
available public databases such as the University of California, Santa Cruz, 
Golden-Path human genome database (released on April 2001) [204]. From 
these varieties of databases, the sequences were piled up and clustered into the 
groups with similar kind of sequences.     
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 The software for managing the Affymetrix microarray data is Affymetrix 
GeneChip Operating Software. The GeneChip helps researchers to scan and to 
know the presence of some specific genes in a biological sample. The probes 
are generated on the chip using a process called photolithography, which uses 
light in order to control the multiple layers of material. Affymetrix focusses on 
oligonucleotide microarrays that are used to know which genes belongs to a 
sample by observing particular components of mRNA. In order to do the 
thousands of experiments side-by-side, a single chip can be used, however it 
can only be used once. Each GeneChip consists of around 1,000,000 features. 
Each single probe is marked as a pair in which one exists as a perfect match 
(PM), whereas the other exists as a mismatch (MM) at the centre. This enables 
the quantification and the reduction of signals caused by the non-specific cross-
hybridisation. In the hybridisation signals, the differences between the partners 
and also with their intensity ratios assist to indicate the specific target 
abundance. Each gene is defined on the GeneChip by 11 probe pairs.  
x Agilent microarrays [126]: Agilent produces probes for microarrays by using 
a method of DNA synthesis which is based on inkjet printing technology. In 
this method, the DNA nucleotides layer is “printed” onto the suitable 
microarray feature locations to integrate probes, avoid various restraints of light 
based synthesis methods, and is also able to produce oligonucleotides probes of 
exceptional quality as well as length. The errors in the microarray probe 
sequences will result in the loss of signal intensity yet a gain in the noise in 
experimental measurements.      
 The software for managing the Agilent microarray data is Agilent 
GeneSpring Software. Experimental analysis shows that Agilent achieves a 
tremendous 99.5% stepwise DNA synthesis yield, and produces probes with 
very high sequence fidelity [126]. Also, the platform of Agilent microarray can 
show accurate relative quantisation of gene expression levels over a range of 
greater than five orders of magnitude, which is higher compared to the 
capabilities of other systems. The factor that is most important in achieving high 
sequence fidelity is to increase the synthesis yield to the maximum extent. 
Agilent now extends its gene expression platform to take advantage of the 
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higher density that is available on the SurePrint G3 platform [4]. It is believed 
the platform of Agilent resolves more differentially expressed genes compared 
to other microarray platforms due to its significant higher dynamic range [126]. 
x Illumina microarrays [61, 103]: Illumina microarrays use microscopic beads 
instead of large solid support. This microarray technology is based on 3-micron 
silica beads that itself assemble in microwells on either of the two substrates, 
i.e., planar silica slides or the fiber optic bundles. If it is randomly assembled 
on either of these two substrates, then the beads will have a uniform spacing of 
~5.7 microns. Each single bead is layered with hundreds of thousands of copies 
of a particular oligonucleotide that can serve as capture sequences in either of 
the Illumina’s assays. BeadArray microarray technology is used in Illumina’s 
iScan array scanners for a diverse range of DNA and RNA analysis applications 
[103].           
 The software for managing the Agilent microarray data is Illumina Genome 
Studio Software. This technology is based on randomly arranged beads with 
every single bead binding many similar copies of a gene specific probe. The 
BeadArray is constructed so there are approximately 30 randomly positioned 
replicates as an average for each kind of bead. This kind of redundant design 
returns higher robust estimations and confidence calls in comparison with other 
kinds of microarrays. Despite this, the distinctness of Illumina design makes 
pre-processing and the quality control steps comprehensively unique from other 
kinds of microarray technologies. Most other analyses considers pre-processing 
methods that are basically designed for the Affymetrix microarrays, and have 
not considered the merits of the distinct property of this microarray technology 
[61]. Due to the effective cost and accuracy of the Illumina microarray, it is 
becoming a popular microarray platform. 
The probe sets in the various microarray technology, are defined in the different 
suffixes to understand their distinctness and/or their capability to adhere different 
genes. 
x “_at”: This suffix describes probe sets which are distinct to a single gene. 
x “_a_at”: This describes probe sets that identify multiple transcripts from the 
same gene. 
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x “_s_at”: This describes probe sets that have common probes among 
multiple transcripts from different genes. 
x “_x_at”: This describes probe sets in a situation where it is not possible to 
select either a unique probe set or probe sets that have identical probes 
among multiple transcripts. These types of probe sets share some probes 
identically with two or more sequences and therefore, these sets can cross-
hybridize in an uncertain way [142]. 
The major differences and similarities among the Affymetrix, Agilent and the 
Illumina microarray technology are explored in Table 2.1. 
Table 2.1: Shows the major difference and similarity among the Affymetrix, Agilent and 
Illumina microarray technology [234]. 
Factors to compare Affymetrix 
Technology 
Agilent 
Technology 
Illumina 
Technology 
What is the analysis software 
that is commonly used? 
GeneSpring, 
BioConductor 
GeneSpring Genome 
Studio 
What is the minimum amount of 
RNA that is required for more 
sensitive amplification, prior to 
the labelling? 
500 pg 
(By using the 
Affymetrix 
amplification assay 
and requires high 
quality RNA) 
50 ng 
(By using the 
Agilent kit) 
100 pg 
(By using the 
second party 
kit) 
What is the number of probes? Has millions of 
features (more than 
5.3 million on 
Human Exon 1.0ST 
array) 
15K, 44K, 
2x105K, 244K, 
1M are the 
formats 
available 
Up to 48K 
(Human whole 
genome array) 
One or two colours? One Both One 
What is the Probe Size? 25-mer 60-mer 50-mer 
Is the amplification of the 
sample involved in labelling the 
amount of RNA? 
Yes Yes Yes 
Is there a labelling protocol for 
the partially degraded samples? 
Yes Yes Yes 
 
Various microarray platforms generate a microarray gene expression dataset, in 
which each sample can be associated with any of the clinical covariates (see Table 
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1.1) or subtypes of breast cancer, e.g., Estrogen Receptor status. In any of the 
microarray gene expression datasets, only one of these covariates can exist, or many 
covariates can exist, depending on the scope and application of the dataset. 
Therefore, on the basis of the microarray gene expression dataset with incorporated 
clinical covariates, the diagnosis, prognosis or treatment outcome prediction of 
breast cancer can be done by using the cancer classifier (see Section 2.2). However, 
the microarray data has some issues which limit the ability to take full advantage 
of microarray gene expressions along with the clinical covariates. These are 
discussed in the next section. 
2.1.1  Issues with the Microarray Data 
Microarray technology that generates microarray data has some characteristics 
which make it relatively complex and challenging (see Section 2.1) compared to 
other types of data. The three prime issues involved with microarray data are shown 
in Table 2.2.             
 When dealing with microarray data, the above issues carefully need to be 
considered in order to obtain robust results. In the next section, we discuss the 
necessary steps of pre-processing the microarray data to bypass the above issues. 
Table 2.2: Issues associated with microarray gene expression data. 
 
Issues 
 
Description 
 
Correlated 
Measurements 
 
From the microarray experiment, the gene expressions measured are not 
independent and many gene expressions are directly or indirectly related to 
other genes. The presence of biological pathways defines these kinds of 
interactions, i.e., the networks of spatiotemporal interactions among biological 
constituents act as the genes product (proteins). These biological pathways 
may only contain a few to the various hundreds of genes responsible for the 
higher correlation of their gene expressions [91, 211] (see Section 2.3.2.2). 
High Level of 
Noise 
 
A large number of steps are required in the microarray experiment, which 
range from the biological sample preparation to the final gene expressions 
quantification. In each biological experiment, the technical inconsistency and 
the purity of the samples are inherited, which dramatically affects the quality 
of the data produced by microarray technology. Despite its biological 
significance, this data is mostly noisy [43, 91]. 
Curse of 
Dimensionality 
issue 
The generation of huge amounts of data using microarray technology allows 
measuring the expression of several thousands of genes in parallel. This 
becomes one of the major limitations in various pattern recognition problems 
when the sample size is very small compared to their features [91]. 
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     The large number of features with a relatively small sample size leads to a 
significant decrease in the performance of the cancer classifiers. This creates 
the problem of ‘Curse of Dimensionality’, which was a term named by Richard 
Bellman [19]. It explains the problem that exists due to the exponential 
increase in the volume as a result of adding more dimensions to a space [220]. 
In the microarray dataset, the number of features (i.e., genes) is in the order of 
several thousand, whereas the number of samples is comparatively very small 
due to the limitations in the availability of samples and other factors, such as 
time and cost [127]. The large number of features in the high dimensional 
dataset will result in noise and error. It is also true to say that not all the features 
in a dataset are significant to perform the classification analysis. The process 
to extract the most essential and relevant features is known as the feature 
selection technique, and is discussed in more detail in Table 2.3. 
          
   
2.1.2 Pre-Processing of Microarray Data 
Analysing microarray data is a critical task that requires biological and statistical 
expertise, as shown in Figure 2.2. Experimental design needs to be set up to analyse 
the type and number of experiments to be performed in order to define the 
biological question of interest and to generate the microarray data from the 
microarray experiments [3, 202]. However, microarray gene expression profiling 
is a highly noisy, expensive, and time consuming procedure. This means it is 
mandatory to use information in gene expression data in the best possible way to 
boost the quality of the data.       
 As discussed above, the microarray data has some issues and needs to be 
pre-processed to improve its quality and to remove any bias that comes across 
during experiments. To pre-process the data, the essential data pre-processing steps 
are Quality Controls, Normalisation, and the Dimensionality Reduction method. 
These are discussed in Table 2.3.        
Table 2.3: Data pre-processing steps. 
Data Pre-processing Steps              Types                                           
Quality Controls (QC): 
In order to improve the quality of the 
data, preliminary steps are essential. 
In some cases, the chip appears 
outside the limits of correction, and 
therefore, would be better discarded 
[91, 202]. 
                                                              
We define the QC (issued by [3]) of two main types. 
1). Single-Chip Quality Controls (SQC): The SQC 
focusses on one chip at a time, such as detecting 
hybridization artefacts by using raw image analysis. For 
example, large areas of low intensity due to air bubbles 
[188].  
2). Multi-Chip Quality Controls (MQC): The MQC 
focusses on a number of quantities that have values 
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which can be comparable over all chips of a dataset. For 
example, background intensities, scaling factors, and the 
percentage of present calls [3, 188]. Therefore, in order 
to discard the anomalous chip, these QCs are essential.    
Normalisation:                                       
Normalisation handles the systematic 
variations among the experimental 
conditions. This kind of method aims 
to remunerate for the technical 
differences among chips, so as to 
improve the analysis of biological 
differences between the samples. 
There have been lots of normalisation 
methods proposed that are particular 
to gene expression techniques [91]. 
However, there are some issues 
associated with normalisation 
methods, including that normalisation 
may distort the global up-regulated 
data distribution that lead to erroneous 
interpretations of gene expression 
profiles, or normalisation may falsely 
produce down-regulated differentially 
expressed (DE) genes while missing 
many truly up-regulated DE genes. 
Therefore, the selection of 
normalisation methods should be 
considered carefully [134, 215]. 
As in QC methods, normalisation can be categorized 
into two prime classes: 
1). Single-Chip Normalisation Methods: These are 
methods with low complexity and which use a single 
chip to illustrate the normalisation transformation, such 
as mean scaling. One of the most widely used single-
chip normalisation is the Microarray Suite 5 (MAS5) [3, 
188].                                           
2). Multi-Chip Normalisation Methods: These are 
methods that use a number of chips suitable for complex 
normalisation transformation. The most widely used 
multi-chip normalisation methods are Robust Multichip 
Average (RMA) [104], RMA using sequence 
information (GCRMA) [108], Variance Stabilisation 
Normalisation (VSN) [121], and the DNA chip analyser 
(dChip) [113, 188].       
 
Dimensionality reduction: 
Currently, the two main methods used 
to reduce the dimensionality of 
microarray data are feature 
transformation and feature selection. 
Depending on the analysis type, 
neither of these two methods can be 
used, only one of them can be used, or 
both of them can be used one after the 
other. More frequently, feature 
transformation is initially performed, 
followed by feature selection [91]. 
 
Dimensionality reduction is categorized into two types: 
1). Feature Extraction/Transformation: This method 
converts the input space (genes) into a feature space 
without using any clinical covariates. The essential 
properties of feature transformation are Interpretability, 
Generalisability, and Information [91]. 
      Usually, after feature transformation, the feature 
space is of a lower dimension, so as to lessen the 
complexity of the analyzing data. 
                     ܺ௡ൈ௠ ՜ ܺᇱ௡ᇲൈ௠ ׷ ݊ ب ݊ᇱ            (2.1) 
Here, ܺ represents the matrix of n gene expressions 
(features) for m patient samples, and ܺᇱ represents the 
matrix of݊ᇱfeatures after the transformation is 
completed.    
2). Feature Selection: This method finds the features 
among the available features, thus providing the 
maximum information for the classification analysis 
[86, 122]. The feature selection method has various 
benefits, such as less measurement and storage 
requirements, assists in data visualisation and 
understanding, and avoids the curse of dimensionality 
issue to improve the classification accuracy. The 
essential properties of feature selection are efficient 
Computational Cost and Information [91]. 
  
19 
 
      For feature selection, the three most essential 
methods are filter, wrapper and embedded methods. The 
filter methods evaluate the relevance of the features, 
while avoiding the effects of the selected feature on the 
model accuracy, such as the Bayesian Network, and 
Markov Blanket Filtering [5]. The wrapper methods 
evaluate the feature subsets according to their relevance 
for a particular model, such as Genetic Algorithm (GA) 
[5]. The embedded methods accomplish the feature 
selection as the component of model fitting and are 
particular to the given models, such as the LASSO 
algorithm, Elastic Net, and Classification Trees [91, 
136].   
 
Generally, after data pre-processing steps, unsupervised or supervised analysis can 
be performed in order to effectively perform the various classification or prediction 
tasks for breast cancer, such as diagnosis, prognosis or treatment outcome 
prediction (see Section 2.2 for details). This depends on the biological question of 
interest, and is discussed in more detail in the next section.        
2.1.3 Microarray Data Analysis  
The data to be analysed depends on the biological question that needs to be 
resolved. The most important goal in the analysis of microarray data is to identify 
the differentially expressed genes (i.e., the genes whose expressions are 
significantly different between two or more given classes, which is also known as 
gene signature) in order to perform the classification task, or any other related tasks. 
Usually, two types of analysis can be performed. These are supervised and 
unsupervised analysis [95], and they are defined in Table 2.4.  
Table 2.4: Supervised and unsupervised analysis. 
  
Supervised Analysis  
 
 
Unsupervised Analysis  
Approach For supervised analysis, a link is found 
between the input data and the output 
data. For example, by using any type of 
supervised analysis, such as a Support 
Vector Machine, it finds a link between 
gene expressions and the survival of a 
patient. 
For unsupervised analysis, the 
structure in the data is found without 
the need to look up any external 
information. For example, by using 
any type of clustering, it finds 
similar gene expressions clustered 
across the samples. 
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Types/   
Techniques  
Supervised analysis can be several 
types, and among the different types, the 
option to choose depends on the output, 
such as: 
1. Regression analysis when the output 
is in the form of a continuous variable. 
2. Classification analysis when the 
output is in the form of a discrete 
variable, which can be in the form of 
binary or multi-class. 
3. Survival analysis when the output is 
in the form of survival data [20, 91]. 
In unsupervised analysis, the three 
main classes of techniques are [20]:  
1. Feature determination, i.e., to 
determine the genes with some 
special properties and without 
looking up a specific priori pattern. 
2. Cluster determination, i.e., to 
determine the groups of genes across 
samples that have similar gene 
expression patterns. 
3. Network determination, i.e., to 
determine the graphs which 
represent gene interactions or gene-
phenotype interactions. 
Essential 
Factors/              
Characteristics 
It is possible to separate the expression 
profiles of the sample into two groups 
i.e., disease state and normal state. Both 
of these can be searched for patterns 
which can distinguish the disease state 
of the sample profile from the normal 
state of the sample profile [13]. 
       To determine whether or not a 
specific gene is differentially expressed 
between two samples, the four 
characteristics considered are: Absolute 
expression level (whether a gene is 
expressed at a high or low level); 
Subtractive degree of change between 
two groups (the difference in expression 
levels across the samples); Fold change 
between groups (the expression levels 
ratio across the samples); and 
Reproducibility of the measurement 
(the samples with similar characteristics 
may or may not have a similar amount 
of the gene transcript) [20, 91].                
Clustering methods make it possible 
to recognize the group of patients 
with similar profiles or 
characteristics, such as identifying 
the group of patients with similar 
gene expressions or to identify the 
group of genes that has similar 
expressions [20, 91].                           
       In this type, usually the output is 
a cluster of similar kinds of objects 
when applied to some clustering 
methodology. For example, groups 
of genes or groups of samples.            
 
Examples Naive bayes, Decision trees, Neural 
networks, Support Vector Machines. 
CAST, k-means Clustering, 
Hierarchical Clustering, Relevance 
Networks. 
 
The purpose of grouping objects, such as genes or samples in the dataset, is to 
discover patterns or structure in the data, which is referred to as clustering analysis. 
The clustering methods are an unsupervised data analysis method which means the 
structure of the data is not known a priori. The objects within the clusters must be 
similar to others but dissimilar to objects in a different cluster. The clustering of 
gene expression data helps to identify genes that have similar features that can be 
used for various classification analyses. The similar features can be evaluated by a 
distance metric which defines the similarity between two objects and is performed 
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before clustering. The most widely used distance metrics are Correlation distance 
[83], Euclidean distance [83], and Manhattan distance [83, 91, 189]. Once the 
similarity measure is chosen, the appropriate clustering methodology can be 
applied.          
 The clustering methods are divided into two major groups, i.e., hierarchical 
and non-hierarchical, as shown in Figure 2.1. The most commonly used clustering 
methods are hierarchical clustering [9, 13], k-means clustering [13, 58], self-
organising maps [13, 20], and principal-components analysis maps [13, 20]. The 
essential benefit of clustering is not to find cancer-related genes, but to find the 
genes that can identify the subclass of breast cancer, such as ER+ or ER-, or the 
genes that can predict the recurrence risk among breast cancer patients. 
 Some of the existing methods or classifiers that come under supervised and 
unsupervised analysis to perform the classification or prediction tasks for breast 
cancer are defined in the following section. 
 
Figure 2.1: The grouping of clustering methods [13]. 
 
2.2 Breast Cancer Classifiers 
Effective and robust breast cancer classifiers are needed to accurately classify the 
dataset samples, such as discovering ER+ or ER- samples (Diagnosis), predicting 
high or low risk for recurrence (Prognosis), or predicting the binary treatment 
outcome.              
 To classify the samples, the data pre-processing steps can be initially 
performed on the gene expressions in the dataset, and then by applying the 
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classifier’s approach (i.e., supervised or unsupervised approach), the gene 
expressions can be incorporated into the algorithm and used for the purpose of 
classifications. For example, in unsupervised analysis, the most similar kinds of 
gene expressions are clustered together so they can be further used for cancer 
classification (see Section 2.2.1).     
 Generally, the classification of cancer classes are supervised learning 
algorithms in the way the outcomes are derived from the training dataset (known), 
which can then accurately predict the outcome on the test dataset (unknown). 
Cancer classification has huge applications in diagnosis, prognosis or treatment 
outcome prediction tasks. The major difference between cancer classification and 
other classification methodologies is the abundance of information explored during 
the classification process.        
 The essential goal in cancer classification is to accurately diagnose, 
prognose, or to predict the treatment response for cancer patients [135]. Since the 
information available for cancers is not so well-advanced, the biologist aims to 
achieve a deeper level of understanding of gene interactions and other biologically 
related information that develops the cancers. Therefore, it is good enough to say 
that cancer classification is not simply related to accuracy, but is also related to 
discovering biological-based information from the statistical results, facts or 
conclusions derived from the classifier. A cancer classifier that does not explore 
biological-based information has only achieved some part of the cancer 
classification paradigm. The cancer classifiers can be categorized into three 
categories and are shown in Table 2.5.      
 The existing classification techniques that come under these three 
categories are defined in Section 2.2.1, whereas Section 2.2.2 shows previous 
related studies that are widely used in diagnosing, prognosing or predicting the 
treatment response for breast cancer patients. The limitations or issues involved 
with existing classifiers are defined in Section 2.2.3. The overall design of the 
microarray experiment, data preprocessing steps, and the data analysis in 
interpreting the biological facts, such as the diagnosis or prognosis of breast cancer, 
are illustrated in Figure 2.2.  
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Table 2.5: Three categories of cancer classifiers. 
Category Definition Examples 
First 
Category 
This category is associated with classifiers that consider the 
structure of data without considering the correlations in the data. 
        These classifiers consider the data only as a set of distributions 
and will perform the classification based on the distribution of data, 
and ignore the context meaning of the data.  
Naive bayesian 
or neural 
network 
classifier [85, 
120]. 
Second 
Category 
This category is associated with classifiers that consider the 
correlations in the microarray data without considering the structure 
of the data. 
         The classifiers in this category consider the correlation 
between the gene expression values regardless of the structure of 
the data 
Cluster-based 
technique 
(CAST) [7, 20] 
or support vector 
machines (SVM) 
[25, 143]. 
Third 
Category 
This category is associated with classifiers that consider the 
correlation of genes, along with the structure of the data. 
         The classifiers in this category discover gene relationships by 
using a stepwise selection of predictor, which gives biologists a 
deeper understanding of the structure of the data and also 
information about the correlation of the genes. However, due to the 
issues associated with the microarray gene expression data (see 
Section 2.1.1), these classifiers may fail to provide good 
classification accuracy.   
Decision tree – 
recursive 
partitioning is 
one example of 
this category 
[229].   
 
  
 
Figure 2.2: The overall framework of the microarray experiment in order to interpret 
biological facts and conclusions. Here, light blue boxes show the steps that require 
statistical expertise; the light yellow boxes show the steps that require biological expertise; 
and the light green box shows the step required for both, i.e., statistical and biological 
expertise [91].   
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2.2.1 Existing Approaches 
Many researchers have put a lot of effort in finding a way to accurately diagnose, 
prognose, or predict the treatment response for breast cancer. In the last few years, 
existing studies have used microarray gene expression datasets in order to identify 
the most relevant gene sets or gene signature for the various breast cancer 
classification or prediction tasks. 
Microarray technology works as a promising tool for breast cancer 
diagnosis, prognosis and treatment outcome prediction, by generating thousands of 
gene expression profiles in the dataset (see Section 2.1). However, due to the size 
of the dataset and other issues, as defined in Section 2.1.1, it is difficult to interpret 
the microarray gene expression data directly [99]. Therefore, various supervised 
and unsupervised techniques are applied to diagnose, prognose, or to predict the 
treatment response for breast cancer. These are discussed in the following sub-
sections [99].   
2.2.1.1 Support Vector Machine 
Definition: The Support Vector Machine algorithm (SVM) was originally 
developed by Vapnik and his colleagues. Later on, this algorithm was used in 
various data mining applications [25, 30, 209].  SVM is widely used for the 
prediction of cancer classes or subtype of test instances when the training instances 
contain the cancer class information.  
Mechanism: SVM generates the hyperplane with maximum margin between the 
classes, closest points. The points that lie on the boundaries are known as support 
vectors (hyperplanes), and the middle of the margin is the optimal separating 
hyperplane. Figure 2.3 illustrates this concept.  
 
Figure 2.3: Framework of Support Vector Machine [143]. 
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Mathematically, let’s assume that a set of binary class training samples are given, 
and each sample, say ݎ௜, can be taken as a data point in an n-dimensional space, 
where n defines the number of attributes. A class label is associated with each of 
the data points, i.e.,ܿ௜ א ሼെͳǡͳሽ. Now, the hyperplane (z) can be identified by: 
ݖሺݎ௜ሻ ൌ ݒ்ݎ௜ ൅ ݑ                       (2.2) 
where,ݒ is a coefficient vector (normal to the hyperplane), and u is the offset from 
the origin. For the linear SVM case, ݖሺݎ௜ሻ ൐ Ͳ corresponds to the closest point on 
one of the classes, and ݖሺݎ௜ሻ ൏ Ͳ corresponds to the closest point on the other class. 
The margin between the support vectors is defined as:      
                           ݉ ൌ  ଶԡ௩ԡ                                                          (2.3) 
It is desirable that for maximum separation, m should be maximised. When the 
training data size is small and the attribute space is large, there exists several such 
hyperplanes. Using the SVM algorithm, a hyperplane can be constructed with a 
maximum margin that separates the positive samples from the negative samples. If 
there is data that is not linearly separable in the input space, a possible solution 
could be to map the input space into a feature space of higher dimension. Letߙ be 
the mapping from input space ܫ ك Ը௡ to the feature space ݂ ك Ըே i.e., ߙǣ ܫ ك
Ը௡ ՜ ݂ ك Ըே,. Therefore, the plane is defined as the maximum margin 
hyperplane, which has the value, say ߚǡmaximized, i.e., 
ߚ ൌ ݉݅݊௜ୀଵ௡ ܿ௜ۃݒǡ ߙሺ݌௜ሻۄ െ ݑ                   (2.4)   
where, term ሺۃݒǡ ߙሺ݌௜ሻۄ െ ݑሻ represents the distance between point݌௜ and the 
hyperplane in the feature space. The sign of this term will provide the side of the 
hyperplane where the point resides. Now, when the signed distance is multiplied 
with ܿ௜ (class label of݌௜) and if the result is positive, this means the sample is 
classified correctly, and if negative, vice- versa.     
 To classify cancer classes, let the set of gene expression training samples of 
size m be given, with each sample in the order of (݌௜ǡ ܿ௜ሻ, and a test sample with 
class label c be given. Here, ݌௜ represents the vector of n gene expression values, 
and ܿ௜ represents the corresponding class label associated with them. Let the 
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maximum margin hyperplane be represented by vector ݒ଴ andݑ଴. Therefore, the 
classification result on y is given by the equation:  
                 ܥ݈ܽݏݏሺݕሻ ൌ ݏ݅݃݊ሺܿۃݒ଴ǡߙሺݕሻۄ െ ݑ଴ሻ                                     (2.5)  
Now, the sign becomes positive when y is classified correctly and negative when 
classified incorrectly. There may be a situation when the training samples have 
been labelled incorrectly due to experimental errors. In this case, there is a chance 
the samples may not become linearly separable in the feature space. Therefore, it is 
advisable the accurate linear separation may not always be the aim if we consider 
the overfitting avoidance. By using any type of parameter tuning that controls the 
overall training error, the desired training error can be accomplished [71].  
Example: Ramaswamy et al. [166] used the dataset of 314 tumor samples that had 
14 distinct human cancer classes and 16,063 gene expression values. After applying 
the quality control data pre-processing step, 218 tumors were left and later used for 
the classification purpose, such as in binary class prediction, i.e., breast cancer vs. 
other remaining types of cancer. Now, the linear SVM algorithm maximizes the 
distance between the hyperplanes, and assigns one of the cancer classes to an 
unknown sample in which the sample resides closest to one of the hyperplanes. 
2.2.1.2 Decision Tree (DT) – Recursive Partitioning   
Definition: The decision tree algorithm has been used widely in various 
classification areas, and is also known as classification trees. This algorithm 
consists of internal nodes and leaf nodes, where the internal nodes define a splitting 
criterion that consists of a splitting attribute and at least one predicates is defined 
on this attribute. Leaf nodes are labelled by using a single class label.  
Mechanism: Based on this approach, Zhang et al. [229] introduces a cancer 
classification method using a microarray gene expression dataset. Let’s assume that 
a microarray dataset contains n samples, and each sample contains the vector of m 
gene expression profiles. Applying Recursive Partitioning on this dataset builds a 
classification rule that is used for the classification of the samples, and the detailed 
mechanism is explained below.       
 The classification tree is constructed using a two-phase process, i.e., phase 
1 and phase 2. In phase 1, if the specific selected predictor is above a chosen cutoff 
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value, then the sample splits into smaller samples, otherwise it does not. The choice 
of selected predictor and its associated cutoff value are used to purify the class 
distribution, such as normal tissue from breast cancer tissue, where the sample 
purity can be measured by a purity based entropy function, i.e., 
                                           ܭ݈݋݃ሺܭሻ ൅ ሺͳ െ ܭሻ݈݋݃ሺͳ െ ܭሻ                  (2.6)                        
where, K is expressed as the probability of a sample to be normal. This function 
achieves maximum when K = 0 or 1, i.e., all samples are of the same type within 
the node, and is the minimum when K = 0.5, i.e., two samples are equally 
distributed. When the tree is constructed, this function is implemented in order to 
find the most suitable gene to split and the best splitting criterion for the selected 
gene. This can be accomplished by checking each unused gene on every possible 
splitting point by using the purity entropy function, and thereby choosing the gene 
which gives the most appropriate result in classifying the cancer class. By using 
this method, the binary tree that is constructed may overgrow. Therefore, phase 2 
is used to prune the tree in order to avoid overfitting of the data by using heuristics. 
Example: Zhang et al. [229] applied this approach to 62 samples that had 22 
normal samples and 40 cancer samples, with 2,000 gene expression profiles. By 
applying Recursive Partitioning on this dataset, it examined each of the 2,000 gene 
expressions with their possible threshold, thereby choosing the best combination of 
gene expression level and threshold as the one that gives the best separation of two 
classes on the basis of purity based entropy function, as defined above. As shown 
in Figure 2.4, by using three optimal gene expression levels, node 1 is divided into 
node 2 and node 3, and node 3 is then split into node 4 and node 5. Further, node 4 
splits into node 6 and node 7. The red boxes in Figure 2.4 represent the cancer class 
that has 40 cancer samples and 1 normal sample, whereas the blue boxes represent 
the normal class which has 21 normal samples [229]. In this case, the recursive 
partitioning algorithm shows 1 error (i.e., a normal sample predicted as a cancer 
sample) due to the small size of a dataset. However, this error may increase as the 
size of the dataset increases and therefore, is dependent on the size of a dataset.
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Figure 2.4: Illustration of the Decision Tree algorithm. Classification trees are generated 
by using the gene expressions of three genes, i.e., M26383, R15447, and M28214, as the 
threshold. Here, CT represents Cancer Tissue, and NT represents Normal Tissue. The circle 
represents internal nodes, and the square box represents the child nodes of internal nodes. 
Under each of the internal nodes, genes split the node into their child nodes, and the chosen 
threshold is shown on the right hand side [229].                 
     
2.2.1.3 Boosting   
Definition: Boosting algorithms are the kind of aggregated classifiers built from 
the aggregation of multiple forms of class predictors using majority voting [28]. 
Mechanism: Ben-Dor et al. [20] incorporate this algorithm in the context of cancer 
classification by making use of the decision function, which acts as a weak 
classifier. Mathematically, the decision function d is defined as: 
                              ݀ሺݒ ׷ ݎǡ ݏǡ ܿሻ ൌ  ൜ ܿݒሾݎሿ ൐ ݏെܿݒሾݎሿ ൏ ݏ       (2.7)                
Here, ݒሾݎሿ represents the vector of r gene expression values, s represents the split 
point (or threshold) for gene r, and c represents the class label of r, where cא
ሼെͳǡ ͳሽ. In order to find the best possible split point that will result in the most 
favourable class separation, d is applied on every gene which will check every 
possible split point, and will return the combination that shows the minimum 
number of errors. Boosting uses the weak learning procedure in order to construct 
classifiers ଵ݂ǡ ଶ݂ǡ ǥ ǡ ௜݂, and then uses the weighted vote among the classifiers. 
Therefore, if a test sample t is given, then its class can be given as: 
ܥ݈ܽݏݏሺݐሻ ൌ ݏ݅݃݊ሺσ ݓ௜ ௜݂ሺݐሻ௜ ሻ        (2.8) 
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where,ݓ௜ is the weight assigned to the classifiers. The basic idea behind this 
approach is that for training data, multiple forms of classifiers are iteratively 
generated, such as the weak learner is first trained on the original training dataset 
D in order to achieve a classifier ଵ݂ሺݐሻ. Then, the samples can find out from D 
which ones were classified inaccurately by ଵ݂. Next, the new training dataset is 
constructed in which these samples are given more weight. Therefore, in each 
iteration, the samples classified inaccurately in the last iteration are given special 
attention. If a sample is misclassified in the ongoing iteration, it will then be 
assigned a higher weight in the next iteration, and so on. The aim of the algorithm 
is to focus on the samples that consistently get misclassified and therefore, the 
algorithm gives the most favourable classification. In other words, it will provide 
an effort that can maximise the margin of the training samples [20]. 
 On the basis of the max-margin technique, the Boosting algorithm shows a 
small number of errors on the test datasets. They define the margin ௝݉ of a sample 
ݐ௝having class label ௝ܿ as:  
 ௝݉ ൌ ܿ௝൫σ ݓ௜ ௜݂ሺݐ௝ሻ௜ ൯                  (2.9) 
Here, the positive value of ௝݉ means that a sample ݐ௝is classified correctly, and 
vice-versa for a negative value. Freund et al. [69] concludes the generalization error 
of boosting relies on the distribution margins of training samples [20]. Therefore, 
the process of boosting contains iterations of split point assessments for each gene 
in the samples, and the test samples can be classified based on the weighted voting 
of classes which are produced by the split point decision functions during each 
iteration.   
Example: Hasan [94] applied this algorithm to a group of 286 lymph node negative 
breast cancer samples that were divided into 180 samples (having lymph node 
negative relapse free patients), and 106 samples (having lymph node negative 
patients that developed a distant metastasis) in order to classify the relapse free 
patients from the metastatic patients. After applying the filtering steps on the 
microarray gene expression dataset, the initial set of 22,000 genes were reduced to 
45, which could be used as the features for the boosting algorithm to classify the 
breast cancer subtypes.     
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2.2.1.4 CAST Algorithm 
Definition: The CAST algorithm is based on the cluster based technique, as 
specified in Section 2.1.3. The clustering of samples can be done by using the 
microarray gene expression profiles, which arrange the samples into a cluster with 
an increased number of similar gene expression profiles. This similarity can be 
evaluated by any kind of similarity measure. 
Mechanism: This algorithm developed by Ben-Dor et al. [20], uses the hierarchical 
clustering approach (see Figure 2.1), where the topmost division splits the samples 
into two groups, with one group in the majority of the normal samples and the other 
in the majority of the tumor samples. The grouping of the training samples into 
different clusters is the core idea behind this algorithm, which is based on the 
similarity of samples already in the cluster and removes samples that no longer 
have similarity with the ongoing cluster.     
 It uses a threshold parameter t that controls the cluster granularity. Now, a 
sample can have high similarity with a group of samples when there is at least a t 
similarity measure between them. In the training phase, if a sample has a higher 
similarity with the samples already in the cluster, then the sample will merge into 
the cluster, and once it is merged, the samples similarity score in the cluster is 
calculated again. Therefore, if its new similarity score is less than t, it will be 
removed from the cluster. The most commonly used similarity measure is defined 
in the form of distance metrics, and is highlighted in Section 2.1.3. This algorithm 
forms one cluster at a time. For example, it forms a cluster of the samples all with 
a similarity score higher than t, then it forms another cluster, and so on till the state 
is reached when each sample is included in any of the clusters. Using the cluster 
structure compatibility measure, the CAST algorithm chooses the most appropriate 
t value. Basically, the compatibility measure checks the cluster structure and 
penalises those with samples of the same class that have separated into different 
clusters, while the samples of a different class merge into a cluster. The 
compatibility score (CS) can be defined as:  
ܥܵ ൌ σ ௔ܲ൬௔א௦௔௠௣௟௘௦௧௛௔௧௛௔௩௘௦௔௠௘௖௟௔௦௦௔௡ௗ௔௦௦௜௚௡௘ௗ௧௢௦௔௠௘௖௟௨௦௧௘௥ ൰ ൅
σ ௕ܲ൬௕א௦௔௠௣௟௘௦௧௛௔௧௛௔௩௘ௗ௜௙௙௘௥௘௡௧௖௟௔௦௦௘௦௔௡ௗ௔௦௦௜௚௡௘ௗ௧௢ௗ௜௙௙௘௥௘௡௧௖௟௨௦௧௘௥ ൰
         (2.10)        
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Using equation (2.10), the choice of clustering parameters can be optimized in order 
to achieve the most robust clustering, which iteratively allows different t values by 
using a binary search. For every t value, the CAST algorithm is used to cluster 
samples of the training data and then the compatibility measure is performed on the 
generated clusters. Finally, the t value, which gives the maximum CS, is then 
chosen for further classification processes. It should be noted that CS is only used 
for training data.           
 Let’s assume that a test dataset is given say S, and a set of training samples 
is given say P. The CAST algorithm applies different t values to cluster S and P in 
order to find the best cluster structure. Therefore, the class label of S can be 
predicted by using one of the classical majority voting approaches [26, 130]. The 
majority voting approaches assign a class label to S, which has a maximum number 
of training samples in the cluster in which S exists. However, if the number is too 
small to be the maximum compared with others in the same cluster, then it is 
assigned as an uncertain class. Figure 2.5 illustrates this approach.      
 
Figure 2.5: The essential processes of CAST algorithm to classify the cancer classes.
  
Example: Ahr et al. [7] applied this algorithm on a group of 73 malignant and 9 
benign breast cancer samples which contained thousands of gene expressions 
across the samples. By normalising the gene expression data and performing 
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average linkage clustering using Pearson Correlation metrics (as a similarity 
measure), they grouped the samples to form clusters, which could be used to 
classify the malignant from benign breast cancer samples. The calculated 
similarities were visualised as a hierarchical tree, where the branch length signifies 
the similarity distance of the expression profiles (i.e., 1-Pearson Correlation). 
2.2.1.5 Neural Network 
Definition: Neural Networks are types of artificial intelligence algorithms [155] 
that have many applications in a broad range of problems [219]. For classification 
of cancer classes, Khan et al. [120] applied neural networks, which performed 
classification in three steps, i.e., principal component analysis, artificial neural 
network prediction, and gene selection. The main purpose of principal component 
analysis is dimensionality reduction so the overfitting error in the supervised model 
can be avoided. Jollife [109] noticed that when class labels of microarray data are 
included in the reduction process, the results are biased and do not achieve optimal 
performance. Therefore, class labels must be excluded from the dimensionality 
process [109]. Once the dimensionality reduction process is completed, the 
artificial neural network (ANN) can be generated. 
Mechanism: The ANN algorithm consists of linear perceptrons that have 10 input 
nodes with 10 associated principal components and 4 output nodes that are 
associated with 4 unique class labels from the input data. Khan et al. [120] shuffled 
the samples and divided them into 3 equal partitions (or 3 ANN models) in which 
2 of them were used as training data, and the remaining one was used as the testing 
data. This process of shuffling and division was repeated around 1250 times and 
each shuffling was used to analyse 3 ANN models. Therefore, the 1250 predictions 
of each validation sample were used as a committee vote, where one evaluates the 
average of all predicted outputs and then converts this average to 0 or 1 by using a 
threshold, such as 0.5, where 0 defines a particular cancer class (example ER+) and 
1 defines the other cancer class (example ER-). In this way, breast cancer samples 
can be classified into their estrogen receptor based binary subtypes. 
 By using the largest average committee vote, each sample can be classified 
whether or not they belong to a particular class. However, in order to reject the test 
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samples that do not belong to any class (for example, an undefined class) or to reject 
the second largest vote of the sample, more stringent criteria is defined, i.e., 
distance function ݀௖that can ignore the class assignment of a particular test sample. 
Mathematically, ݀௖ is defined as the evaluation of the distance from a test sample 
to the given vote for each cancer class c i.e,          
               ݀ࢉ ൌ  ૚૛σ ൫ܽ௜ െߜ௜ǡ௖൯
ଶ௖௜ୀଵ              (2.11)  
where, ܽ௜ defined the average committee vote of class i, and ߜ௜ǡ௖corresponds to 
unity if i belongs to c, and null otherwise. The performance of the ANN algorithm 
is dependent on the network parameters, such as the input nodes and distance 
parameter used [6].         
 Therefore, to evaluate the contribution of each gene to the classification by 
ANN models, the genes are ranked on the basis of Sensitivity of the classification. 
Mathematically, let’s assume that a microarray dataset is given with N samples, and 
C classes that are represented as:ܿଵǡ ܿଶǡ ǥ ǡ ܿ௡. Therefore, the sensitivity of a gene, 
say݃௜ in respect of class labels, is defined as:                                  
                  ௜ܵ  ൌ  ଵே
ଵ
஼ σ σ ቚ
డ௖೛
డ௚೔ቚ
஼௣ୀଵே௝ୀଵ                   (2.12)                         
Here, ߲ܿ௣Ȁ߲݃௜represents the derivative of the class label. Using this equation, it 
will tell the gene essentiality in comparison with the total classification. However, 
the specificity of a gene ݃௜ in respect of class label ௝ܿ is defined as:                
ܵ௜௝ ൌ  ଵே
ଵ
஼ σ ቚ
డ௖ೕ
డ௚೔ቚ
ே௣ୀଵ                (2.13)                   
where, ௝ܿ defines the class label of the jth class. Each ௜ܵ௝ has a sign that signals 
whether the largest contribution to the sensitivity is due to negative or positive, 
where a positive sign defines an increase in gene expression level also increases the 
likelihood of a sample belonging to this cancer class, and for a negative sign, vice-
versa. Therefore, the sensitivity and specificity of each gene can be calculated, and 
assigned a rank which is based on their significance that is associated with an 
individual cancer class (separate rank) and also associated with total classification 
(total rank). Once assigned the rank, the top k significant genes are then picked and 
the entire calibration procedure is re-done. By using the separate rank, each gene 
from the top k significant genes is then classified to that cancer class which shows 
high expressions. Therefore, the samples can be classified on the basis of 
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hierarchical clustering using the most significant related genes generated from 
ANN.      
Example: Gruvberger et al. [85] applied this algorithm to the group of 58 samples 
that were divided into 47 training samples (consists of 23 ER+ and 24 ER-) and 11 
test samples (consists of 5 ER+ and 6 ER-) in order to classify the two estrogen 
receptor based subtypes of breast cancer, i.e., ER+ and ER- (see Section 1.1.2). 
After applying the data pre-processing steps, the original set of 6,728 genes were 
reduced to 3,389.  
2.2.1.6 Regression-based Algorithm     
Definition: The Regression-based Algorithm is a statistical process for evaluating 
the relationships between variables. It covers many techniques for modeling and 
analysing various variables, in order to evaluate the relationship between a 
dependent variable (DV) and one or more independent variables (IV). In other 
words, regression analysis helps to understand how the DV value alters when any 
one of the IVs is varied at the same time as others are held fixed. Regression 
analysis is widely used for prediction and forecasting, and to understand which 
among the IV are linked to the DV. There are various techniques developed for 
performing regression analysis, such as linear regression, ordinal least squares, 
polynomial regression, and logistic regression, etc. [221]. 
Mechanism: Yusuff et al. [226] performed logistic regression analysis to correctly 
diagnose breast cancer by using mammograms and referring to the patient’s history. 
Various tests were performed in the logistic regression analysis, including model 
fitting test, parameter estimation and classification. The model fitting test is to 
ensure whether all the variables are fit to be used to perform logistic regression, 
and is done by using the likelihood ratio statistic defined as: 
ܮܴሾ݅ሿ ൌ െʹ൫ܮܮሺܽሻ െ ܮܮሺܽǡ ܤሻ൯                           (2.14) 
where, ܮܮሺܽሻis the log-likelihood of the initial model and ܮܮሺܽǡ ܤሻis the log-
likelihood of the final model. Likelihood ratio is distributed chi-square with i 
degree of freedom.        
 Next, the parameter estimation is to evaluate each IV which checks the 
presence of breast cancer, and is done using the log-odd ratio defined as: 
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                              ܤ ൌ ݈݊ ቂ௉ሺ௒ୀ௠ሻ௉ሺ௒ୀ଴ሻ ቃ ൌ ߚ଴ ൅σ ߚ௜ݔ௜௡௜ୀଵ                         (2.15)   
where, ݉ = 1, 2…n.  In order to find the log-odd ratio, the probability of each event 
is calculated. The odds ratio measures the occurrence when IVs increase by one 
unit and is defined as: 
                                      ௉ሺ௒ୀ௠ሻ௉ሺ௒ୀ଴ሻ ൌ ሺߚ଴ ൅σ ߚ௜ݔ௜௡௜ୀଵ ሻ                           (2.16)   
Therefore, the classification can be made that predicts the presence of breast cancer 
or not. From the above calculated coefficients, the probability of each patient 
sample can be calculated, as defined below: 
ܲሺܻ ൌ ݉ሻ ൌ  ୣ୶୮ሺ௚ሺ௫ሻሻଵାσୣ୶୮ሺ௚ሺ௫ሻሻ  
whereas for the reference category,  
ܲሺܻ ൌ Ͳሻ ൌ  ଵଵାσୣ୶୮ሺ௚ሺ௫ሻሻ                                       (2.17)   
Example: Yusuff et al. [226] applied this algorithm to the group of 176 patients 
that were divided into 130 training samples and 46 test samples. Logistic regression 
analysis was performed by using the variables from the mammogram results, 
including mass, architectural distortion, skin thickening and calcification. For 46 
test data samples, 67.4% of the samples were correctly classified, whereas for the 
176 training data samples, 91.7% of the samples were correctly classified. Their 
results showed that the odds of getting breast cancer were 1.63 times if a patient 
has a family member with another type of cancer. Also, they showed that a patient 
with a mass detected on a mammogram screening had a five times higher 
probability of getting breast cancer, while patients with architectural distortion 
(skin thickening) had a high probability of getting breast cancer, and patients with 
calcification detected, had a probability of getting breast cancer 18 times higher 
[226]. 
2.2.1.7 Pros and Cons 
The pros and cons of the above discussed classifiers are provided in Table 2.6. 
From all of the above classifiers, it can be analysed that no classifier was superior 
over the others in terms of performance, robustness, computational time, and 
biological relevancy. 
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Table 2.6: Pros and Cons of existing classification techniques. 
Classifier Pros Cons 
SVM The SVM approach is appropriate for 
the analysis of broad patterns of 
microarray gene expression data to 
classify the cancer classes. This 
approach can handle the large 
number of features with a small 
number of training samples (Curse of 
dimensionality issue, see Table 2.2), 
and can integrate the pattern selection 
and the feature selection process in a 
single framework that is consistent 
[87]. 
SVM is only applicable for binary class 
problems. However, there are alternatives 
that splits multiclass problems to binary 
class (e.g. one type vs. all the other types), 
however none of these alternatives are 
effective in performing the classification 
tasks [25, 87, 143]. 
DT The results drawn from the DT are 
interpretable. DT is not dependent on 
any input parameter and is scalable, 
and the tree construction algorithm is 
relatively fast. Also, if the dataset size 
increases, the DT gives a satisfying 
performance over larger gene 
expression datasets. 
The disadvantages of DT includes: error-
prone results when the number of training 
samples for each class is low, the 
oversensitive nature of DT when the 
training samples contain noisy or biased 
data [229]. 
Boosting The Boosting algorithm achieves 
comparable classification 
performance with other methods. 
Also, Hasan [94] shows that the 
classification accuracy of the 
Boosting algorithm is significantly 
better than the decision tree 
classifiers [94]. 
The repetition of the classification of the 
weighted training samples in order to 
improve classification accuracy is time-
consuming. Since the boosting algorithm is 
time-consuming and achieves comparable 
accuracy, the boosting algorithm does not 
have any superiority when compared with 
other algorithms [20, 94]. 
CAST The CAST algorithm classifies the 
samples by considering the similarity 
of gene expressions, and therefore 
makes them less error prone to noise. 
 
One of the major disadvantages of CAST 
algorithm is they are non-scalable as every 
sample in the testing dataset needs to check 
with every sample in the training dataset to 
determine the types most similar. Also, 
with larger gene expression datasets, this 
method loses its advantages as it needs 
more computational time, and therefore 
makes them computationally expensive 
and inefficient [7, 20]. 
ANN The advantages of the ANN 
algorithm include better 
classification strength compared to 
other regression models, lower 
numbers of false positives without 
much of an increase in the number of 
false negatives, and the strength to 
accept a certain amount of inaccurate 
The major disadvantages of the ANN 
algorithm includes initialization and the 
need for many individual parameters to fit 
so the classification performance can be 
affected. Compared to white-box statistical 
methods, these methods are black-box 
based methods since it is hard to 
understand the interactions being modelled 
in the hidden layers. Also, they are prone 
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data without much of an effect on the 
classification accuracy [6].  
to overfitting and take a longer time to 
optimise [6, 60, 120, 179].   
Regression The Regression algorithm uses data 
very efficiently, fair results can be 
obtained from relatively small data 
sets, and the theory associated with 
linear regression is well-understood 
and enables for construction of 
various types of easily-interpretable 
statistic intervals for calibrations, 
optimizations, and predictions. 
One of the major disadvantages of the 
Regression algorithm is they are sensitive 
to outliers. Also, it gives optimal estimates 
of unknown parameters. Further, Linear 
regression looks at a relationship between 
the mean of the dependent variable and 
independent variable. However, 
sometimes we need to look at the extremes 
of the dependent variable [221, 226]. 
      
2.2.2 Previous Popular Studies  
Previous studies that have made diagnosis, prognosis, or treatment outcome 
prediction of breast cancer are discussed below: 
x van’t Veer et al. [208] 
Description: Developed a 70 genes set based on DNA microarray analysis, 
which initially contained 25000 genes among 117 primary breast cancer 
samples. The MammaPrint test was based on this 70 genes set. They applied 
a supervised classification technique to extract the gene signature that 
predicts short intervals to distant metastasis, and an unsupervised cluster 
analysis distinguished the ER+ breast cancer samples from the ER- samples. 
The supervised classification technique includes three steps: (1) selection 
of discriminative genes by their correlation with the category; (2) 
identification of the optical set of genes using a leave-one-out cross 
validation (LOOCV) method; (3) prediction based on the gene expression 
of the optimal set of genes. The unsupervised classification technique was 
performed independently using an agglomerative hierarchical clustering 
algorithm. The major validation of the 70 genes set was performed by van 
de Vijver et al. [206] who used microarray gene expression analysis in order 
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to classify the 295 group of primary breast cancer patients into good or poor 
prognosis [167].    
Size of Gene Signature: 70 
Whether Statistically Evaluated:    Yes 
Whether Biologically Validated: No   
x Sotiriou et al. [190] 
Description: Used an approach based on population in order to determine 
the genes associated with classification and relapse-free survival among 
breast cancer patients. Hierarchical clustering analysis separates the tumors 
into two main groups (based on the ER status) that correlate with the basal 
and luminal characteristics. By applying cox proportional hazard regression 
analysis, they identified a 485 probe set from a total number of 7650 probes, 
which distinguishes 99 patients relapse-free survival with p < 0.05 
(statistically significant). In order to choose the most significant prognostic 
genes, the 485 probes set was then compared with the 231 genes, which 
were the prognostic genes of van’t Veer et al. [208] that identified 11 unique 
overlapped genes (14 probes) [167]. These 11 genes separated the patients 
into two groups based on relapse-free survival. Their findings concluded 
that the ER status of the sample was more strongly correlated with the gene 
expression than the tumor grade. Their study design did not show any 
correlation of BRCA1 and BRCA2 status with the expression patterns of the 
selected probes set. 
Size of Gene Signature: 485 
Whether Statistically Evaluated: Yes 
Whether Biologically Validated: No   
x Ma et al. [138] 
Description: Developed a two-gene expression ratio based gene signature 
by using a training set of 60 estrogen receptor positive (ER+) breast cancer 
samples treated with adjuvant (treatment usually given after the surgery) 
tamoxifen therapy. Gene expression analysis was performed on 60 samples 
and based on variance-based gene filtering (based on overall variance of 
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each gene) and t test screening (performed on each gene comparing 
recurrences versus non-recurrences), 3 differentially expressed genes were 
identified (HOXB13, IL17BR, AI240933). However, based on their 
analysis, HOXB13 was overexpressed in recurrence cases, whereas, 
IL17BR and AI240933 were overexpressed in non-recurrence cases. 
Therefore, pairing HOXB13 with AI240933 or analysis of all three markers 
together did not provide robust prediction. In fact, their findings conclude 
that the HOXB13:IL17BR expression ratio is a robust predictor of 
tamoxifen response and particularly useful for stratifying ER+ breast cancer 
patients into low or high risk of recurrence.     
Size of Gene Signature: 2 
Whether Statistically Evaluated: Yes 
Whether Biologically Validated: Yes 
x Paik et al. [157] 
Description: Developed a 21 gene signature (that measures 16-cancer 
related genes with 5-reference genes) by using a set of 447 lymph-node 
negative, ER+ with tamoxifen treated breast cancer patients with 250 
candidate genes from three independent preliminary studies. The 16-cancer 
related genes were selected primarily based on their performance and 
consistency of probe performance in the assay. The Recurrence Score (RS) 
was then generated based on the 21 genes and the possible range of 
recurrence scores exist between 0 to 100, where a score towards 0 reflects 
lower likelihood of recurrence and a score towards 100 reflects a higher 
likelihood of recurrence. Further, more stringent cut-offs were then defined 
to classify the patients as low-risk to recurrence if RS<18, intermediate-risk 
to recurrence if 18≤RS <31, and high-risk to recurrence if RS≥31. Their 
findings conclude that the Recurrence Score based on 21 genes predicts the 
likelihood of breast cancer recurrence and also assesses the treatment 
benefit of chemotherapy.         
Size of Gene Signature: 21 
Whether Statistically Evaluated: Yes 
Whether Biologically Validated: No 
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x Wang et al. [216] 
Description: Developed a 76 gene signature by using a training set of 115 
breast cancer samples, in which 80 were ER+ and 35 were ER-. Cox 
proportional-hazards regression was then applied to extract the genes that 
had expression correlated with the length of distant metastasis-free survival. 
Based on the ER status, patients were grouped and each subgroup was 
analysed individually for the biomarker selection process. This 76 gene 
signature composed 60 genes selected from the ER+ subgroup, and 16 
genes selected from the ER- subgroup. In order to identify the patients at 
high risk of distant metastasis or to identify the patients with ER+ or ER- 
subgroup, the 76 gene signature works as a robust tool [167]. 
Size of Gene Signature: 76 
Whether Statistically Evaluated: Yes 
Whether Biologically Validated: Yes  
x Sotiriou et al. [192] 
Description: Developed a set of 128 probes (97 genes), called the Genomic 
Grade Index (GGI), by using a set of 189 primary invasive breast cancer 
patient samples in order to summarise the similarity between the gene 
expression profile and the tumor grade. GGI uses a scale and offset 
parameter for each dataset to standardise the gene expression grade index 
values. A high gene expression grade index is associated with a high grade, 
and vice-versa. When the GGI value of a sample is negative, they assigned 
a GGI value of 1 (Low grade sample). However, when the GGI value of a 
sample is zero or positive, they assigned a GGI value of 3 (High grade 
sample). In their study, they discovered that grade 1 and 3 breast cancers 
had distinct gene expression profiles, while grade 2 breast cancers had 
heterogeneous expression profiles that varied from grade 1 to grade 3. 
Therefore, the GGI algorithm categorizes the Grade 2 breast cancer patients 
into two recurrence groups, i.e., high risks to recurrence and low risks to 
recurrence. These subgroups were then compared with the already defined 
ER+ molecular classifications [167, 192]. 
Size of Gene Signature: 97 
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Whether Statistically Evaluated: Yes 
Whether Biologically Validated: No 
x Ivshina et al. [106] 
Description: Developed a set of 264 gene expression markers associated 
with the tumor grade. They used a set of 347 primary invasive breast cancer 
patient samples that were analysed on affymetrix microarrays. The cancer 
classification algorithms (prediction analysis of microarrays and 
statistically weighted syndrome) were applied and identified 264 markers, 
and among them, six were able to classify Grade 1 and Grade 3 tumors 
accurately, and classify Grade 2 tumors into two further subclasses, i.e., 
G2a and G2b [167]. Statistical analysis was then used to separate the G2a 
from G2b subtype, and also from the G1 and G3 subtypes.  
Size of Gene Signature:  264 
Whether Statistically Evaluated: Yes 
Whether Biologically Validated: Yes   
x Garcia et al. [75] 
Description: Developed an algorithm called Interactome-Transcriptome 
Integration (ITI) to predict the distant metastasis among breast cancer 
patients. ITI identified prognostic gene signatures using multiple and 
heterogeneous microarray datasets (consists of 930 breast cancer patients 
with multiple microarray platforms) incorporated with the protein 
interaction datasets. They identified two distinct subnetwork-based gene 
signatures generated from two discriminative subnetworks of ER+ and ER- 
breast cancer subtypes in order to classify the two risk groups (low or high) 
of distant metastasis among breast cancer patients. Their findings conclude 
that the subnetwork-based gene signatures of the ITI algorithm reflect the 
large biological conclusions of metastasis and were less sensitive to 
microarray platforms compared with previous classifiers. 
Size of Gene Signature: variable size from two study designs, i.e., 2485 
and 1753. 
Whether Statistically Evaluated: Yes 
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Whether Biologically Validated: Yes 
Some of these studies that have made a diagnosis, prognosis, or treatment outcome 
prediction of breast cancer are currently commercially available (or in their 
developmental phase), and are reported in Appendix A.     
2.2.3 Issues with the Existing Approaches  
In order to understand the mechanism of the biological processes that take place 
inside a cell, gene networks are essential to defining gene interactions. Since genes 
perform their functions by interacting with other genes directly (i.e., one gene is 
interacting with another gene without any common gene in between them) or 
indirectly (i.e., a gene is interacting with another gene with common gene/s in 
between them), examination of the functional interactions at a genetic level means 
researchers can learn more about gene mechanisms and explore a wider variety of 
biological information, such as how a genotype translates to a phenotype [59].  
Previous studies show that a disease phenotype cannot be predicted accurately on 
the basis of single gene, and that interactions among genes need to be considered 
[112, 225]. Therefore, established networks that generate gene interactions are 
essential towards molecular system biology [112]. Figure 2.6 (A, B) illustrates the 
framework of single gene-based (or gene-list based) approaches and network-based 
approaches, respectively. 
  
 
Figure 2.6: (A) Framework of single gene-based (or gene-list based) approaches, and (B) 
Framework of network-based approaches. Here, phenotype relates to cancer class.
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The advantages of network based approaches over single-gene based approaches 
are [42]:  
x The subnetwork markers have more chance of being reproducible across 
datasets, which can provide more robust results. 
x Improved classification accuracy to a significant degree. 
x Informative for non-discriminative cancer genes.                                                        
In other words, by studying interactions between genes, novel information can be 
discovered in regards to cancer diagnosis, prognosis, or treatment outcome 
prediction tasks.        
 Although there are some existing network based approaches for performing 
breast cancer diagnosis, prognosis, or treatment prediction tasks (such as ITI [75]), 
they do have the limitation (as defined below) of being a perfect classification 
algorithm. The most popular network based approaches are [75]: (1) In existing PPI 
(protein-protein interaction, where protein is the gene product) data, Chuang et al. 
[42] identified differentially expressed subnetworks by using local subnetworks 
aggregation; (2) Zhu et al. [232] used an SVM framework (see Section 2.2.1.1) 
which directly incorporated interaction data within a classifier; (3) Hanisch et al. 
[92] used a co-clustering expression and graph data by proposing a novel distance 
based on expression and network interactions; and (4) Garcia et al. [75] used PPI 
incorporated with the breast cancer microarray dataset to generate the  subnetworks, 
which were validated by randomly shuffling the interactions and the gene 
expression data. These approaches were able to address the biological question of 
interest, such as diagnosis of breast cancer. However, existing network-based 
approaches or single gene-based approaches do have some issues, such as:   
x High computational time.  
x The association of cancer class is not easy to interpret making it difficult to 
describe the results.  
x Algorithm performance is significantly affected by the dataset size and the 
microarray platforms. 
x Data may be underfitted or overfitted. For example, neural networks have 
hypothesis space of a fixed size which may underfit or overfit the data. 
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x Since training and testing is done on a single dataset that contains a very 
low number of samples, this signifies the curse of dimensionality issue (see 
Section 2.1.1) is not taken into consideration and still needs to be resolved 
[75]. 
x The construction of networks using microarray data alone suffers from the 
problem of sparse data. 
x Prior biological information included in these approaches biases the data 
because biological networks are not usually perfectly completed due to 
limitations in the experimental sources or the techniques involved. For 
example, Garcia et al. [75] incorporated protein-protein interaction data 
along with microarray data. As it is believed that protein-protein interaction 
datasets have unreliable (or false) interactions [51, 175, 176], unrelated 
proteins in the interaction network may be connected, and as a consequence, 
irrelevant biological conclusions may be drawn. 
x For network-based approaches (such as [75]) that use the existing protein 
interaction datasets (such as: HPRD [160], DIP [177], no kind of reliability 
criteria was incorporated that could validate the interactions in the dataset 
(where reliability defines the reliable interaction between any two proteins 
in a given dataset). 
Therefore, in order to achieve the basic aims of breast cancer classifiers, i.e., high 
accuracy with high sensitivity and specificity (statistical evaluation) and biological 
validation of a gene signature, in addition to resolving the above issues, it is 
essential to develop either novel breast cancer diagnosis, prognosis or treatment 
outcome prediction based algorithms that give optimal accuracy with biologically 
validated conclusions in diagnosing, prognosing, or predicting the treatment 
outcome for breast cancer patient samples, or alter the existing network-based 
breast cancer algorithms that can resolve the above issues and biologically validate 
them. The question now is how to evaluate, validate or compare the performance 
of algorithms. In the next section, we discuss the evaluation methods to assess the 
diagnosis, prognosis or treatment outcome prediction based breast cancer 
classifiers.           
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2.3 Evaluation Methods 
The evaluation methods are categorised into statistical evaluation methods and 
biological validation methods, and are discussed in Section 2.3.1 and 2.3.2, 
respectively.        
2.3.1 Statistical Evaluation Methods  
The classification of breast cancer samples into their subtypes, their prognostic 
groups, or their treatment outcome groups usually generates errors. These errors 
can be categorised into two types, i.e. misclassification rate and non-classification 
rate. The misclassification rate is defined as the ratio of samples wrongly classified, 
whereas the non-classification rate is defined as the ratio of samples that are not 
classified at all due to the experimental limitations or the lack of confidence in a 
classifier to predict the class label of a sample. The misclassification rate is further 
subdivided into false-positives and false-negatives, where false-positives define the 
normal samples that are classified into cancerous samples, and false-negatives 
define the cancerous samples that are classified into normal samples [20, 135]. 
 These two rates are relatively essential in the context of cancer classification 
because if the patient is classified incorrectly, the consequences can be serious. For 
example, due to a false-negative error, a cancer patient might be classified into the 
normal type and no treatment given to lessen the risk of the cancer spreading to 
other parts of the body (distant metastasis). Therefore, in order to fairly evaluate 
the algorithm’s performance, both misclassification error rates should be 
considered [135].         
 The Cross-Validation technique is used to evaluate the classification 
performance of cancer diagnosis, prognosis or treatment outcome prediction based 
algorithms. We divided the Cross-Validation approach into two major types, i.e., 
Leave One-Out Cross-Validation (LOO-CV) and k-fold Cross Validation (k-CV). 
2.3.1.1 Leave One-Out Cross-Validation testing (LOO-CV) 
LOO-CV is based on measuring the accuracy (i.e., the ability of the algorithm to 
accurately identify the patients with positive (cancer) or negative (normal) class), 
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sensitivity or recall (i.e., the ability of the algorithm to accurately identify the 
patients with positive class), specificity (i.e., the ability of the algorithm to 
accurately identify the patients with negative class), precision (i.e., the ability of 
the algorithm to predict the patients with positive class identifies the accurate 
positive class), and F-value (i.e., a combined effect of precision and recall in one 
term) by using the leave one-out technique, which assumes a sample in a dataset 
with a labelled class to be unlabelled (testing dataset), and all other classes labelled 
in the microarray gene expression dataset (training dataset). This procedure is 
repeated for each sample in a dataset, with each sample used exactly once in a 
testing dataset. Figure 2.7 shows the LOO-CV mechanism. Therefore, the class of 
an unlabelled sample is predicted by using the various cancer diagnosis, prognosis 
or treatment outcome prediction based algorithm. The results of each sample (or 
each testing dataset) are then averaged to give a single estimation.         
 Mathematically, Let       
x TP (True Positive) defines the number of correctly predicted cancer 
class,  
x FP (False Positive) defines the number of incorrectly predicted cancer 
class,  
x TN (True Negative) defines the number of correctly predicted normal 
class, and  
x FN (False Negative) defines the number of incorrectly predicted normal 
class.  
Therefore, the accuracy (ACC), sensitivity (SE) or Recall (R), specificity (SP), and 
precision (P) of any dataset d can be defined as:   
ACC = ்௉ା்ே்௉ାி௉ା்ேାிே;   SE or (R) =
்௉
்௉ାிே;    SP =  
்ே
்ேାி௉  ; P =
்௉
்௉ାி௉;    
F-value = ଶכ௉כோ௉ାோ   or  
ଶכ୘୔
ଶ୘୔ା୊୔ା୊୒ 
  (2.18) 
Keeping track of all these measures and to analyse it in a more effective way, a 
confusion matrix is used, as shown in Table 2.7.   
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Figure 2.7: LOO-CV Mechanism (with k = n, i.e., number of samples). 
 
Table 2.7: Confusion matrix 
   
Predicted Class 
 
         Positive Negative 
          
Actual 
Class 
Positive TP FN 
Negative FP TN 
 
 
By using ACC, SP and SE, a cancer diagnosis, prognosis or treatment outcome 
prediction based algorithm can be evaluated against other algorithms. The larger 
the ACC, SP and SE of an algorithm, the more effective an algorithm will be. The 
other less effective measure for evaluating an algorithm is by using precision and 
recall (precision-recall (PR) curve) and by using sensitivity and 1- specificity 
(receiver operating characteristic (ROC) curve).     
 The precision-recall curve [164] is often used in information retrieval and 
provides a clear picture of the performance of an algorithm. The PR curve can be 
plotted for different decision thresholds, and the larger the precision-recall data 
point on the PR curve of an algorithm, the more effective an algorithm will be.   
 The ROC curve is the function of sensitivity (recall) and specificity for 
different decision thresholds of the dataset. Mathematically, the ROC curve is a 
plot of sensitivity (or true positive rate (TPR)) versus 1-specificity (or false positive 
rate (FPR)) that defines a summary of TPR and FPR across a range of points. The 
TPR and FPR can be defined as [46]: 
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TPR = Sensitivity  
                                        FPR = 1 - Specificity     
The area under the ROC curve (AUC) is a statistic used for the performance 
measurement. TPR and FPR depends on the classifier function c and the threshold 
ߠ used to convert c(x) to classification (where x can be any sample). Plotting the 
TPR and FPR by varying the threshold ߠ results in the ROC curve. The larger the 
area under the ROC curve of an algorithm, the more effective the algorithm will be 
[46]. The prime advantage of ROC analysis is that it significantly shows the trade-
offs between sensitivity and specificity for a given classifier.    
 Using LOO-CV, all samples in the dataset get into both the training and 
testing set. However, LOO-CV is computationally expensive since it needs many 
training repetitions, and also a small change in the dataset can affect a large change 
in the selection of classifier [52, 187].        
  In general, by using the LOO-CV technique, not only can the error or 
misclassification rate be evaluated, but comparison among the cancer diagnosis, 
prognosis or treatment outcome prediction based algorithms by assessing which 
one is less prone to overfitting can also be performed [187].   
2.3.1.2 k-Fold Cross-Validation testing (k-CV) 
k-CV is based on measuring the accuracy, sensitivity (or recall), specificity, and 
precision  by dividing the original dataset into k sub-datasets, where k-1 sub-
datasets are used to construct the classifiers (training dataset) and the remaining 1 
dataset is used to validate the constructed classifier (testing dataset). Therefore, the 
samples class in a testing dataset is predicted by using the various cancer diagnosis, 
prognosis or treatment outcome prediction based algorithm. This procedure is 
repeated k times or folds with each of the k sub-datasets used exactly once in order 
to validate the constructed classifier. Figure 2.8 shows the k-CV mechanism. 
Therefore, the results from the k sub-datasets are then averaged to give a single 
estimation. It is to be noted that each sample of a dataset gets into a testing set 
exactly once, and gets into a training dataset k-1 times. A very common choice of 
k is 10, but in general the choice of k depends on the size of the dataset, e.g. for a 
very large dataset sometimes 5-fold CV will be sufficient. Large numbers of 
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estimates are always preferred in order to obtain reliable performance estimation. 
Therefore, k-CV can also be performed as a repeated k-CV, where k-folds are 
performed multiple times (e.g., performing 5 times 10-fold CV.), and the dataset is 
reshuffled before the start of each round.  
 
 
Figure 2.8: k-CV Mechanism (with k = 4). 
 
In general, k-CV is basically used to estimate the generalization error of a given 
classifier or used in selecting the most optimal classifier from several classifiers 
that have the smallest generalisation error. The prime advantage of this method is 
that all the samples in a dataset are used for both training as well as testing dataset 
and is less dependent on how the dataset gets divided into k-parts. Table 2.8 below 
shows the pros and cons of LOO-CV, k-CV, and repeated k-CV.   
Table 2.8: Pros and cons of LOO-CV, k-CV, and repeated k-CV. 
Approach Pros Cons 
LOO-CV  x Unbiased estimation of 
performance 
x Large variances occur 
k-CV  x Accurate estimation of 
performance 
x Small samples for estimating 
performance 
x Overlapped training data 
x Underestimated performance 
variance 
Repeated 
k-CV 
 x Very large number of estimation 
for performance 
x Overlapped training data 
between each run 
x Underestimated performance 
variance 
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2.3.2 Biological Validation Methods 
In the past, cancer classifiers were usually evaluated on the basis of statistical 
evaluation and not much attention was given to biological validation. We discussed 
some of the various essential approaches for breast cancer diagnosis, prognosis or 
treatment outcome prediction in Section 2.2, and deduced that no algorithm is 
superior over other algorithms in respect to classification performance across the 
range of datasets. Since many of these algorithms in Section 2.2 do not consider 
any real biological meaning of the gene signatures, this makes them unable to 
biologically validate the association of the genes/samples with class labels.  
 The main goal of gene expression data analysis is to provide biologists with 
an insight into biologically meaningful information related to genes (and other 
factors) that can strengthen the knowledge of biologists to effectively diagnose, 
prognose or predict the treatment outcome of the particular type of cancer from 
others. The gene interaction network is of utmost importance in the context of 
cancer classification (see Section 2.2.3), as it enables biologists to have a clear 
understanding of how a gene performs its function in the development of cancer. 
Therefore, the biological relevancy and its validation are equally essential as the 
statistical evaluation, and needs to be considered to fairly evaluate the algorithm’s 
performance.          
 The following biological validation methods have been used to biologically 
validate the classifiers.         
2.3.2.1 Gene Ontology Analysis 
Gene Ontology (GO) is a popular bioinformatics tool that represents the gene and 
gene product characteristics of various species. GO provides a controlled 
vocabulary of terms to describe gene product data and gene annotation data, and 
provides annotation to three non-overlapping domains: molecular function, 
biological process and cellular component [200]. Therefore, instead of defining the 
terms, it defines the relationships among the terms, and is organized as a directed 
acyclic graph.          
 The structure of GO can be defined in terms of a graph, with each node 
representing a GO term and the relationship between the terms are the arcs between 
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the nodes [200]. Figure 2.9 shows a small group of terms that represents a GO 
structure and their relations.   
  
 
Figure 2.9: The small group of terms from Gene Ontology [201]. 
GO analysis can be performed by using the GO biological process and examining 
the enriched annotations of the gene signature of an algorithm. Hartwell [93] and 
Kastan et al. [115] defined the uncontrolled rate of cell division as being directly 
associated with the development of cancer and its processes, such as cell cycle 
checkpoint, and DNA damage checkpoint, which is possibly responsible for cancer 
[75]. Also, Garcia et al. [75] identified the GO terms that might be associated with 
metastasis. These are cell proliferation, immune system, focal adhesion, cell 
migration and cytoskeleton organization. Therefore, in order to biologically 
validate the gene signatures of a cancer classifier, GO analysis identifies the cell 
cycle related GO terms that are overexpressed in the tumors in comparison to 
normal specimens [142].       
 If genes from a gene signature of an algorithm show a majority of similar 
related GO terms (as mentioned above), then a classifier gene signature can said to 
be biologically validated. In other words, the more overlap between the cancer 
related GO terms of a classifier gene signature, the more biologically validated the 
classifier algorithm will be.        
2.3.2.2 Gene Regulatory Network (or Pathway) Analysis 
The Gene Regulatory Network regulates thousands of gene expressions for 
developmental processes. Their main function is to designate the gene sets that 
must be expressed in specific spatial and temporal patterns.  In respect of physical 
terms, it has thousands of modular DNA sequences, and in the form of regulatory 
proteins, it has regulatory modules that receive and integrate multiple inputs that 
identify the particular sequences within them. The final result has accurate 
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transcriptional control of the associated genes, and the functional linkages between 
these genes with regulatory modules describe the core networks. Some of the 
regulatory modules are able to control gene activities (which encode the regulatory 
proteins), while others may not [50].     
 Therefore, gene regulatory networks are essential in understanding the basis 
of developmental processes, and define how accurate the genomic sequence 
encodes the regulation of the gene expression sets that iteratively generate the 
developmental patterns. Figure 2.10 shows the small component of the Glycolysis 
process. 
  
  
 
Figure 2.10: The small component of the Glycolysis process. It is a process for converting 
glucose into pyruvate and producing a small volume of ATP (energy) and NADH (reducing 
power) [117].         
  
Currently, there are various databases that represent essential biological pathway 
maps of humans, such as KEGG [118], Pathway Interaction Database (PID) [153], 
Human Pathway Database (HPD) [101], BioCarta [23], and Reactome [168]. These 
databases are used to determine which genes are associated with which pathway. 
 The pathway analysis can be performed using the pathway database that 
examines the enriched pathways of a gene signature of an algorithm. In order to 
biologically validate the gene signatures, Pathway analysis assesses the potential 
functional convergence of a gene signature on the basis of activated oncogenic 
pathways, such as cell cycle related pathways that are overexpressed in tumors 
compared to normal specimens [142, 182].      
 The main aim of pathway analysis is to assess the co-regulation of a 
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pathway, which can be done by considering all the genes in a gene signature that 
co-operate in a similar pathway [57, 195]. In other words, the more overlap between 
the oncogenic pathways of a gene signature of an algorithm, the more biologically 
validated the algorithm will be.      
   
2.4 Summary 
In this chapter, microarray technology with various existing approaches for breast 
cancer diagnosis, prognosis or treatment outcome prediction have been discussed. 
Existing approaches were based on supervised or unsupervised analysis that was 
unable to achieve high accuracy and unable to resolve other issues (see Table 2.2). 
Due to increasing and easy availability of microarray gene expression data, 
researchers have put a lot of effort into this field, such as the diagnosis, prognosis 
or treatment outcome prediction of cancer. However, due to lower numbers of 
samples available in the microarray gene expression dataset, classifiers can give 
biased results and their performance varies across different sizes of the dataset. 
 One of the essential goals of breast cancer classifiers is to generate robust 
gene signatures that can accurately diagnose, prognose or predict the treatment 
outcome of breast cancer, and correlate statistical results with biological 
conclusions. In other words, a cancer classifier should be evaluated based on four 
essential factors, i.e., computational time, robustness, statistical evaluation, and 
biological validation, and their performance should not be based on only one of 
these essential factors. Also, adequate care must be taken for the selection of 
components, such as preprocessing steps, experimental design and evaluation 
criteria to assess accuracy and robustness of a classifier. We hypothesize that 
improvements in these components will maximise the robustness and the reliability 
of breast cancer classifiers.       
 To conclude, this chapter primarily provides a comprehensive survey on the 
microarray gene expression data based breast cancer classifiers for diagnosing, 
prognosing or predicting the treatment outcome, and the limitations that restrict 
them from being a perfect classifier. The influence of microarray data pre-
processing steps is also demonstrated, which makes it one of the essential steps.  
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 Although a significant amount of work has been done in this area over a 
number of years, a vast amount of work still needs to be done by researchers in 
order to derive the most appropriate and reliable breast cancer diagnostic, 
prognostic or treatment outcome prediction approach. Here we list and highlight 
four issues that will be addressed in this thesis:      
1. The first is the reliable interaction dataset issue. The analyses of high-
throughput protein interactions indicate that protein interactions identified 
by experiments usually contain many irrelevant or unreliable interactions. 
Specifically, the identification of reliable or biologically true protein 
interactions from original experimental interaction datasets is becoming one 
of the most vital and challenging issues when using protein interaction data 
to effectively discover reliable biological knowledge, such as accurate 
diagnosis of breast cancer. 
2. The second is the breast cancer diagnosis issue. Due to the heterogeneous 
nature of existing algorithm based gene signatures, many patients have been 
classified into the wrong breast cancer subtype and treated with unnecessary 
therapy (chemo or radiation therapy). Specifically, the accurate 
classification of a breast cancer subtype can provide the optimal 
classification performance across datasets and the appropriate therapy can 
be provided. 
3. The third is the breast cancer prognosis issue. The early stage prediction of 
prognosis after being diagnosed with breast cancer remains one of the 
significant challenges. Specifically, the accurate prediction of a breast 
cancer prognosis group based on metastasis or recurrence can increase the 
survival rate of breast cancer patients and also assist in the decision for 
appropriate therapy.    
4. The fourth is the prediction of treatment outcome issue. The prediction of 
the response to standard chemotherapy regimens has shown to be a far more 
complex problem since breast cancers are biologically heterogeneous 
diseases with regards to different responses to chemotherapy. Specifically, 
the accurate prediction of a neoadjuvant (preoperative) chemotherapy 
response can improve the survival rate of breast cancer patients for those 
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achieving a pathologic complete response (pCR), or reciprocally can spare 
the patients this aggressive therapy and the associated high-costs involved, 
while achieving non-pathologic complete response (npCR).             
This thesis focuses on the reliable interaction dataset issue in Chapter 3. Chapter 4 
and 5 focus on the breast cancer diagnosis issue and the breast cancer prognosis 
issue, respectively. The prediction of the treatment outcome issue is investigated in 
Chapter 6. Finally, in Chapter 7, both the breast cancer diagnosis issue and the 
prediction of treatment outcome issue becomes the focus. In addition to the reviews 
on related research in this chapter, more detailed reviews for each issue investigated 
will be provided in each chapter. 
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Chapter 3  
 
Semantically Assessing the 
Reliability of Protein Interactions 
 
3.1 Introduction 
Protein interactions play important roles in various biological processes in which 
the physiological interactions of many proteins are involved in the construction of 
biological pathways, such as metabolic and signal transduction pathways. Over the 
past few years, high-throughput technologies have identified a large number of 
protein-protein interactions (PPI) for many species and mapped protein interactions 
to their biological processes [165, 214]. These protein interactions can be used to 
perform various biological tasks, such as merging with gene expression data (see 
Section 2.1 for more details) in order to perform the tasks of cancer diagnosis, 
prognosis, or treatment prediction, effectively.     
 However, the analyses of high-throughput protein interactions indicate that 
protein interactions identified by experiments usually contain many false-positive 
interactions, i.e., the interactions identified by the experiment never take place in 
cells. Only 30-50% of the interactions identified by high-throughput experiments 
were biologically relevant, with only a few overlaps among protein interaction 
datasets from different resources [51]. As a consequence, the discovered knowledge 
or inferred facts from protein interactions, such as the protein function prediction, 
cancer diagnosis, prognosis, or their treatment prediction, may be distorted or 
incorrect. Therefore, identifying and extracting reliable or biologically true protein 
interactions from original experimental interaction datasets is becoming one of the 
most vital and challenging issues when using protein interaction data to effectively 
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discover reliable biological knowledge.      
 Various approaches have been proposed to assess the reliability of protein 
interaction data based on the analysis of this data. von Mering et al. [213] and Bader 
et al. [15] analysed protein interactions from different datasets and resources. Both 
concluded that interactions identified by multiple experiments and resources were 
reliable interactions. However, due to the low overlap or limited coverage of 
different protein interaction datasets, this method may identify few reliable 
interactions. Deane et al. [51] proposed the paralogous verification method (PVM) 
that exploits the paralogs of two interacting proteins and the corresponding 
paralogous interactions to verify high-throughput protein-protein interactions. This 
method was restricted within cases where two proteins involved in an interaction 
had homologues, and even for these kinds of interacting proteins, only half of the 
interactions were identified with a high reliability confidence under the homology 
criterion. Deng et al. [52], von Mering et al. [213] and Sprinzak et al. [193] 
proposed methods that used the cellular localisation and cellular role properties to 
assess the reliability of protein-protein interactions. These methods only exploited 
the proteins internal structural information for assessing the reliability of protein 
interactions without considering the external interactions between proteins.   
 Since proteins perform their functions in various biological processes via 
their interactions [41], other approaches have been developed that exploit 
information conveyed by the protein interactions to assess the reliability of 
interactions. One of the most representative methods has been the ‘Interaction 
Generality’ (IG1) method [175].  The basic idea of the IG1 method was based on 
an assumption that an interacting pair of proteins (i.e., an interaction) that appeared 
to have many other interacting partners with no further interactions was likely to 
be a false-positive interaction. The IG1 method did not consider the topological 
properties of the interaction network beyond the target protein pair or interaction. 
To overcome this problem, Saito et al. [176] proposed a new interaction generality 
(IG2) method which improved the ability of IG1 to assess the reliability of protein 
interactions. IG2 exploited network topological classifications to determine how 
well an interaction fitted into the expected topology of a protein-protein interaction 
network, and used principal-component analysis when assessing the interaction 
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reliability. Using the ideas behind the IG1 and IG2 methods, Chen et al. [38] 
proposed a method called interaction reliability by alternative path (IRAP) which 
used only network topological metrics to rank protein interactions according to 
their computed reliability scores, and then identified the reliable interactions. Other 
approaches tried to integrate existing methods in order to assess the reliability of 
interactions, such as the probabilistic decision tree [230], logistic regression model 
[16], Naïve Bayes [107], and Bayesian network models [80]. All of these 
approaches only exploit the topological structural information of a protein 
interaction network to assess the interaction reliability. However, since the 
reliability of the interactions that construct the interaction network is uncertain and 
yet to be assessed, only using the interaction structural information from the 
original interaction datasets to assess the interaction reliability does have inevitable 
limitations.         
 It has already been discovered that proteins often perform their function by 
interacting with other proteins [41]. Therefore, the reliability of protein interactions 
should be assessed by their semantic meanings, such as the common cellular roles 
they share and the functional similarity they have. In this chapter, we propose a 
new semantic reliability (SR) method to assess the reliability of protein interactions, 
and in turn, extract reliable interactions from original interaction datasets for 
reliable knowledge discovery. For an interaction between two target proteins, the 
proposed SR method assesses the reliability of the interaction by a reliability score 
that combines two reliability measures: one is the semantic reliability measure 
between proteins that interact with the target proteins, and the other is the semantic 
reliability measure between the target proteins themselves. With the SR method, 
reliabilities of all interactions in an interaction dataset are assessed and sorted by 
their reliability scores. The interactions with low reliability scores are identified as 
unreliable and removed from the protein interaction dataset, and the remaining 
interactions form a new reliable interaction dataset. The evaluation of the method 
and the experimental comparisons with other existing methods on real protein 
interaction datasets showed new protein interaction datasets generated by the SR 
method contained fewer false-positive interactions. The experiments also 
demonstrated the effectiveness of the proposed SR method.   
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 This chapter is organised as follows. In Section 3.2, two semantic reliability 
measures of a protein interaction are proposed, and the SR method which combines 
these two reliability measures is presented. Section 3.3 provides evaluations, as 
well as comparison results of the proposed method on real protein interaction 
datasets. Finally, we summarise this chapter in Section 3.4.  
 
3.2 Semantic Reliability 
For an interaction between two proteins (a.k.a, the target interaction and target 
proteins respectively), we propose two measures to assess the reliability of the 
interaction from two perspectives: one is from the semantic relationship between 
the interacting partners/neighbours of the two target proteins, and the second is 
from the semantic relationship between the two target proteins themselves. The 
semantic relationship between the two proteins is based on the functions of 
involved proteins. In this chapter, we adopt the Function Catalogue (FunCat) [170] 
scheme for protein function annotation. With the FunCat, a protein function is 
expressed in up to six digital layers and the number of each layer represents a 
specific function category. For example, the FunCat notation “01.03.01.01” 
represents the function “purine nucleotide/nucleoside/nucleobase catabolism”, 
while the notation “01.03.01.01.03” represents the function “xanthine catabolism”. 
Within a FunCat function notation, the lower level number represents a sub-
function of the higher level function. Based on this function annotation scheme, we 
define two reliability measures in the following two sub-sections. 
3.2.1 Semantic Interaction Reliability 1 (R1) 
This reliability measure is based on the semantic relationship between the 
neighbour proteins of two target proteins of an interaction. Therefore, this measure 
is regarded as an external reliability measure of an interaction. Neighbour proteins 
of a target protein are those that directly interact with the target protein. We denote 
an interaction as a pair of proteins (a, b), where a and b are known as the target 
proteins of the interaction. Suppose the protein interaction dataset is S. For a protein 
p in S, its neighbour proteins (or simply say neighbours) are represented as a set of 
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proteins ௣ܰ ൌ ሼݍ א ܵȁݍ݄ܽݏܽ݀݅ݎ݁ܿݐ݅݊ݐ݁ݎܽܿݐ݅݋݊ݓ݅ݐ݄݌ሽ. For an interaction (a, 
b), we define the sets of neighbour protein functions for the proteins a and b as 
follows: 
ܨ݈௔ ൌ ሼ݂ݑ݊ܿݐ݅݋݊ݏ݋݂݌ȁ݌ א ሺ ௔ܰ െ ሼܾሽሻሽ,  
ܨ݈௕ ൌ ሼ݂ݑ݊ܿݐ݅݋݊ݏ݋݂݌ȁ݌ א ሺ ௕ܰ െ ሼܽሽሻሽ. 
Then, the semantic interaction reliability 1 (r1) of an interaction (a, b) is defined 
as 
                                            ݎͳሺܽǡ ܾሻ ൌ ȁሺி௟ೌ׫ி௟್ሻିሺி௟ೌתி௟್ሻȁȁி௟ೌתி௟್ȁ                              (3.1) 
where |•| stands for the size of a set, i.e., the number of set elements. It can be seen 
from the above equation (3.1) that the numerator is the number of unmatched 
functions among the neighbour functions of a and b, while the denominator is the 
number of matched functions among the neighbour functions a and b share. 
Therefore, the reliability of an interaction (a, b) is actually determined by the ratio 
of unmatched and matched functions among the neighbour functions of the target 
proteins a and b. The value of r1(a, b) is within the rangeሾͲǡ λሿ. The lower the r1 
value, the higher the reliability of the interaction. Figure 3.1 illustrates the 
calculation of r1 for an interaction (a, b).     
 
Figure 3.1: Illustration of calculating the semantic interaction reliability 1 (r1). r1(a,b) is 
the ratio of unmatched and matched functions among the neighbour functions of the target 
proteins a and b.        
  
Since the value of r1(a, b) is within the rangeሾͲǡλሿ, we define the normalised 
semantic interaction reliability 1, R1(a,b), as follows: 
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 ܴͳሺܽǡ ܾሻ ൌ ൝
௥ଵሺ௔ǡ௕ሻି௥ଵ೘೔೙
௥ଵ೘ೌೣି௥ଵ೘೔೙ ݂݅ݎͳሺܽǡ ܾሻ ് λ
ͳ݂݅ݎͳሺܽǡ ܾሻ ൌ λ
,         (3.2) 
where 
  ݎͳ௠௔௫ ൌ  ሼݎͳሺܽǡ ܾሻȁ ݎͳሺܽǡ ܾሻ ് λǡ ሺܽǡ ܾሻ݅ݏ݅݊ݐ݄݁݀ܽݐܽݏ݁ݐሽ, 
  ݎͳ௠௜௡ ൌ  ሼݎͳሺܽǡ ܾሻȁ ሺܽǡ ܾሻ݅ݏ݅݊ݐ݄݁݀ܽݐܽݏ݁ݐሽ. 
It can be seen the value of R1(a,b) is within the range [0,1]. 
3.2.2 Semantic Interaction Reliability 2 (R2) 
Different from R1, the Semantic Interaction Reliability 2 (R2) measures the 
reliability of an interaction by directly measuring the functional similarity of two 
target proteins. If two target proteins are functionally similar, their interaction is 
more reliable because the target proteins are more likely to be in the same functional 
complex and cooperate with each other in biological processes. Therefore, the R2 
is regarded as the internal reliability measure of an interaction.  
 To measure the interaction reliability from the functional similarity, we first 
define a similarity between two protein functions in terms of the FunCat annotation 
scheme. For any two protein functions f and g with FunCat annotations, we define 
their similarity, ௙ܵǡ௚, as: 
௙ܵǡ௚ ൌ 
݂݃
݂݃  
It can be seen that ௙ܵǡ௚ defines the weight of matched functional layers of two 
protein functions. For example, suppose function f = 10.01.05.03.01 and g = 
10.01.05, then the number of consecutive matched functional layers is 3, i.e., 
10.01.05, and the maximum number of functional layers is 5, therefore ௙ܵǡ௚= 
3/5=0.6.         
 Since a protein usually has various functions, we denote the set of functions 
of protein p as F(p). For a protein interaction (a, b) where a and b are two target 
proteins, the semantic interaction reliability 2 (r2) of the interaction is defined as: 
      ݎʹሺܽǡ ܾሻ ൌ ݉ܽݔ ቆσ ሺ
௚אிሺ௕ሻ ௙ܵǡ௚
ሻ௙אிሺ௔ሻ ǡ σ ሺ ௙אிሺ௔ሻ ௚ܵǡ௙௚אிሺ௕ሻ ሻቇ      (3.3) 
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The first element σ ሺ
௚אிሺ௕ሻ ௙ܵǡ௚
ሻ௙אிሺ௔ሻ  in equation (3.3) measures the functional 
similarity from target protein a, while the second element σ ሺ ௙אிሺ௔ሻ ௚ܵǡ௙௚אிሺ௕ሻ ሻ 
measures the functional similarity from target protein b. It can be seen from 
equation (3.3) that the value of r2(a, b) is within the rangeሾͲǡ λሻ. With this measure 
(3.3), the higher the r2 value, the higher the reliability of the interaction. Similar to 
r1, we define the normalised semantic interaction reliability 2, R2(a,b), as follows:  
                 ܴʹሺܽǡ ܾሻ ൌ ௥ଶሺ௔ǡ௕ሻି௥ଶ೘೔೙௥ଶ೘ೌೣି௥ଶ೘೔೙  ,        (3.4) 
where 
  ݎʹ௠௔௫ ൌ  ሼݎʹሺܽǡ ܾሻȁ ሺܽǡ ܾሻ݅ݏ݅݊ݐ݄݁݀ܽݐܽݏ݁ݐሽ, 
  ݎʹ௠௜௡ ൌ  ሼݎʹሺܽǡ ܾሻȁ ሺܽǡ ܾሻ݅ݏ݅݊ݐ݄݁݀ܽݐܽݏ݁ݐሽ.  
The value of R2(a,b) is within the range [0,1]. 
The calculation of the R2 value is based on the condition that the functions of two 
target proteins a and b are known. If one of the target proteins (a or b) or both target 
proteins (a and b) are unannotated (i.e., their functions are unknown), we adopt the 
commonly used neighbour counting method [180] to assign functions to the target 
protein(s). With this method, functions that occur most frequently in the neighbours 
of the target protein are assigned to the target protein as its functions. 
3.2.3 Semantic Reliability (SR) Method 
Based on the semantic interaction reliability measures R1 and R2, which 
respectively measure the reliability of a protein interaction externally and 
internally, our semantic reliability method combines these two reliability measures 
to assess the overall reliability of an interaction, and in turn, to remove unreliable 
interactions from the interaction dataset.     
 For an interaction (a, b), we define its combined reliability CR(a,b) as the 
logarithmic ratio of R2 and R1. This combined reliability is used to measure the 
overall reliability of an interaction. Since the values of R1 and R2 vary in different 
cases, the calculation of the CR(a,b) varies accordingly. Table 3.1 provides details 
for calculating the CR(a,b) values, where the min values are across the whole 
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interaction dataset and the intersections of R1 and R2 value columns provide the 
formulas for calculating CR(a, b) values. Our experimental observation shows that 
the values of R1 and R2 for an interaction are independent. Therefore, the value of 
CR for an interaction is not overestimated.     
 With Table 3.1, each interaction in an interaction dataset is assigned a CR 
value. Since proteins implement their functions by locally interacting with their 
neighbour proteins, the reliability of an interaction should be assessed locally. To 
do this, we define the average combined reliability of protein a,ܣܴ௔, as 
                                              ܣܴ௔ ൌ σ ஼ோሺ௔ǡ௕ሻ್אಿೌȁேೌȁ                                               (3.5) 
whereȁ ௔ܰȁ stands for the number of neighbour proteins of protein a. Whether an 
interaction (a, b) is reliable or not is determined as follows: 
If ܥܴሺܽǡ ܾሻ ൒ ܣܴ௔ or ܥܴሺܽǡ ܾሻ ൒ ܣܴ௕ 
then the interaction (a,b) is reliable; 
else 
the interaction (a,b) is unreliable. 
If an interaction in a dataset is identified as unreliable, it is removed / filtered from 
the dataset. Figure 3.2 and Figure 3.3 show part of an original protein interaction 
dataset and the filtered dataset respectively. 
Table 3.1: Calculations for the Combined Reliability (CR) of an interaction for different 
R1 and R2 values. 
  
R1                            R2 
 
0 (0, 1] 
0 ݈݊ ൭
ோଶஷ଴ ܴʹ
ோଵஷ଴ ܴͳ
൱ ݈݊ ቆ
ோଶஷ଴ ܴʹ
ܴͳ ቇ 
(0,1] ݈݊ ൭ ܴʹோଵஷ଴ ܴͳ
൱ ݈݊ ൬ܴʹܴͳ൰ 
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Figure 3.2: Part of an original protein interaction network. The network has two core 
proteins YOL006c and YDL042c (highlighted in thick red circles). The R1 and R2 values 
of each interaction are marked in the format (R1, R2). The interactions with R1 and R2 
values in thin oval-circles are reliable according to our method.   
  
 
Figure 3.3: The filtered interaction network of Figure 3.2. The identified and unreliable 
(false-positive) interactions in the original interaction network have been removed.  
 
3.3 Results 
We conducted experiments on real protein interaction datasets of yeast 
Saccharomyces cerevisiae to evaluate the effectiveness of the proposed semantic 
reliability assessment method SR. To this end, we took an indirect way, i.e., we 
used the reliability of the knowledge inferred from the generated reliable datasets 
to assess the effectiveness of the reliability assessment method. In detail, we applied 
our method SR and other representative reliability assessment methods to an 
original protein interaction dataset. Each method generated a new reliable protein 
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interaction dataset. We then chose some representative methods of protein function 
prediction, and used each prediction method to predict protein functions (inferred 
knowledge) from each generated reliable protein interaction dataset. If all or almost 
all prediction methods receive the higher function prediction precision, recall and 
F-value from a generated reliable dataset, then the reliability assessment method 
that generated this reliable dataset is more effective. The idea behind this evaluation 
approach was that existing protein function prediction methods that exploit protein 
interaction data to predict protein functions were based on an assumption that 
available protein interactions were reliable. Therefore, if a protein function 
prediction method can achieve the higher prediction precision, recall and F-value 
from a protein interaction dataset, it means this dataset contains more reliable 
interactions. Accordingly, the reliable assessment method that generates this dataset 
is more effective.        
 The protein interaction dataset of yeast Saccharomyces cerevisiae was used 
for evaluations due to the easy availability and increased coverage of interactions 
in a dataset and was obtained from the BioGrid site (http://thebiogrid.org/). The 
dataset contained 66,174 interactions among 26,439 proteins. Since the reliability 
assessment in our method was based on local interaction information of proteins 
(see Section 3.2), and in order to evaluate that the effectiveness of our method was 
not biased to any specific datasets and dataset sizes, we constructed two different 
datasets with different sizes by randomly selecting some proteins with the 
interactions among them from the original interaction dataset. One dataset (named 
Dataset-1) contained 889 interactions among 196 proteins; another (named Dataset-
2) contained 1060 interactions among 536 proteins.    
 We compared our SR method with representative reliability assessment 
methods IG2 (Interaction Generality 2 [176]), PVM (Paralogous Verification 
Method [51]) and IRAP (Interaction Reliability by Alternative Path [38]). The 
protein function prediction methods we used in the evaluation were the PClustering 
[173], PRODISTIN [29] and the MCL-Approach [66]. The PClustering method 
predicts functions by clustering proteins progressively, the PRODISTIN method 
assigns a weight to each interaction when predicting functions, while the MCL-
Approach predicts functions by simulating the stochastic information flow in a 
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network. Therefore, these prediction methods represent three different kinds of 
prediction approaches. The performance of a function prediction method was 
measured by the precision, recall and F-value. Let ௉ܶ be the total number of 
predicted protein functions of an annotated protein, ோܶ be the total number of 
functions an annotated protein really has, and ஼ܶ be the total number of accurately 
predicted functions of an annotated protein. The precision, recall and F-value of a 
prediction are then defined as follows: 
ܲݎ݁ܿ݅ݏ݅݋݊ ൌ ்಴்ು ,      ܴ݈݈݁ܿܽ ൌ
்಴
்ೃ, ܨ െ ݒ݈ܽݑ݁ ൌ
ଶൈሺ௉௥௘௖௜௦௜௢௡ൈோ௘௖௔௟௟ሻ
ሺ௉௥௘௖௜௦௜௢௡ାோ௘௖௔௟௟ሻ . 
The F-value is the harmonic mean of precision and recall, which measures the 
overall performance of a prediction.      
 Following our evaluation approach, we applied the SR, IG2, PVM and 
IRAP reliability assessment methods to the original protein interaction datasets 
Dataset-1 and Dataset-2, and generated two new reliable Dataset-1 and Dataset-2 
for each method. Therefore, there were eight reliable datasets generated. For 
simplicity, we used the reliability assessment method name to represent the new 
reliable dataset generated by the method.     
 We then applied the protein function prediction methods PClustering, 
PRODISTIN, and MCL to eight new reliable datasets generated by four reliable 
assessment methods from the original Dataset-1 and Dataset-2 respectively, and 
compared the prediction performance on these generated reliable datasets. The 
comparison results are presented in Figure 3.4 and Figure 3.5, respectively. Figure 
3.4 shows the prediction performance (in terms of precision, recall and F-value) of 
three prediction methods on four new reliable datasets generated from Dataset-1, 
while Figure 3.5 shows the prediction performance of three prediction methods on 
four new reliable datasets generated from Dataset-2. It can be seen from Figure 3.4 
and Figure 3.5 that all prediction methods achieved higher precisions, recalls and 
F-values on the reliable datasets generated by the SR method. Table 3.2 provides 
detailed average F-values of three prediction methods on all new reliable datasets 
generated by the SR, IRAP, IG2 and PVM reliability assessment methods. The 
results in the table show that the reliable datasets generated by the SR method 
enabled all prediction methods to achieve higher F-values.    
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Figure 3.4: Performance of the function prediction methods PClustering, PRODISTIN and 
MCL on new reliable datasets generated by the SR, IG2, PVM and IRAP methods 
respectively from Dataset-1.       
    
 
Figure 3.5: Performance of the function prediction methods PClustering, PRODISTIN and 
MCL on new reliable datasets generated by the SR, IG2, PVM and IRAP methods 
respectively from Dataset-2.       
   
Table 3.2: Average F-values for the prediction methods PClustering, PRODISTIN and 
MCL on generated reliable datasets. 
Reliability 
Methods 
 
 
 
PClustering PRODISTIN MCL 
Average F-Value 
 
Overall  
Average 
F-Value 
 
Average F-Value 
 
Overall  
Average 
F-Value 
 
Average F-Value 
 
Overall  
Average 
F-Value 
   
Dataset-
1 
   
Dataset-
2 
   
Dataset-
1 
   
Dataset-
2 
   
Dataset-
1 
   
Dataset-
2 
SR 0.580 0.903 0.740 0.540 0.825 0.680 0.550 0.897 0.720 
IRAP 0.520 0.740 0.605 0.430 0.660 0.560 0.510 0.560 0.475 
IG2 0.470 0.790 0.585 0.460 0.775 0.610 0.390 0.460 0.390 
PVM 0.380 0.760 0.640 0.450 0.730 0.580 0.320 0.490 0.500 
0
0.2
0.4
0.6
0.8
1
SR IG2 PVM IRAP SR IG2 PVM IRAP SR IG2 PVM IRAP
PClustering                    PRODISTIN                       MCL
Precision
Recall
F-Value
0
0.2
0.4
0.6
0.8
1
SR IG2 PVM IRAP SR IG2 PVM IRAP SR IG2 PVM IRAP
PClustering                           PRODISTIN                        MCL
Precision
Recall
F-Value
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To demonstrate the effectiveness of our method from another angle, we conducted 
other experiments to compare our predicted interactions with the interactions in the 
MINT database [35], within which each protein interaction has a reliability MINT 
score. The higher score an interaction has, the more reliable the interaction is.
 We applied our method SR and other reliable prediction methods (i.e., IG2, 
PVM and IRAP) to our experimental Dataset-1 and Dataset-2, and observed the 
MINT scores of the predicted interactions for each method. Since the situation for 
Dataset-2 is quite similar to that for Dataset-1, we only present the results for 
Dataset-1 in Table 3.3. 
Table 3.3: MINT scores of reliable datasets generated by SR, IG2, PVM and IRAP, and 
the percentages of reliable/unreliable interactions in the datasets that match/do not match 
the reliable interactions in the MINT dataset. 
  
Dataset-1 
Reliable Interactions Unreliable Interactions 
SR IG2 PVM IRAP SR IG2 PVM IRAP 
Min. 0.171 0.276 0.171 0.171 0.171 0.171 0.171 0.322 0.171 
Max. 0.857 0.857 0.857 0.857 0.857 0.678 0.851 0.322 0.851 
Avg. 0.438 0.550 0.493 0.438 0.450 0.326 0.328 0.322 0.408 
Match 
Int. 
24.2% 42% 20.5% 31.8% 18.8% 17% 25.8% 0.05% 36.6% 
                  
Here, the method name (e.g., SR) stands for the reliable dataset generated by the 
method. Min. Max. and Avg. denote the minimum, maximum and average MINT 
scores respectively in the corresponding dataset, and Match Int. denotes the 
percentage of interactions in the corresponding dataset that match the interactions 
in the MINT dataset. From the above comparison results, it can be seen that our SR 
method significantly increased the percentage of reliable interactions in the 
generated dataset (i.e., from 24.2% to 42%), while the average MINT score (0.55) 
of the SR generated dataset is higher than the average scores of other datasets 
generated by other methods. For the interactions considered reliable, the higher the 
average MINT score, the better the performance of the reliable interaction 
prediction method. On the other hand, the interactions considered unreliable by our 
SR algorithm have a lower average MINT score (0.326) than the average scores of 
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IG2 (0.328) and IRAP (0.408), and have nearly the same average score as that of 
PVM (0.322). For the interactions considered unreliable, the lower the average 
MINT score, the better the performance of the reliable interaction prediction 
method. The results in Table 3.3 demonstrate that our method SR outperformed 
other methods in terms of effectively selecting reliable interactions and removing 
unreliable interactions.        
 Next, we performed experiments to evaluate the robustness of our method. 
Our experiments were based on Dataset-1, as the experimental results on Dataset-
2 were similar. First, we randomly removed proteins with their corresponding 
interactions at different percentages from Dataset-1 to obtain some sub-datasets of 
Dataset-1, applied our SR method to these sub-datasets, and then checked whether 
the selected reliable interactions from these sub-datasets were the same or almost 
the same as those selected directly from the original Dataset-1. Specifically, we 
checked the selected reliable interactions in terms of True Positive (TP), True 
Negative (TN), False Positive (FP) and False Negative (FN). The results are 
presented in Table 3.4. In this table, the Accuracy (ACC) means the percentage of 
interactions selected from a sub-dataset of Dataset-1 that match the interactions 
selected directly from the original Dataset-1.  
Table 3.4: Robustness experiment results by removing proteins and their interactions at 
different percentages from the original Dataset-1. 
Proteins 
Removed 
Corresponding 
interactions 
removed 
        
TP 
       
TN 
       
FP 
       
FN 
       
P 
       
R 
       
F 
        
ACC 
10% 16% 129 465 0 0 1 1 1 1 
20% 25.20% 114 416 0 0 1 1 1 1 
30% 28% 114 402 0 0 1 1 1 1 
45% 38% 76 367 0 1 1 0.987 0.993 0.997 
65% 76% 45 118 5 4 0.900 0.918 0.908 0.947 
85% 88.60% 42 27 6 5 0.875 0.894 0.884 0.862 
95% 97.70% 5 2 1 7 0.833 0.417 0.556 0.467 
     Note: P stands for Precision, R stands for Recall, and F stands for F-value.  
    
The results in Table 3.4 show that our algorithm was highly robust even if more 
than 50% of proteins and their interactions were removed from the original dataset. 
 Furthermore, we evaluated the robustness of our method by shuffling the 
edges and protein labels in Dataset-1, and applying our SR method to this shuffled 
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dataset to obtain a dataset containing reliable interactions. We named this obtained 
dataset ShuffledSR and the dataset UnshuffledSR which contained reliable 
interactions directly selected by the SR method from the original Dataset-1.  We 
then applied the function prediction methods (i.e., PClustering, PRODISTIN and 
MCL) to both datasets and observed the prediction performance in terms of 
precision, recall and F-value. The comparison results of function prediction 
performance on these two datasets are provided in Table 3.5.         
 It can be seen from Table 3.5 that the function prediction performance of 
all three methods on the ShuffledSR dataset is poor compared with the performance 
on the UnshuffledSR dataset. This comparison demonstrated the robustness of our 
SR method. 
Table 3.5: Comparison results of function prediction performance of the methods 
PClustering, PRODISTIN and MCL on the UnshuffledSR and ShuffledSR datasets. 
Reliable 
Dataset 
PClustering PRODISTIN MCL 
P R F P R F P R F 
UnshuffledSR 0.940 0.910 0.903 0.830 0.820 0.825 0.930 0.890 0.897 
ShuffledSR 0.750 0.547 0.620 0.438 0.401 0.397 0.470 0.460 0.427 
     Note: P stands for Precision, R stands for Recall, and F stands for F-value.  
   
To further demonstrate the effectiveness of our proposed reliability algorithm, we 
also conducted 10-fold cross-validation (CV) experiments on the original entire PPI 
dataset that contains approximately 66,000 protein interactions. We performed 10 
times/runs of 10-fold CV experiment on the original entire dataset by applying 
protein function prediction methods PClustering, PRODISTIN and MCL to the 
reliable datasets generated by the SR, IRAP, IG2 and PVM methods. The 
performance was evaluated in terms of the average F-value of the prediction 
methods. Figure 3.6 shows the average F-value results of 100 datasets (i.e., 10 X 
10 = 100 datasets) for three different function prediction methods on the generated 
reliable datasets (represented by the reliability method names). The results show 
that even for the original entire dataset, the prediction methods achieved higher F-
values on the reliable datasets generated by our SR method. The experiments 
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further demonstrated that our proposed reliability algorithm outperforms other 
reliability algorithms in terms of being able to identify more reliable protein 
interactions.  
 
Figure 3.6: Average F-values of the function prediction methods PClustering, PRODISTIN 
and MCL from 10 times of 10-fold cross-validation on the reliable datasets generated by 
the SR, IG2, PVM and IRAP methods from the original entire PPI dataset that contains 
approximately 66,000 protein interactions. 
We also closely observed the reliability assessment performance of the evaluated 
methods. The observation intended to check whether the rate of unmatched 
functions between a chosen protein and its neighbours decreased after the 
unreliable interactions were removed. If the rate decreased after the unreliable 
interactions were removed by a reliability assessment method, the method was 
effective in generating reliable datasets. The rationale was that proteins involved in 
reliable interactions should have more common / matched functions. We randomly 
selected two proteins, “YBR154C” and “YDR045c” from Dataset-1, as well as 
their neighbour proteins to observe. The results are displayed in Figures 3.7 and 
3.8, respectively. It can be seen, compared to other reliability assessment methods, 
the SR method significantly decreased the rate of unmatched functions between a 
protein and its neighbours, and increased the rate of matched functions. For 
instance, regarding protein “YBR154C”, the rate of unmatched functions decreased 
from the original 46% to 23% when the SR method was used, while the rate 
decreased from 46% to 41% when the PVM method was used.  
 The evaluation results demonstrated that our reliability assessment method 
SR identified reliable interactions more effectively than other representative 
methods.  
0
0.2
0.4
0.6
0.8
PClustering PRODISTIN MCL
SR
IG2
PVM
IRAP
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Figure 3.7: Matched and unmatched function rates (in percentage) between protein 
“YRB154C” and its neighbour proteins, before and after the unreliable interactions were 
removed by different methods. (A) The original rates before unreliable interactions were 
removed. (B) The rates after the unreliable interactions were removed by the SR method. 
(C) The rates after the unreliable interactions were removed by the IG2 method. (D) The 
rates after the unreliable interactions were removed by the PVM method. (E) The rates 
after the unreliable interactions were removed by the IRAP method. The results show the 
SR method removed more unmatched functions. 
 
Figure 3.8: Matched and unmatched function rates (in percentage) between protein 
“YDR045c” and its neighbour proteins, before and after the unreliable interactions were 
removed by different methods. The results show the SR method removed more unmatched 
functions.       
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Finally, in Table 3.6 we provide an overview of the SR based reliable and unreliable 
interactions in Dataset-1 in terms of percentage, functional characteristics of the 
interactions and experimental evidence.  
Table 3.6: Overview of the SR based reliable and unreliable interactions in Dataset-1. 
 Reliable interactions identified by SR Unreliable interactions identified by SR 
Percentage of 
interactions  
23.4 75.6 
Most common 
cellular 
functions 
(percentage) 
 
Nucleus (98.44), 
Cytoplasm (26.56), 
DNA-directed RNA III complex (25.00), 
Nucleolus (18.50), 
DNA-directed RNA I complex (14.94), 
Chromosome telomeric region (10.38), 
Nucleus (97.87), 
Cytoplasm (24.47), 
DNA-directed RNA III complex (18.51), 
Nucleolus (32.98), 
DNA-directed RNA I complex (7.45), 
Chromosome telomeric region (7.45) 
Experimental 
evidences 
(percentage) 
Affinity Capture-MS (85.5) ,                       
Affinity Capture-Western (7.5),                  
Dosage Rescue (7) 
Affinity Capture-MS (70),                            
Affinity Capture-Western (7),                       
Two-hybrid (5) 
                       
The overview shows that our SR algorithm identified unreliable interactions with a 
high percentage (75.6%), and the identified reliable and unreliable interactions did 
not depend on any specific cellular functions or any specific experimental 
evidences.         
  
3.4 Summary 
In this chapter, we propose a novel method that exploits the semantic relationship 
between protein functions to assess the reliability of protein interactions. For a 
protein interaction, this method combines the external (R1) and internal (R2) 
reliabilities of the interaction to assess the overall reliability of the interaction. The 
criterion for selecting reliable interactions was also proposed. The evaluations on 
real protein interaction datasets demonstrate the effectiveness of the proposed 
reliability assessment method SR when compared with existing representative 
reliability assessment methods.      
 In the reliability assessment measures R1 and R2 (i.e., equations (3.2) and 
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(3.4)), we take different approaches to exploit functional information to measure 
the reliability. In R1, the method requires functions to be exactly the same when 
checking whether the functions are shared by the neighbour proteins, while in R2, 
the method does not require the functions of two target proteins to be exactly the 
same, but does require the functions to be matched at certain functional levels. This 
is because in R1, before the interactions are assessed, some proteins may not be the 
real neighbours of the target protein. Therefore, we apply a stricter criterion, i.e., 
functions must be matched exactly when checking whether functions are shared by 
neighbours, so the impact of noisy neighbour proteins on the reliability 
measurement can be reduced. However, for two target proteins in the R2 measure, 
we examined at what functional levels the functions of these two proteins exactly 
match, even if the functions were not exactly the same. This approach means the 
R2 measure is more objective and reasonable because the interacting proteins are 
more likely to be in a functional category even though their functions are not 
exactly the same [41]. Therefore, combining the R1 and R2 reliability measures 
into the SR method more objectively reflects the real situations of original protein 
interaction datasets.        
 The proposed reliability assessment method can be used to generate reliable 
interactions for the protein interaction dataset of any organism species. The reliable 
interactions can be incorporated with microrarray gene expression datasets to 
extract highly accurate gene signatures for cancer diagnosis, prognosis, treatment 
prediction or various other tasks. This is an interesting area to investigate and in the 
next chapter we implement this idea to diagnose the breast cancer subclasses using 
integrated gene expression and reliable interaction data. 
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Chapter 4  
 
Diagnosis of Estrogen Receptor 
based Breast Cancer Subtypes 
 
4.1 Introduction 
The diagnosis of cancer is seen as one of the most significant research areas in the 
bioinformatics field. Traditionally, cancer classification was solely based on 
clinical evidence and required pathological expertise for biological interpretation. 
A major challenge in clinical cancer research is the accurate classification of 
cancers for improving treatment. With the rapid development of high-throughput 
technologies, researchers and biologists have generated a massive amount of data 
at different levels, such as gene expression profiles using microarrays [76], protein-
protein interactions (PPI) [105, 205], gene ontology (GO) terms [11], and pathways 
[114]. These biological data make it possible for biologists and researchers to find 
solutions to various biological questions of interest, such as the diagnosis of breast 
cancer by identifying cancer-associated genes.     
 Due to the increasing use of microarray technology that obtains the 
expression levels of all genes simultaneously, a set of gene expression markers 
(also known as gene signatures) can be used to diagnose breast cancer in a 
comprehensive manner [74]. However, existing gene signatures do show variable 
performances across datasets which makes the classification results unstable [75]. 
Due to the heterogeneous nature of existing gene signatures, many patients have 
been classified into the wrong breast cancer subtype and treated with unnecessary 
adjuvant therapy (chemo or radiation therapy). To solve this problem, various 
microarray data based breast cancer classification methods have been proposed that 
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use statistical and machine-learning methods for the molecular classification of 
breast cancer [47, 75, 89, 192, 206, 216]. It was observed that gene signatures 
generated in these studies were not robust and were heavily depended on the chosen 
training set [144]. In order to derive the gene signatures from the microarray data, 
and to accurately uncover the molecular forms of breast cancer, plus use the gene 
signatures for various clinical purposes, the robustness and biological meaning of 
gene signatures are equally essential [75].    
 Chuang et al. [42] indicates that a disease like cancer originates from the 
driver genes that progressively change the expressions of greater amplitude in 
genes that participate (or interact) with the driver gene (also called mutations). For 
the classification of breast cancer, it is therefore good to incorporate the gene 
network based approach for the following reasons:  
(1) The gene networks provide models of the molecular mechanisms 
underlying breast cancer, 
(2) The detected subnetworks from a gene network are comparatively more 
reproducible across different breast cancer cohorts than traditional 
individual genes selected without consideration of network related 
information, and  
(3) The gene network based approach achieves higher accuracy in 
classifying breast cancer subtypes [42].  
Various network based approaches have been proposed for microarray data 
analysis. Gill et al. [78] constructed condition-dependent networks from differential 
gene expression with no prior interaction information used (such as PPI or gene 
regulatory information), which limited the biological validation of their results 
[75]. Chuang et al. [42] proposed the network based approach that detects 
differentially expressed subnetworks from the existing PPI data by making use of 
the local subnetworks aggregation. A network based algorithm (ITI) has been 
proposed by Garcia et al. [75] that identified the subnetwork based gene signatures 
generalizable over multiple and heterogeneous microarray datasets by making use 
of the PPI data incorporated with the gene expression datasets.  
 These existing network based approaches address the biological question of 
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interest to some extent. However, these approaches have some issues associated 
with them, for example: 
(1)  The classifier performance is largely affected by the dataset size [75], 
(2) The curse of dimensionality issue (too few samples (in the order of 
hundreds) for too many genes (in the order of tens of thousands)) (see Table 
2.2) is not considered carefully and still needs to be resolved [75], and most 
importantly,     
(3) Existing PPI datasets, such as DIP [222] and HPRD [160], contain many 
false-positive interactions (i.e., interactions identified by experiments but 
never actually occurring) [51]. Therefore, existing approaches that use PPI 
datasets in discovering knowledge or biological facts (such as breast cancer 
classification, distant metastasis prediction) may be distorted or biased.   
As discussed in Chapter 3, the identification and the extraction of reliable protein 
interactions from the original experimental PPI datasets is becoming one of the 
most significant and challenging tasks when using PPI data for biological analyses. 
Therefore, to resolve the above issues when classifying cancers, it is essential to 
develop a novel network based breast cancer classifier which maximises the 
reliable information for the interactions in the network, and is able to provide the 
optimal classification performance across datasets.    
 In this chapter, we propose a novel subnetwork based breast cancer 
classification approach to distinguish two subtypes of breast cancer, i.e., ER+ and 
ER-. To increase the sample size of the study and to lessen the dependence on a 
single training set, we integrated multiple datasets. We used six training gene 
expression sets on the basis of the histologic grade and the estrogen receptor status 
in order to derive the subnetwork based gene signatures, and we also used two 
testing gene expression sets for evaluating the performance of gene signatures. We 
propose a statistical model to determine the reliability weights, which are then 
incorporated with the gene expressions to form reliable gene expressions. The 
reliable gene expressions then extract the subnetworks (isolated networks) and the 
associated hub genes (a gene that has a maximum number of interactions in a 
subnetwork) for the gene signature construction that can be used for the ER+/ER- 
breast cancer classification paradigm. We call our algorithm the robust reliability 
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based hub gene expression (RRHGE) algorithm. The evaluation of our approach 
and the experimental comparisons with existing approaches demonstrated that 
RRHGE significantly increased the classification performance. Further, in addition 
to the statistical evaluations, thorough biological evaluations were also conducted 
to show the effectiveness and stability of the proposed algorithm.  
 The remaining chapter is structured as follows. The training and testing sets 
used in this study are defined in Section 4.2. The proposed RRHGE algorithm is 
defined in Section 4.3. Statistical validation with patient classification results and 
biological validation are presented in Section 4.4. Finally, we conclude this chapter 
in Section 4.5.         
  
4.2 Materials 
We downloaded six PPI datasets (BIOGRID, INTACT, MINT, DIP, BIND, and 
HPRD) and five breast cancer microarray gene expression datasets (GSE7390, 
GSE6532, GSE21653, GSE11121, and van de Vijver), and mapped the proteins to 
the genes in the microarray gene expression dataset to construct the gene interaction 
network. We integrated four of the microarray gene expression datasets, namely 
GSE7390, GSE6532, GSE21653, and GSE11121 to increase the dataset size, while 
the fifth microarray dataset, namely van de Vijver was used as an independent 
testing dataset. Six training sets were then generated from the integrated dataset for 
the extraction of the subnetwork based gene signatures, which is a set of genes that 
show stability not only on a specific dataset but across multiple datasets that have 
distinct platforms. Two testing sets (the Desmedt (GSE7390) [55] and van de 
Vijver [206]) were also used for evaluating the algorithm’s performance. The 
details are presented in the following sub-sections.      
4.2.1 Breast Cancer Gene Expression Datasets 
We used five publicly available breast cancer microarray gene expression datasets, 
by considered the following factors in the dataset, i.e., estrogen receptor status 
(ER+ and ER-), histologic grade (Grade 1, Grade 2, Grade 3), overall survival (OS), 
and distant metastasis free survival (DMFS). In our study, 703 ER+ samples and 
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255 ER- samples were used for experimental analysis (selected on the basis of 
availability of the above criterion), with a total of 958 samples. The detailed 
information regarding the size of the samples is shown in Table 4.1.  
Table 4.1: Microarray datasets used in this study. 
  
*Desmedt [55] 
(GSE7390) ж 
 
 
van de           
Vijver [206]ж 
 
*Loi  [133]  
(GSE6532) 
 
*Sabatier 
[171] 
(GSE21653) 
 
*Schmidt 
[178] 
(GSE11121) 
 
Platform 
 
HG-U133A 
 
Agilent Human 
Genome 
 
HG-U133A,     
HG-U133B 
 
HG-
U133Plus2.0 
 
HG-U133A 
 
Samples 
 
198 
 
295 
 
327 
 
255 
 
200 
 
ER 
    ER+ (# of samples) 
    ER- (# of samples) 
 
 
134 
64 
 
 
226 
69 
 
 
263 
45 
 
 
150 
102 
 
 
156 
44 
 
Tumor Grade 
    Grade 1 (# of samples) 
    Grade 2 (# of samples) 
    Grade 3 (# of samples) 
 
 
30 
83 
83 
 
 
- 
- 
- 
 
 
52 
158 
57 
 
 
44 
88 
116 
 
 
29 
136 
35 
 
Metastasis Free Survival 
   Yes (# of samples) 
   No  (# of samples) 
 
 
62 
136 
 
 
101 
194 
 
 
 
70 
224 
 
 
81 
160 
 
 
46 
154 
Age (in Years) 
<=40  (# of samples) 
41-70 (# of samples) 
>70    (# of samples) 
Average (in Years) 
 
42 
156 
0 
46 
 
- 
- 
- 
- 
 
19 
241 
55 
59 
 
49 
171 
34 
54 
 
- 
- 
- 
- 
 
 
Total Samples  
 
1253 ( 929 (ER+) and 324 (ER-) ) 
 
  
Total Samples Selected in 
our Study                                 
(On the basis of histologic 
grade and receptor status) 
 
958 (703 (ER+) and 255 (ER-) ) 
 
Patients with missing histologic grade and estrogen receptor status based information are excluded 
from the training sets. * represents the datasets used in our training sets, ж denotes the testing sets. 
           
The normalised microarray gene expression datasets (݈݋݃ଶintensity for single-
channel platforms or ݈݋݃ଶratio in dual channel platforms) were downloaded as 
published by the original studies from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) [18]. The probe expressions 
of the cohorts were then converted to gene expressions as indicated by [169]. When 
multiple probes mapped the same gene, the mean of the probes was considered. 
The probes that began with “AFFX” were deleted, as there were no associated 
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genes for these probes. The training and validation cohorts were processed 
separately to ensure the independency of the validation cohorts.    
 The study by Sun et al. [196] indicated larger-scale computational studies 
with more patient samples are required to best perform the classification given all 
the available information. To achieve this goal, the training cohorts were integrated 
by performing the following steps. First, the samples with missing gene expressions 
were deleted to remove any bias associated with them. Next, for any dataset d, gene 
expression values were normalised between 0 to 1 by using equation (4.1).  
Ƹ݁௜ሺ௚ሻ ൌ 
௘೔
ሺ೒ሻି௘ౣ౟౤ሺ೒ሻ
௘ౣ౗౮ሺ೒ሻି௘ౣ౟౤ሺ೒ሻ                 (4.1) 
where, ݁௜ሺ௚ሻ expresses the ݃୲୦ feature gene expression value for the ith sample, and  
݁୫୧୬ሺ௚ሻ and ݁୫ୟ୶ሺ௚ሻ represents the ݃୲୦ feature minimum and maximum gene 
expression value [196]. This normalisation mapped the gene expression values 
generated from different protocols into a uniform framework so the impact of the 
different protocols on the data integration could be reduced. Compared with the 
original data, the normalised gene expressions did not show any significant 
differences among study objects.  
Further, a common list of genes from the distinct microarray platforms was 
extracted by cross-referencing each probe annotation in the microarray dataset, 
which consisted of 9,717 genes. The cross-referencing of microarray gene 
expression data was done by the UniGene database [218]. The training cohorts were 
then directly integrated. This enabled the gene signature to be independent of 
microarray datasets or their platform types.    
4.2.2 Transformation of PPI datasets 
We incorporated six PPI datasets into our study, namely Biological General 
Repository for Interaction Datasets (BIOGRID) [194], INTACT [119], The 
Molecular Interaction Database (MINT) [129], Database of Interacting Proteins 
(DIP) [222], The Biomolecular Interaction Network Database (BIND) [14], and the 
Human Protein Reference Database (HPRD) [160]. The genes in the microarray 
dataset were then used to construct the gene interaction network from these PPI 
datasets using the Universal Protein Resource Database [203]. The self-interactions 
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and the duplicate edges within the constructed gene interaction network were 
removed as they did not have any significant meaning in terms of interaction with 
other genes. The resulting gene interaction network from the above mentioned six 
PPI datasets contains 13,012 unique genes with 69,914 unique interactions among 
them. All the protein interaction datasets were downloaded on April 19, 2013.  
 The PPI datasets contain a large number of protein interactions and are 
considered a rich information source from which biological knowledge and facts 
can be discovered, such as classifying ER+/ER- breast cancer subclasses or 
classifying patients according to their treatment outcome. However, as discussed in 
the previous chapter, the identification and extraction of reliable protein 
interactions from the original published protein interaction datasets is considered 
an important yet challenging issue (see Section 3.1 for details). With this attention, 
the quality of the protein interaction datasets can significantly improve, and as a 
result strengthen the confidence of the discovered biological knowledge and facts. 
Since gene interaction networks are constructed from PPI networks, we combine 
three distinct reliability metrics to form a weighted reliability metric (μ) to measure 
the reliability of gene interactions. In this chapter, the details are presented in 
Section 4.3.1.  
4.2.3 Training and Testing sets 
To resolve the ‘curse of dimensionality issue’, we used five breast cancer gene 
expression datasets across four unique platforms in order to increase the sample 
size and also to balance the other factors mentioned in Table 4.1. The integrated 
dataset was constructed by merging four microarray datasets, namely GSE7390, 
GSE6532, GSE21653, and GSE11121, which contained 958 samples. Six training 
sets were then constructed from the integrated dataset by initially dividing the 
integrated dataset on the basis of estrogen receptor status, i.e., ER+ and ER-. Then, 
we divided the ER+ and ER- set on the basis of histologic grade, i.e., Grade 1, 
Grade 2, and Grade 3, which led to three training sets for each estrogen receptor 
status. Thereby, generating six training sets that were used for deriving the estrogen 
receptor based gene signatures.     
 Sotiriou et al. [192] observed that breast cancer datasets based on histologic 
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grades had distinct gene expression profiles. In our study, the generation of six 
training sets on the basis of estrogen receptor status and the histologic grade 
reduced the bias in the dataset and increased the correlation of gene expressions 
within them. The six training sets used in our algorithm constructed effective gene 
signatures for two estrogen receptor subtypes of breast cancer, as presented in 
Section 4.3. The subnetwork based gene signatures generated from the training sets 
were then tested on two testing sets (the Desmedt dataset and the van de Vijver 
dataset). The results are presented in Section 4.4.     
   
4.3 Algorithm 
Our main focus was to extract the gene subnetworks that showed highly correlated 
gene expressions with the estrogen receptor status. For this, the reliable gene 
expression metric was established to target real gene interactions that occur in 
biological processes and which are related to ER+/ER- breast cancers. By using the 
generated reliable gene expressions, the subnetwork based gene signatures were 
extracted which can classify ER+/ER- breast cancer patients. All the statistical 
validation was performed using R Statistical Toolbox [163]. Details of our 
algorithm are presented in the following sub-sections.  
4.3.1 Reliability Metrics 
For an interaction between any two genes, we combined three reliability measures 
to assess reliability in terms of three distinct factors, i.e, Data Sources (e.g., HPRD), 
Experimental Methods (e.g., two hybrid), and Level-based Interaction Partners 
(e.g., level-2 interaction partners of a gene). The corresponding reliability measures 
are namedܴଵǡ ܴଶand ܴଷ (data sources, experimental methods and interaction 
partners, respectively). These reliability measures are defined below. 
Data Source Based Reliability (܀૚): Our first reliability measure is concerned 
with data sources that contain protein-protein interactions and from which protein 
interactions are mapped to the interaction of genes. In our study, we considered 
data sources, such as those defined in Section 4.2.2. The basic aim of ܴଵ is to 
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evaluate the weight of gene interactions across data sources. For an interaction y 
between any two genes (a, b), ܴଵ is calculated by counting the number of data 
sources that contain y, i.e,      
                                       ܴଵሺ௬ሻ ൌ σ ܦ௡ሺ௬ሻௌ௡ୀଵ                     (4.2) 
where,ܦ௡ሺ௬ሻ ൌ  ൜ͳǡ ݂݅݀ܽݐܽݏ݋ݑݎܿ݁݊ܿ݋݊ݐܽ݅݊ݏ݅݊ݐ݁ݎܽܿݐ݅݋݊ݕͲǡ ݋ݐ݄݁ݎݓ݅ݏ݁  
Here, S defines the number of data sources. The rationale for this definition is the 
more data sources the interaction is regenerated in, the more reliable it is. Therefore, 
the higher theଵ, the more reliable the gene interaction is.  
Experimental Method Based Reliability (܀૛): The second reliability measure 
evaluates the reliability of an interaction on the basis of the experimental methods. 
The basic idea is the same asܴଵ, however this time we consider how many 
experimental methods (e.g, affinity-chromatography, in vivo, in vitro) identified a 
particular interaction. Therefore, ܴଶ is defined as the reliability measure which 
evaluates the reliability of any interaction y between (a, b) by counting the number 
of experimental methods that identified y, i.e,       
ܴଶሺ௬ሻ ൌ σ ܧ௡ሺ௬ሻே௡ୀଵ          (4.3) 
     where,ܧ௡ሺ௬ሻ ൌ  ൜ͳǡ ݂݅݁ݔ݌݁ݎ݅݉݁݊ݐ݈ܽ݉݁ݐ݄݋݀݊݅݀݁݊ݐ݂݅݅݁݀݅݊ݐ݁ݎܽܿݐ݅݋݊ݕͲǡ ݋ݐ݄݁ݎݓ݅ݏ݁ 
Here, N defines the number of experimental methods. The higher the ܴଶof an 
interaction, the more reliable the gene interaction is.  
Interaction Level-based Reliability (܀૜): The third reliability measure evaluates 
the reliability by considering the gene partners of two directly interacting genes. In 
a gene interaction network, if any two interacting genes have a higher number of 
level-2 neighbours (if any gene a is interacting to gene b, then b is level-1 neighbour 
of a, and the interaction partners of b are level-2 neighbours of a.), they are 
considered more reliable among those with a lower number of level-2 neighbours 
[173, 175]. The principle behind this reliability measure is that the interacting gene 
pairs that interact with the genes but which have no further interactions are more 
likely to be an unreliable or false-positive interaction. However, if they have further 
interactions, they are seen as reliable interactions because the biological processes 
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performed their functions in the group of interactions which is more complex 
compared to others.        
 Therefore, ܴଷ is defined as the reliability measure that evaluates the 
reliability of any interaction y between (a, b) by counting their number of level-2 
neighbours, i.e, 
        ܴଷሺ௬ሻ ൌ σ ቂܫ௡ሺ௔ሻ ൅ܫ௡ሺ௕ሻቃெ௡ୀଵ         (4.4) 
                  where,ܫ௡௔ ൌ  ൜ͳǡ ݂݅݃݁݊݁݊݅ݏ݈݁ݒ݈݁ െ ʹ݄ܾ݊݁݅݃݋ݑݎ݋݂݃݁݊݁ܽͲǡ ݋ݐ݄݁ݎݓ݅ݏ݁  
Here, ܯdefines the total number of genes in the interaction network. For any 
interaction y, ܴଷ can be evaluated, where the higher the value ofܴଷ, the more 
reliable the gene interaction is, and vice-versa. 
Weighted Reliability measure: After evaluating the reliability measure based on 
data sources (ܴଵ), experimental methods (ܴଶ), and level-based interaction partners 
(ܴଷ), we then performed two major steps. First, each of the reliability measures was 
normalised (by using the formula similar to equation (4.1)) across gene interactions, 
where the normalised reliabilities were within the range [0, 1].  The essentiality of 
normalisation is to propose a global scale of reliability that defines the reliability 
strength of each reliability measure within that scale. For simplicity, we still denote 
the normalised reliabilities asܴଵǡ ܴଶܴଷ, which were then used to construct a 
multivariate linear regression model to form the Weighted Reliability Measure (μ), 
and is defined as, 
Ɋሺ௬ሻ ൌ ߚ଴ ൅σ ߚ௡ܴ௡ሺ௬ሻଷ௡ୀଵ        (4.5) 
where, Ɋሺ௬ሻ defines the weighted reliability measure for yth interaction, ߚ଴defines 
the constant, and ߚ௡defines the regression coefficient for the nth reliability measure 
(i.e., ܴ௡ሺ௬ሻvariable). Here, ܴ௡ሺ௬ሻis a promoting factor ifߚ௡ ൐ Ͳ, and ܴ௡ሺ௬ሻis a 
supressing factor ifߚ௡ ൏ Ͳ. A complete model with a p-value less than or equal to 
0.05 was considered to be statistically significant.  
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4.3.2 Gene Expression Metrics 
For each k training set, the gene expression values of each gene are summarized by 
calculating the generalized mean of gene expressions (G) across the samples, which 
is defined as                
                                             ܩሺ௔ሻ ൌ ටଵ௡ σ ቂ݁௜
ሺ௚ሻቃଶ௡௜ୀଵ                                             (4.6)           
where, n is the total number of samples, and ݁௜ሺ௚ሻ defines the gene expression value 
of gene ݃ in the ith sample. Next, each gene in our gene interaction network is 
assigned a summarised value from each training set using equation (4.6), thus 
leading to a total of k gene interaction networks (from k training sets). Finally, in 
each gene interaction network, each interaction y between (a, b) is then assigned a 
merged gene expression (ߪ) value from their interacting genes, which is defined as, 
ߪሺ௬ሻ ൌ  ଶכீሺೌሻכீሺ್ሻீሺೌሻାீሺ್ሻ            (4.7) 
However, the gene interactions are not reliable and contain many false-positive 
interactions that do not take place in real biological processes (see Section 4.2.2). 
Therefore, we need to combine the ߪ values and the reliability measure μ to 
accurately identify the reliable subnetwork based differentially expressed genes. 
4.3.3 Reliable Gene Expression Metrics 
To construct the gene network that signifies the reliability of each gene interaction 
with their associated gene expressions, we incorporated the proposed reliability 
measure (μ) with the merged gene expression value (ߪ) of gene interactions, and 
called it reliable gene expression (Ʌ). As the μ measure assesses the reliability of 
each gene interaction on the basis of three vital criteria, the ߪ measure assesses the 
integrated gene expression of each gene interaction.    
 However, before defining the Ʌ metric, we need to define the correlation 
between μ and ߪ to evaluate whether or not the μ and ߪ of any interaction y between 
(a, b) is positively correlated. We evaluate the correlation coefficient (ߜሻ as:
                       ߜሺ௬ሻ ൌ  ൫ஜሺ೤ሻିஜഥ൯൫ఙሺ೤ሻିఙഥ൯
ට൫ஜሺ೤ሻିஜഥ൯మ൫ఙሺ೤ሻିఙഥ൯మ
                          (4.8) 
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where, Ɋത and ߪത represents the μ and ߪ mean of all the interactions in a training set, 
respectively.          
 With this measure (4.8), the relationship between μ andߪ can be evaluated, 
i.e., whether it’s positively correlated (ߜሺ௬ሻ ൌ ͳሻ, negatively correlated (ߜሺ௬ሻ ൌ
െͳ), or not correlated at all (ߜሺ௬ሻ ൌ Ͳ). We are interested in extracting the 
positively correlated terms as they are more strongly related to patterns that can 
construct gene signatures that qualitatively classify the ER+/ER- subtypes of breast 
cancer. In other words, for a gene interaction y, if the relationship strength of their 
μ and ߪ showsߜሺ௬ሻ ൌ ͳ, then a gene interaction has more chance of being 
biologically true and related to the phenotype.      
 Once the positively correlated interactions are extracted for each of the six 
training sets, the Ʌ can then be evaluated. The Ʌ of any interaction ݕcan be 
evaluated by performing multivariate linear regression analysis of μ andߪ, which 
is represented as, 
                                         Ʌሺ௬ሻ ൌ ߚ଴ ൅ߚଵሺɊሺ௬ሻሻ ൅ߚଶሺߪሺ௬ሻሻ            (4.9) 
where,ߚଵ and ߚଶ represents the regression coefficients for Ɋሺ௬ሻ andߪሺ௬ሻ, 
respectively. Once evaluated, the significant gene interactions (with p-value < 
0.05) are extracted for each training set. These are then used to construct the gene 
signatures to classify the samples based on the ER+/ER- status. Details are 
presented in the following sub-sections. 
4.3.4 Robust Reliability based Hub Gene Expression 
Algorithm (RRHGE)   
Significant positively correlated reliable gene interactions are used to construct the 
discriminative subnetworks for each training set by using the Cytoscape [181]. The 
Ʌ values of the interactions in the discriminative subnetworks are then taken for the 
hub gene evaluation, where the hub gene is the gene in the subnetwork that contains 
maximal interactions amongst other genes. For each training set, it may be possible 
that several subnetworks exist, with each subnetwork used for the hub gene 
evaluation. Figure 4.1 illustrates this concept. 
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Figure 4.1: The eight subnetworks for any training set d. In each subnetwork, the 
symbol̶̶۪shows the hub gene/s which have the highest number of interactions among 
other genes. In Subnetworkܵ଺, two hub genes are identified, as they both have a maximal 
and equal number of interactions, i.e, each gene has 2 interactions.  
 
For each of the k training sets, once the subnetwork based hub genes are identified, 
two major steps are performed. First, the subnetwork score (ߣ) is calculated for 
each subnetwork in a training set by using equation (4.10), i.e,  
    ሺߣሻை೙ ൌ σ Ʌሺ௬ሻ௬א௒೙                               (4.10) 
where, ܱ ௡ (n = 1, 2… N) be any subnetwork, and ܻ ௡is the set of all gene interactions 
in ௡ܱ. A subnetwork with a maximum subnetwork score (ߣ) is chosen and retained 
for further analysis. A maximum ߣ based subnetwork is chosen because that 
subnetwork shows highly connected reliable gene interactions amongst other 
subnetworks for a given training set, and is believed to indulge in essential real 
biological processes that relate to cancers. By using this step, only the subnetwork 
with the maximum ߣ is chosen, and other subnetworks are ignored. However, other 
subnetworks might contain essential genes which have the strength to be effective 
and stable gene signatures. Therefore, to identify those significant genes, the 
following operations are performed which use hub gene topology.  
 For each training set, a hub gene with their interactors for each subnetwork 
are identified (as shown in Figure 4.1). Then, the hub gene score (߯) is evaluated 
as:    
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                   ሺ߯ሻ௦೙ ൌ  ଵȁு೙ȁ σ Ʌ
ሺ௛ሻ௛אு೙     (4.11) 
where, h is an interaction between any gene with the hub gene, and ȁܪ௡ȁstands for 
the number of gene interactions that occur for the hub gene in ௡ܱ. In other words, 
for a given subnetwork, the hub score is the average Ʌ of the genes that interact 
with the hub gene. In this way, the hub score for each subnetwork in a training set 
can be evaluated.            
 The associated hub gene score (߯) of the chosen subnetwork with the 
maximum subnetwork score (ߣ) is then used as a threshold for extracting significant 
gene interactions. This can be done by comparing the ߯ of a chosen subnetwork 
with all of the other ߯ from other subnetworks in a given training set. If any of the 
other subnetworks have ߯ greater than the ߯ of the chosen subnetwork, their hub 
gene with their interactors is chosen. The reason for selecting the hub gene as the 
benchmark is that a hub gene has the maximum number of interactions in a given 
subnetwork, with high probability these interactions will act as driver genes for 
cancers that indulge in several essential biological functions and processes [96]. 
Chang et al. [36] discovered that hub genes are significantly related to metastasis-
related genes. Also, Jonsson et al. [110] showed that cancer-associated genes, 
which are translated from human proteins, show an increase in the number of 
interactors they interact with, and also show them working as the central hubs. 
Therefore, hub gene topology is used to extract the significant genes from the 
subnetworks (other than the chosen subnetwork) of a given training set. 
 Finally, for each training set, the subnetwork list, i.e., a subnetwork chosen 
from equation (4.10) and the hub genes with their interactors chosen from equation 
(4.11), is retained to extract the gene signature to classify ER+ and ER- breast 
cancer subtypes. Figure 4.2 shows the pseudocode of these steps.  
  
89 
 
                                                                                                                                                             
// Let ܴீௌ defines the set of subnetwork based-gene signatures, ܪௌ೙denotes the hub gene with 
their interactors in subnetwork ܵ௡, ܦ௞defines the kth training set 
 
FORܦ௞ሺ݇ ൌ ͳǡʹǡ ǥ ǡ ܭሻ 
{ 
      Initialize:ܴீௌ = ׎ 
      //STEP1: Evaluate ߣ for all subnetworks and identify the top ߣbased subnetwork. 
      { 
 FOR each subnetwork ܵ௡ from the list of available subnetworks in ܦ௞ 
 { 
              COMPUTE ሺߣሻௌ೙  
               } 
               ENDFOR 
               IF ሺߣሻௌభ ൒  ሺߣሻௌమ ǥ ൒  ሺߣሻௌ೙ 
               THEN ܴீௌ ൌ ܴீௌ ׫  ሼ ଵܵሽ 
               AND remove  ଵܵfrom the list of available subnetworks in ܦ௞ 
      } 
      //STEP2: Evaluate ߯ for all subnetworks and identify the significant hub genes with their 
interactors.     
      { 
COMPUTE ሺ߯ሻோಸೄ  
 FOR each subnetwork ܵ௡ from the list of available subnetworks in ܦ௞   
 { 
           COMPUTE ሺ߯ሻௌ೙     
         { 
                                   IF ሺ߯ሻௌ೙ ൒ ሺ߯ሻோಸೄ  
                                   THEN ܴீௌ ൌ ܴீௌ ׫  ሼܪௌ೙ሽ 
                      } 
              } 
              ENDFOR 
      } 
} 
RETURN ܴீௌ 
END 
 Figure 4.2: Pseudocode for the RRHGE algorithm  
 
4.3.5 Classification Process and Performance Assessment 
First, the common genes are extracted from the subnetwork lists of ER+ training 
sets. Operations are similar for the ER- training sets. After that, duplicates were 
then removed between the common genes of ER+ and ER- subnetwork lists. 
Finally, the RRHGE gene signature was constructed which consists of the ER+ 
subnetwork lists, called the ER+ gene signature (for ER+ subtype), and ER- 
subnetwork lists, called the ER- gene signature (for ER- subtype).  
 The RRHGE gene signature, which consists of ER+ and ER- gene 
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signatures, is then used to classify ER+/ER- samples in the testing sets by 
transforming each sample j into ER+ score (ܵା) and ER- score (ܵି), using 
 ܵାሺ݆ሻ ൌ σ ௝݁ሺ௚ሻ ȁܺȁൗ௚א௑ ,     and  ܵିሺ݆ሻ ൌ σ ௝݁ሺ௞ሻ ȁܻȁൗ௞א௒     (4.12) 
where, ܺ = {genes of the ER+ gene signature}, ܻ = {genes of the ER- gene 
signature}, ȁȈȁstands for the number of set elements, and ௝݁ሺ௚ሻis the expression of 
gene ݃ in sample j. With these two scores, each sample j can be mapped as a point 
in a two-dimensional feature spaceԹଶ. Then, the classification can be performed 
by the three-nearest neighbour (3NN) classifier with ܮଵ distance [49]. 
 Since microarray datasets usually contain an unequal ratio between the 
number of ER+ and ER- samples, accuracy is not a good criteria to measure the 
classification performance of an algorithm in the testing datasets. Rather, we used 
a classification performance measure called Matthews Coefficient Correlation 
(MCC) to compare different algorithms [31]. If TP represents the number of true 
positives, TN represents the number of true negatives, FP represents the number of 
false positives, and FN represents the number of false negatives. Then, the MCC 
can be evaluated as:  
                                 ൌ ሺ୘୔ൈ୘୒ሻିሺ୊୔ൈ୊୒ሻඥሺ୘୔ା୊୔ሻሺ୘୔ା୊୒ሻሺ୘୒ା୊୔ሻሺ୘୒ା୊୒ሻ      (4.13) 
In the above equation, if any of the four sums is 0, then the denominator is set to 1, 
as this results in a MCC equaling zero. In general, a MCC value of 1 reflects perfect 
prediction, -1 reflects false prediction, and 0 reflects random prediction. MCC is a 
recommended measure for evaluating classification performance in comparison 
with other measures [17, 49].       
    
4.4 Results 
As indicated in Section 4.2.2, our gene interaction network contained 13,012 
unique genes with 69,914 unique interactions between them, generated from six 
data sources. For evaluating the reliability of the gene interaction network, the 
weighted reliability measure (μ) was constructed (see equation (4.5)). The ‘stats’ 
package of the R-project [163] has been used to evaluate the regression coefficients 
of μ along with their p-value, i.e, 
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     Ɋሺ௬ሻ ൌ ͲǤ͹ͳ͵ͺቀܴଵሺ௬ሻቁ ൅ ͲǤʹͻͳʹቀܴଶሺ௬ሻቁ ൅ ͲǤ͵Ͳ͹ʹሺܴଷሺ௬ሻሻ     (4.14) 
Here, ߚ଴ is very small, i.e, -4.83E-15, and so we assigned ߚ଴ as zero. The complete 
model was significant (p-value < 0.001). With this measure (4.14), the higher 
theɊሺ௬ሻ value, the higher the reliability of the interaction.   
 Next, the integrated microarray dataset of 1,253 samples was constructed 
(see Table 4.1). The samples with repetitions or a missing histologic grade and 
estrogen receptor status based information were excluded. 958 samples remained, 
consisting of 703 ER+ samples and 255 ER- samples. Six training sets were then 
constructed from the integrated dataset, i.e., three for ER+ and three for ER- (i.e., 
Grade 1, Grade 2 and Grade 3, respectively)), which generated six gene interaction 
networks with their merged gene expression (ߪ) value  (see Section 4.3.2 for 
details).          
 Further, the μ and ߪ were incorporated to construct a reliable gene 
expression (Ʌ) (see equation (4.9)) for each of the six training sets by using a 
multivariate linear regression model, with their regression coefficients shown in 
Table 4.2. 
 Therefore, by applying the RRHGE algorithm, the final gene signature set 
consisted of 471 genes, i.e., 326 distinct genes for the ER+ subtype (called a ER+ 
gene signature) and 145 for the ER- subtype (called a ER- gene signature) (see 
Table 4.3), which classified the samples as either ER+ or ER-, as defined in Section 
4.3.5. The complete algorithm workflow is shown in Figure 4.3. The list of the 
genes in our RRHGE gene signature is provided in Appendix B. 
Table 4.2: Regression coefficients of μ (ߚଵ) and ߪ (ߚଶ) in each of the six training sets, 
respectively. 
Training Set ߚ଴* ߚଵ ߚଶ p-value 
ER+ (Grade 1) -8.06E-16 0.4601 0.7066 <0.001 
ER+ (Grade 2) 3.64E-15 0.4878 0.6846 <0.001 
ER+ (Grade 3) 9.81E-16 0.4650 0.7094 <0.001 
ER- (Grade 1) 1.49E-15 0.4273 0.7274 <0.001 
ER- (Grade 2) -2.68E-15 0.4484 0.7199 <0.001 
ER- (Grade 3) 1.20E-15 0.4673 0.7078 <0.001 
       *Here, ߚ଴ in each training set represents a very small value and so assigned ߚ଴ as zero.
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Table 4.3: RRHGE gene signature size.   
Training  
set 
ER+ ER- 
 Subnetwork List 
      (# of Subnetworks) 
Subnetwork List 
 (# of Subnetworks) 
Grade 1 45 31 
Grade 2 35 37 
Grade 3 39 34 
Final Gene  
Signature set 
                       
326 
                              
145 
Our gene signature set consists of 471 genes that compose 326 genes for the ER+ subtype and 145 
genes for the ER- subtype. 
 
 
 
Figure 4.3: The proposed algorithm workflow. In our study, six training sets were used to 
generate the robust RRHGE gene signature, and two testing sets were used to classify the 
ER+/ER- breast cancer samples. The RRHGE gene signature set consists of 471 genes (326 
for ER+ and 145 for ER- subtype). 
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The classification results on the two testing datasets, in addition to a comparison 
with previously established algorithms, are detailed in the following sub-sections. 
4.4.1 Classification Performance 
We define sensitivity as the ability of the algorithm to identify the ER+ samples as 
ER+, specificity as the ability of the algorithm to identify the ER- samples as ER-, 
and accuracy as the ability of the algorithm to accurately identify the patients as 
either ER+ or ER- samples.       
 To test the classification performance of the gene signatures, we applied 
them on two testing sets, i.e, the Desmedt and van de Vijver dataset. We compared 
the RRHGE algorithm based gene signature with RRHGE-H (i.e., gene signatures 
extracted from the six training sets by only considering hub genes), RRHGE-HI 
(i.e., by only considering hub genes with their interactions in each of the six training 
sets), RRHGE-TSN (i.e., by only considering the top subnetwork in each of the six 
training sets), and also with five other previously existing algorithms. These are: 
the 70-gene signature (Mammaprint) [206], the 76-gene signature [216], the 
Genomic Grade Index (GGI) [192], the Interactome-Transcriptome Integration 
(ITI) [75], and the Hub based Reliable Gene Expression (HRGE) [174]. Table 4.4 
shows the detailed classification results of RRHGE, along with RRHGE-H, 
RRHGE-HI, RRHGE-TSN, and other existing algorithms, and Figure 4.4 shows the 
MCC comparison of algorithms in the Desmedt and van de Vijver dataset, 
respectively. The results show that the RRHGE approach was able to achieve better 
results and was superior if only considering hub genes in each of the six 
subnetworks, or if only considering hub genes along with interactions in each of 
the six subnetworks, or if only considering the top-subnetwork in each of the six 
subnetworks. Also, RRHGE is superior to other existing algorithms. 
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Table 4.4: Classification results of the RRHGE gene signature and other existing gene 
signatures on two testing sets, i.e., (A) the Desmedt dataset and (B) the van de Vijver 
dataset.         
 Algorithm N TP FN TN FP       SE SP ACC MCC 
 
 
 
 
    (A) 
Desmedt 
 
GGI 190 84 45 29 32 0.651 0.475 0.595 0.121 
70g 190 53 76 27 34 0.411 0.443 0.421 -0.137 
76g 190 78 51 23 38 0.605 0.377 0.532 -0.018 
ITI 190 95 34 33 28 0.736 0.541 0.674 0.271 
HRGE 190 115 14 36 25 0.891 0.590 0.795 0.511 
RRHGE-H 190 103 26 46 15 0.798 0.754 0.784 0.532 
RRHGE-HI 190 100 29 48 13 0.775 0.787 0.779 0.535 
RRHGE-TSN 190 119 10 54 7 0.922 0.885 0.911 0.798 
RRHGE 190 123 6 56 5 0.953 0.918 0.942 0.868 
           
 
 
 
 
(B)  
Van de 
Vijver 
GGI 150 77 37 17 19 0.675 0.472 0.627 0.131 
70g 150 71 43 19 17 0.623 0.528 0.600 0.131 
76g 150 72 42 20 16 0.632 0.556 0.613 0.162 
ITI 150 59 55 19 17 0.518 0.528 0.520 0.039 
HRGE 150 70 44 20 16 0.614 0.556 0.600 0.146 
RRHGE-H 146 92 22 14 18 0.807 0.438 0.726 0.235 
RRHGE-HI 150 94 20 22 14 0.825 0.611 0.773 0.414 
RRHGE-TSN 150 101 13 26 10 0.886 0.722 0.847 0.592 
RRHGE 150 105 9 28 8 0.921 0.778 0.887 0.692 
Here, N defines the total number of samples, TP defines true positive (ER+ samples predicted as 
ER+), TN defines true negative (ER- samples predicted as ER-), FP defines false positive (ER- 
samples predicted as ER+), FN defines false negative (ER+ samples predicted as ER-), SE defines 
sensitivity, SP defines specificity, ACC defines accuracy, and MCC defines the Matthews 
coefficient correlation. For simplicity, we represent the Genomic Grade Index as GGI, the 70 gene 
signature as 70g, the 76 gene signature as 76g, Interactome-Transcriptome Integration as ITI, and 
the Hub based Reliable Gene Expression as HRGE. The RRHGE subnetwork based gene signature 
provides superior performance in both (A) Desmedt, and (B) van de Vijver dataset. 
   
 
 
Figure 4.4: Bar charts represent the MCCs of various classification algorithms on the 
Desmedt and van de Vijver dataset, respectively.   
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Specifically, the results show that our RRHGE approach achieved a MCC of 0.87 
and 0.70 in the testing sets of the Desmedt and van de Vijver, respectively. On the 
Desmedt dataset, RRHGE gave better MCC as compared to RRHGE-H which gave 
0.53, RRHGE-HI which gave 0.54, RRHGE-TSN which gave 0.80, HRGE which 
gave 0.51, ITI which gave 0.27, GGI which gave 0.12, 76g which gave -0.02, and 
70g which gave -0.14. Amongst the existing algorithms, HRGE showed the second 
best MCC after RRHGE on the Desmedt dataset. Similar results can be observed 
from the van de Vijver dataset, which demonstrated the RRHGE is still superior to 
other algorithms based on MCC. However, on the van de Vijver dataset, 76g 
showed the second best MCC after RRHGE. This suggests the classification 
performance of other existing gene signatures is heavily dependent on datasets and 
other factors, such as microarray platforms. We believe the dependency on datasets 
can be reduced and the classification performance can be strengthened by 
increasing the training compendia and incorporating multiple platforms across 
multiple datasets.        
 In the testing sets of Desmedt and van de Vijver, the HRGE, ITI, GGI, 70g, 
and 76g MCC patterns varied significantly. In other words, these algorithms were 
not stable enough to obtain similar classification results in distinct datasets, which 
indicates these algorithms were biased towards the dataset used for classification 
analysis. However, the RRHGE subnetwork based algorithm showed stable 
classification performance in both testing datasets by achieving the highest MCC 
amongst other representative algorithms. 
 We also noticed that the RRHGE-TSN shows little lower classification 
performance compared with RRHGE (see Table 4.4). Therefore, if the 
computational costs is a concern, then RRHGE-TSN can serve the optimal classifier 
as it only requires the top subnetwork. However, if classification performance is of 
prime concern, which is the initial aim of this study, then RRHGE serves as the best 
classifier.  
 Since the ER+ subtype generally shows a higher survival rate of patients 
compared to ER-, we called this a good prognosis group. However, the ER- subtype 
shows a lesser survival rate and is also more aggressive compared to ER+, so we 
called this a poor prognosis group [62, 123] (see Section 5.1 for the details of 
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prognosis groups). Now, in order to determine if the RRHGE gene signature is able 
to separate the ER+ (good prognosis) patients group and the ER- (poor prognosis) 
patients group using the distant metastasis free survival rate (DMFS) and overall 
survival rate (OS) information in the microarray dataset, we performed Kaplan-
Meier Survival analysis.      
 The ‘survival’ package of the R-project [163] has been used to perform the 
survival analysis between the ER+ and ER- patient groups for the Desmedt dataset, 
which generated the DMFS and OS survival curves of RRHGE, as shown in Figure 
4.5.           
 
Figure 4.5: Kaplan-Meier survival graphs for ER+ and ER- patient groups in the Desmedt 
dataset using the RRHGE gene signature (similar results were achieved for the van de 
Vijver dataset). A log-rank test was performed to evaluate the p-value, which signifies the 
lower the p-value, the better the separation between the two prognosis groups. (A) 
Incorporating the DMFS rate to distinguish between ER+ or good prognosis groups (lower 
risk of distant metastasis) and ER- or poor prognosis groups (higher risk of distant 
metastasis). (B) Incorporating the OS rate that distinguishes ER+ or good prognosis groups 
(lower risk of death) and ER- or poor prognosis groups (higher risk of death). Both survival 
analysis graphs show good separation between the two prognosis groups, respectively.    
  
We first performed the Kaplan-Meier survival analysis for the distant metastasis 
free survival ER+ and ER- patient groups. The log-rank statistical test gave p-value 
of 3.15e – 08, which was statistical significant (i.e. p <0.001) and showed good 
separation between the two patient groups (Figure 4.5 (A)). Similarly, the Kaplan-
Meier survival analysis of overall survival for ER+ and ER- patient groups showed 
a p-value of 1.47e – 05, suggesting good separation between the two patient groups 
(Figure 4.5 (B)).These results validate that the RRHGE gene signature is effective 
in separating patients into two prognosis groups on the basis of the DMFS rate and 
the OS rate, which can determine the patient’s expectancy level for the event 
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(distant metastasis or death). Therefore, we can identify the patient group that may 
require a more or less aggressive treatment strategy.    
 To illustrate the behavioural pattern of ER+ and ER- gene signatures of 
RRHGE on the Desmedt dataset, heatmaps were drawn that show the differential 
expressions of genes in ER+ samples and ER- samples. Although the genes in a 
gene signature group seem correlated with two estrogen receptor based subtypes, 
no single gene shows uniformity of expressions across samples (see Figure 4.6). 
This illustrates the significance of the gene signatures as a multigene classification 
method.          
 Using the heatmaps, distinct gene expression patterns can be visualised for 
the ER+ and ER- breast cancer samples. From Figure 4.6, it is true to say the 
RRHGE gene signature is highly instructive in distinguishing the behavioural 
patterns of the ER+ and ER- breast cancer subtypes.   
 
Figure 4.6: The Heatmap of the RRHGE gene signature by using the expression values of 
the genes from the Desmedt dataset is drawn by using the R statistical package [163]. Here, 
each row corresponds to the genes and each column corresponds to the samples (sorted 
from ER+ to ER-). The Expression levels of each gene are normalised across the samples 
with zero mean and standard deviation equaling one, where blue represents high expression 
levels and yellow represents low expression levels. (A) Shows the genes highly expressed 
in the ER+ samples, i.e., by applying our ER+ gene signature (326 genes) on the Desmedt 
dataset visualises two groups; one is highly expressed (ER+) and the other is not. (B) 
Shows the genes highly expressed in ER- samples, i.e., by applying our ER- gene signature 
(145 genes) on the Desmedt dataset visualises two groups; one is highly expressed (ER-) 
and the other is not.        
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4.4.2 Signature Stability with Existing Gene Signatures 
As indicated by Garcia et al. [75], the gene signatures of van de Vijver and Wang 
show three mutual genes among them which comprise less than 5% of all the genes 
in their signatures. We performed the gene signature stability analysis of RRHGE 
with other existing algorithm based gene signatures, as mentioned in Section 4.4.1. 
When compared with the ITI gene signature, 175 genes were found in common, 
corresponding to nearly 37% of genes. Compared with the 70 gene signature, only 
3 genes were found in common, and with the 76 gene signature, only 2 genes were 
found in common. In addition, the 186-gene “invasiveness” gene signature (IGS) 
[131] was compared with the RRHGE gene signature, and 10 genes were found in 
common. These comparison results are shown in Table 4.5. These small overlaps 
of genes signified that datasets were biased, and possibly the genes in the gene 
signature were not biologically relevant due to the algorithm’s limitations.  
 We discovered that the gene signatures extracted from the subnetworks 
were able to achieve better results than the gene signatures extracted from the gene 
lists, i.e., non-subnetwork based gene signatures. As ITI is a subnetwork based 
approach, we found more than 35% of these genes were in common with RRHGE. 
This is significantly greater than the gene lists based gene signatures. This signifies 
that subnetwork based gene signatures are able to achieve higher classification 
performance (Table 4.4), and also shows higher numbers of overlapped genes 
amongst other gene list based gene signatures (Table 4.5). However, the overlap 
amongst subnetwork based gene signatures can be largely increased by 
incorporating significantly larger numbers of training sets with multiple platform 
types. Table 4.5 shows the number of genes in the RRHGE gene signature that 
overlapped with other gene signatures. 
Table 4.5: Number of overlapped genes of the RRHGE gene signature with ITI, 76g, 70g 
and IGS. 
 ITI 76g 70g IGS 
RRHGE Overlapped Genes 
 (Number (Percentage)) 
                      
175 (37.16%) 
                       
03 (00.64%) 
                       
05 (01.06%) 
                       
10 (02.12%) 
The ITI gene signature shows the highest number of overlapping genes with the RRHGE gene 
signature, as compared to other gene signatures.      
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4.4.3 Biological Analysis of RRHGE Gene Signature 
To identify the significant enriched GO terms and pathways associated with the 
ER+ and ER- breast cancer subtypes, the enriched biological process GO terms [11] 
and the KEGG pathways [114] were computed for each gene in our gene signature 
using DAVID (the Database for Annotation, Visualization and Integrated 
Discovery) [102]. For each gene, DAVID output the enriched biological process 
GO terms and the pathways associated with it by providing the p-values that were 
computed with hyper geometric distribution. This program was helpful to identify 
the significant GO terms and KEGG pathways. Therefore, for all genes in the gene 
signature, their enriched GO terms and pathways can be calculated with their p-
values in order to biologically validate the results.     
 First, we performed GO analysis. The Table 4.6 shows the enriched GO 
terms for the RRHGE gene signature. From Table 4.6, it can be seen that the 
biological process GO terms of our subnetwork based gene signatures were 
correlated with the processes that were seen to be disrupted in cancers such as 
apoptosis, cell death, DNA damage response, insulin stimulus response, cell 
proliferation, nuclear mRNA splicing via spliceosome, cell cycle regulation, and 
many others. This demonstrates that the biological meaning of the gene signature 
is significant and highly associated with the cancers. The genes associated with 
these significant enriched GO terms are also shown in Table 4.6.  
 Next, we performed pathway analysis. Table 4.7 shows the enriched 
pathways for the RRHGE gene signature. From Table 4.7, it can be seen that the 
pathways associated with the genes in the RRHGE gene signature were correlated 
with cancers, such as ATM signaling pathway, p53 signaling, focal adhesion class 
pathway, cellular aging and immortality, and many others. The genes associated 
with these significant enriched pathways are also shown in Table 4.7.  
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Table 4.6: Enriched GO Terms for genes in the RRHGE gene signature. 
GO GO Description Genes p-value 
GO:0010941 
 
 
 
regulation of apoptosis 
 
 
 
RTN4, XRCC4, XIAP, NFKBIA, MLH1, TNFSF13, 
BCL2L1, BAK1, IGF1R, CASP3, PPP2CA, PRKRA, 
DIABLO, STAMBP, PPP2R1A, VAV3, LIG4, BAD, 
YWHAE, BRCA1, TAX1BP1, DDIT3, CDKN1A, 
NME3, HDAC1, BAX, RIPK1, BIK, MAPK8 
681E-11 
 
GO:0010941 
 
 
regulation of cell death 
 
 
RTN4, XRCC4, XIAP, NFKBIA, MLH1, TNFSF13, 
BCL2L1, BAK1, IGF1R, CASP3, PPP2CA, PRKRA, 
DIABLO, STAMBP, PPP2R1A, VAV3, LIG4, BAD, 
YWHAE, BRCA1, TAX1BP1, DDIT3, CDKN1A, 
NME3, HDAC1, BAX, RIPK1, BIK, MAPK8 
916E-11 
 
GO:0006917 
 
 
 
induction of apoptosis 
 
 
 
PPP2R1A, VAV3, MLH1, TNFSF13, BAD, 
YWHAE, BRCA1, BAK1, CDKN1A, CASP3, 
NME3, PPP2CA, BAX, RIPK1, PRKRA, DIABLO, 
BIK, MAPK8 
241E-10 
 
GO:0042127 
 
 
regulation of cell proliferation 
 
 
STAMBP, XRCC4, KAT2B, STK11, IGFBP7, 
TNFRSF13B, NFKBIA, TNFSF13, RB1, BCL2L1, 
LIG4, IRS1, BRCA1, CDK2, IGF1R, CASP3, 
CCND1, CDKN1A, HDAC1, BAX, PRKRA, 
MDM4, LDOC1 
130E-07 
GO:0006366 
 
 
transcription from RNA 
polymerase II promoter 
 
CCNT2, TAF1, TAF1A, CCNT1, CDK9, TBP, 
GTF2B, DDIT3, MED4, TAF12, GTF2F1, TCEB2, 
NFE2L2, PARP1 
714E-09 
 
GO:0030521 
 
 
androgen receptor signaling 
pathway 
 
AR, MED4, NCOA4, RB1, RNF14, BRCA1 
 
290E-07 
 
GO:0032868 
 
 
response to insulin stimulus 
 
IGF1R, AR, KAT2B, FBP1, APPL1, PARP1, IRS1 
 
528E-06 
 
GO:0045597 
 
 
positive regulation of cell 
differentiation 
 
XRCC4, MAPT, FOXA1, RB1, LIG4, BAD 833E-04 
GO:0042770 
 
 
DNA damage response, signal 
transduction 
 
CCND1, MLH1, CEP63, BRCA1 
 
475E-04 
 
GO:0000087 
 
 
M phase of mitotic cell cycle 
 
MAD1L1, CHFR, CDC25B 
 
612E-03 
 
GO:0009967 
 
 
positive regulation of signal 
transduction 
 
MEN1, REL, TBK1, RAC1 510E-03 
 
 
 
Table 4.7: Enriched pathways associated with genes in the RRHGE gene signature. 
Pathway Class Genes p-value 
Cell cycle E2F1, CDKN1A, CCND1, HDAC1, GADD45G, RB1, YWHAE, CDK2, 
MAD1L1, YWHAZ, YWHAH, CCND3, GADD45A, CDC25B 
264E-05 
 
Apoptosis 
 
CASP3, XIAP, RIPK1, CASP7, BAX, NFKBIA, BCL2L1, BAD, 
 
307E-06 
 
Focal adhesion 
 
COL4A2, COL4A1, CCND3, ACTN4, GRB2, FYN, RAC1, THBS2, 
IGF1R, CDC42, CCND1, VAV3, XIAP, MAPK8, BAD, PARVA 
 
244E-04 
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Adherens junction 
 
 
IGF1R, CDC42, CTNNA1, CSNK2A2, CSNK2A1, ACTN4, FYN, 
RAC1, CSNK2B, WAS 
 
754E-06 
 
p53 signaling  
 
 
CDKN1A, CCND1, CASP3, BAX, GADD45G, DDB2, MDM4, CDK2, 
CCND3, APAF1, GADD45A 
 
641E-07 
 
TGF-beta signaling  
 
SMURF2, SMAD1, SMURF1, THBS2, SMURF2, SMAD1, SMURF1, 
THBS2 
 
129E-03 
 
ErbB signaling  
 
CDKN1A, CBL, MAPK8, BAD, NCK2, GRB2, NCK1 
 
144E-03 
 
Insulin signaling  
 
CBL, FBP1, MAPK8, BAD, IRS1 
 
147E-03 
Neurotrophin signaling  
 
 
IGF1R, CCND1, CASP3, BAX, MLH1, MAPK8, BAD, APPL1, 
YWHAZ, MAP3K5, YWHAH, GRB2, RAC1 
 
247E-06 
 
Wnt signaling  
 
 
PPP2R1A, CCND1, BTRC, PPP2CA, MAPK8, CTNNBIP1, CSNK2A2, 
CSNK2A1, CCND3, RAC1, CSNK2B 
 
647E-04 
 
ATM Signaling  
 
CDKN1A, NFKBIA, MAPK8, BRCA1, RAD51 
 
332E-05 
 
Jak-STAT signaling  
 
CCND3, GRB2, STAM, CCND1, CBL, BCL2L1 
 
658E-03 
 
Chemokine signaling  GRB2, RAC1, WAS, CDC42, VAV3, NFKBIB, NFKBIA 543E-03 
 
MAPKinase Signaling  
 
MAP3K5, GRB2, RAC1, MAP3K3, RIPK1, NFKBIA, MAPK8 
 
492E-03 
 
Apoptotic Signaling in 
Response to DNA Damage 
CASP3, CASP7, BAX, BCL2L1, BAD, PARP1 
 
 
523E-06 
 
 
 
  
Many of the genes in the RRHGE gene signature are already defined as well-known 
oncogenes, such as AR, BRCA1, CDK2, CCND1, whose differential expression has 
been associated with the subtypes of breast cancer. For other genes not previously 
reported as oncogenes, these could be newly discovered genes that may act as breast 
cancer driver genes and may promote cancer aggressiveness by distant metastasis. 
         
4.5 Summary  
In this chapter, we proposed a reliable gene expression metrics (Ʌ) to measure and 
extract the reliable gene interactions from gene interaction networks in terms of 
real biological processes, and incorporated the extracted reliable gene interactions 
into our proposed algorithm; the robust reliability based hub gene expression 
algorithm (RRHGE).The RRHGE algorithm uses hub gene topology to identify 
significant genes for classifying ER+ and ER- breast cancer samples effectively. 
The resultant RRHGE gene signature consists of 471 genes, i.e., 326 genes for ER+ 
and 145 genes for the ER- subtype. From this study, we observed that subnetwork 
based gene signatures were more reproducible across the datasets and were able to 
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provide higher classification performance amongst the non-subnetwork based gene 
signatures.         
 The classification results (Table 4.4) demonstrated our RRHGE based gene 
signature was able to accurately characterise a high number of ER+ and ER- 
samples without depending on any specific dataset or any other factors. The gene 
signature of our RRHGE algorithm was also validated biologically using GO and 
pathway analysis, and the results demonstrated that the significant enriched GO 
terms and pathways of the genes in our gene signature were associated with the 
processes shown to be disrupted in cancers.      
 We observed that if gene interactions in the network were reliable, then 
classification performance significantly increased compared to cases where the 
reliability criterion was not considered. As a matter of fact, this provides us with a 
possible research direction to improve the reliability metrics by incorporating 
highly biologically-related information. 
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Chapter 5  
 
Breast Cancer Prognosis Risk 
Estimation  
 
 
5.1 Introduction     
The leading cause of death among breast cancer patients is from distant metastasis 
and recurrence [217]. The early stage prediction of prognosis after being diagnosed 
with breast cancer remains one of the significant challenges in breast cancer based 
clinical research. The accurate prediction of a good prognosis (low risk) or poor 
prognosis (high risk) breast cancer patients based on metastasis or recurrence, can 
assist in the decision regarding appropriate therapy. Patients categorised as low risk 
patients can be spared aggressive therapies, e.g., chemotherapy, and can be treated 
with less toxic treatments, e.g., tamoxifen or hormonal therapy. However, for 
patients categorized as high risk patients, chemotherapy or a combination of 
chemotherapy with other therapies may be the optimal therapy solution (see 
Chapter 6 for more details). These adjuvant therapies have high medical costs and 
also have vital short-term or long-term side effects [64]. Therefore, accurate 
classification of two prognosis groups can increase the survival rate of breast cancer 
patients and also reduce unnecessary costs associated with treatment. This can be 
achieved by developing robust prognostic tools that can help clinicians accurately 
categorise the prognosis group of patients and make effective and timely decisions 
about available treatments. Therefore, a challenge is to extract novel prognostic 
clinical or gene expression markers directly associated with the breast cancer that 
can accurately categorise the two breast cancer prognosis groups.  
 During recent years, a wide number of disease markers have been identified 
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from microarray based gene expression profiles that have shown great potential in 
predicting the prognosis outcome for breast cancer [8, 12, 39, 42, 75, 131, 157, 191, 
192, 206, 216, 223, 224]. Currently, treatment guidelines such as the US National 
Institutes of Health (NIH) [64] and St. Gallen [81] use clinical prognostic factors 
such as lymph node status, tumor size and histologic grade in order to evaluate the 
distant metastasis risk for breast cancer patients. In breast cancer, Mammaprint or 
a 70-gene marker (or signature) [206] and a 76-gene signature [216], available 
commercially as a prognostic test [42], performs well in predicting metastasis that 
opposes the performance of clinical criteria. Even though these guidelines and the 
commercially available prognostic tests are popular, they are incapable of 
accurately characterising breast cancer patients into high risk or low risk. As a 
result, many patients receive unnecessary adjuvant therapy, even when they can 
survive without it. Due to these issues, various groups now aim for an effective and 
robust gene expression signature that consists of genes with prognostic biological 
significance.          
 The results from existing studies raise some key questions. First, are the 
genes (from the gene signature) significantly associated with breast cancer or their 
metastasis? Second, if they are associated with breast cancer, are they cancer-
causing genes (since a gene may be associated with cancer but not cause cancer)? 
Third, are the genes reproducible across different datasets or heavily depended on 
the chosen training set? Fourth, are the genes robust, providing similar 
classification results on different testing datasets? Fifth, do the genes represent the 
cancer related biological process GO terms or the pathways associated with the 
cancers?         
 Microarray based breast cancer gene expression datasets usually consist of 
a small number of samples due to the fact they are time consuming and expensive, 
which has always been an issue for accurately categorizing the breast cancer 
prognosis groups [65]. Furthermore, at the time of predicting clinical outcomes, the 
sample size is reduced even further due to missing clinical factors for some of the 
samples in the microarray dataset [186]. This problem can be greatly reduced by 
integrating multiple microarray datasets from different studies that can increase the 
sample size, possibly in the order of thousands.     
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 Shen et al. [183] and Teschendorff et al. [199] used “meta-analysis” to 
integrate different microarray datasets to develop breast cancer based prognostic 
gene signatures [224]. However, it is worthwhile noting that integrating microarray 
datasets from different studies is not so simple due to the different microarray 
platforms across different datasets, different experimental protocols and different 
preprocessing methods. Therefore, in order to resolve all of these above issues and 
be able to classify the two prognosis groups of breast cancer patients effectively, it 
is essential to develop a novel breast cancer prognosis classifier that shows the good 
and stable classification performance from independent datasets.  
 In this chapter, we focus on utilising an integrated dataset (that consists of 
a very large number of samples) along with clinical data to improve the 
performance of the breast cancer prognosis classification. We define the two 
prognosis groups as good prognosis, which corresponds to the breast cancer-free 
state for at least 5 years, and the poor prognosis state, which corresponds to the 
recurrence of breast cancer or metastasis within 5 years. The prime goal of this 
study is to achieve high classification accuracy for the good prognosis group and 
then achieve high classification accuracy for the poor prognosis group. To 
accomplish this aim, we propose a breast cancer prognosis based classification 
algorithm by developing a Virtual Chromosome (VC) consisting of two 
components (Correlation-factor and Penalized-factor), which are used to extract 
our prognostic gene signature that consists of 79 genes. The extracted gene 
signature is then incorporated into a multivariate logistic regression model along 
with clinical variables for generating the risk score formula. A cut-off score of -
1.480 was then used to classify the samples as a good-prognosis if the risk score 
was less than -1.480, and a poor-prognosis if the risk score was greater than or equal 
to -1.480. We reported that when using the training dataset consisting of an equal 
number of two prognosis groups, it achieved a high classification performance in 
comparison to the training dataset that consisted of an unequal ratio of two 
prognosis groups. The evaluation of our algorithm, called Integrated Prognosis 
Risk Estimation (IPRE), and the experimental comparisons with other prognosis 
based classifiers, demonstrated the IPRE algorithm outperformed other classifiers 
by achieving a high classification accuracy.     
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 The remaining chapter is structured as follows. The training and testing sets 
used in this study are defined in Section 5.2. The proposed IPRE algorithm is 
defined in Section 5.3. Statistical validation with classification results and 
biological validation are presented in Section 5.4. Finally, we conclude this chapter 
in Section 5.5.         
  
5.2 Materials  
Seventeen breast cancer microarray gene expression datasets were downloaded 
from the publicly available National Center for Biotechnology Information (NCBI) 
Gene Expression Omnibus (GEO) [18] or the supporting website [8] that has 
multiple platform types, i.e., HG-U133A, HG-U133B, HG-U133PLUS 2.0, and the 
Agilent Human Genome. Overlapping samples or samples that have no clinical 
follow-up were removed from the datasets. The remaining samples were assigned 
either a high risk for metastasis/recurrence (if the metastasis/recurrence was 
observed within 5 years of follow-up) or low risk for metastasis/recurrence (if the 
metastasis/recurrence was not observed within 5 years of follow-up). The sample 
selection was independent of age, tumor grade, or any other clinical parameters.    
5.2.1 Training and Testing Datasets 
Thirteen microarray gene expression datasets (see Table 5.1) were used as a 
training dataset to extract the prognostic gene signature, and the two microarray 
gene expression datasets, the Desmedt dataset (GSE7390) [55] and the van de 
Vijver dataset [206] were used as a testing dataset for evaluating the performance 
of the algorithm. The two testing datasets were chosen, since they are benchmark 
datasets used by many of the existing studies for evaluating the algorithm 
performance. These training and testing datasets were selected first on the basis of 
metastasis or recurrence rate availability and then on tumor size availability. For 
patient samples with a missing Estrogen Receptor (ER) status and Progesterone 
Receptor (PR) status, the dichotomized ER gene (ESR1) and PR gene (PgR) mRNA 
(positive and negative) value was used instead.     
 We have used normalised microarray datasets as published by the original 
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studies. The probe expressions of the datasets were then converted to gene 
expressions as defined in Section 4.2.1. The training and testing datasets were 
processed separately to ensure the independency of the testing datasets. The 
detailed information of the training and testing datasets are shown in Table 5.1.  
Table 5.1: Breast Cancer microarray gene expression datasets used in this study. 
Data Set Country Poor/Good 
Prognosis 
Samples Platform IHC Refs. 
GSE1456 * Sweden 41/118       159 HG-U133A,   
HG-U133B 
NA [64] 
GSE2990 * Sweden, UK 37/85 189 HG-U133A ER [42] 
GSE6532 * Belgium 56/61,        
100/150,      
19/68 
327, 
255,      
87 
HG-U133A,        
HG-U133B,        
HG-U133Plus 2.0 
ER, PR [39] 
E-TABM-158 
* 
USA 54/63 118 HG-U133A ER, PR, HER2 [8] 
GSE5327 * USA 11/47 58 HG-U133A ER [81] 
GSE2603 * USA 36/46 121 HG-U133A ER, PR [65] 
GSE31519 * Germany 52/10 67 HG-U133A ER, PR, HER2 [55] 
GSE3494 * Sweden 60/176     251    HG-U133A,        
HG-U133B 
ER, PR [40] 
GSE4922 * Singapore 91/158 255 HG-U133A,        
HG-U133B 
ER [56] 
GSE19615 * USA 14/0 115 HG-U133Plus 2.0 ER, PR, HER2 [63] 
GSE2034 * Netherlands 106/180 286 HG-U133A ER [68] 
GSE12276 * Netherlands 190/14 204 HG-U133Plus 2.0 NA [84] 
GSE11121 * Germany 47/153 200 HG-U133A NA [90] 
GSE7390 § Europe 44/154 198 HG-U133A ER [102] 
van de Vijver 
§ 
Netherlands 84/211 295 Agilent Human 
Genome 
ER [24] 
Total: 15  8 Countries 1,042/1,694 3,185 4 Platforms   
* represents the training datasets and § represents the testing datasets.   
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5.2.2 Integrated Training Dataset 
In this study, the task is to build a computational model that can accurately predict 
the good prognosis and poor prognosis breast cancer patients. As indicated by Sun 
et al. [196], larger-scale computational studies with more patient samples are 
required to best perform the breast cancer prognosis given all available information. 
In order to achieve this goal, first the data normalisation (see equation (4.1)) was 
performed as defined in Section 4.2.1. 
 Next, to increase the dataset size, a common list of genes (see Section 4.2.1 
for more details) from thirteen training microarray gene expression datasets with 
three unique Affymetrix platforms were then extracted, which consisted of 11,837 
genes. The training cohorts were then directly integrated. This enabled the gene 
signature to be independent of microarray datasets or their platform types. The 
integrated training dataset consists of GSE6532, GSE3494, GSE2990, GSE4922, 
GSE 31519, GSE 19615, GSE 1456, GSE 2603, GSE 2034, GSE 5327, GSE 12276, 
GSE 11121, and E-TABM-158, which makes a total of 13 datasets with 2,692 
samples. 
  
5.3 Integrated Prognosis Risk Estimation 
Algorithm 
The integrated dataset is used to construct the Virtual Chromosome (VC) in order 
to extract the prognostic gene signature. Furthermore, the clinical variables and our 
prognostic gene signature are incorporated in a multivariate logistic regression 
model which formed the risk score formula for predicting the prognosis outcome 
of breast cancer patients. Details of our IPRE algorithm are presented in the 
following sections.     
5.3.1 Virtual Chromosome (VC)  
We introduced a term called Virtual Chromosome (VC) that evaluates the 
prognostic score (observes significant differentially expressed gene expressions 
between two prognosis groups) of each gene in order to extract the prognosis based 
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gene signature. A Virtual chromosome consists of two components, i.e., a 
Correlation-factor (α) and a Penalised-factor (β) (as shown in equation (5.4)). The 
prime concept of VC is to transform these two components into a combined value 
that reflects the prognostic significance of the genes.   
 In particular, α assesses the prognostic significance of each gene across all 
the samples in the integrated dataset. From the integrated dataset, we formed two 
groups. Group 1 had a metastasis or recurrence rate less than or equal to 5 years 
(most common point used in the literature), and Group 2 had a metastasis or 
recurrence rate greater than 5 years. The gene expression value of 0.5 (the middle 
value) was chosen as the probability measure, where the gene expressions less than 
0.5 and greater than (or equal to) 0.5 were regarded as underexpressed and 
overexpressed gene expressions, respectively. To evaluate α for any gene, we first 
defined the correlation-coefficient (cc) between metastasis or recurrence rate and 
gene expression as: 
ܿܿ ቀܶܶ ௜ܲǡ ݁௜ሺ௚ሻቁ ൌ ቊͳǢ ݂݅ሺܶܶ ௜ܲ ൑ ͷǡ ݁௜
ሺ௚ሻ ൏ ͲǤͷሻܱܴሺܶܶ ௜ܲ ൐ ͷǡ ݁௜ሺ௚ሻ ൒ ͲǤͷሻ
െͳǢ ܱݐ݄݁ݎݓ݅ݏ݁        
                            (5.1) 
where, ܶܶ ௜ܲdefines the time to progression (i.e., metastasis or recurrence rate (in 
years)) for ith sample,݁௜ሺ௚ሻ defines the gene expression of gene g in the ith sample, 
and ܿܿሺܶܶ ௜ܲǡ ݁௜ሺ௚ሻሻ defines correlation-coefficient between ܶܶ ௜ܲand݁௜ሺ௚ሻ. 
Therefore, the Correlation-factor (α) for any gene g can then be evaluated as:   
                              ߙሺ௚ሻ=  ଵே ሺ݌ െ ݍሻ                                (5.2)  
where, N defines the total number of samples in a dataset, p defines the total number 
of samples from the two groups that have a correlation-coefficient equaling 1, and 
q defines the total number of samples from the two groups that have correlation-
coefficient equaling – 1. Here, α evaluates the difference between two prognostic 
groups from a micro-level, and the higher the α of a gene, the higher chance of 
being prognostically associated with breast cancer, and vice-versa. However, α 
considered the micro-level dichotomized gene expression with dichotomized TTP 
(i.e., with two prognostic groups). Therefore, in order to reflect the actual difference 
between two prognostic groups, we used Ⱦ (see equation (5.3)) that incorporated an 
actual gene expression level from a macro point of view.           
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 Specifically, the Penalised-factor (β) penalises each gene across all samples 
depending on the size of difference between the two groups (i.e., Group 1 and 
Group 2, as mentioned above). For any gene g, we first evaluate the mean of each 
group based on the actual gene expression level, and the higher the difference 
between the mean of the two groups, the lesser it will be penalized, and vice-versa. 
Mathematically, β for any gene g can then be evaluated as:   
                           Ⱦሺ௚ሻ = 1 - ቤቀσ ௘೔
ሺ೒ሻಸభ೔సభ ቁ
ீభ െ
ቀσ ௘ೕ
ሺ೒ሻಸమ
ೕసభ ቁ
ீమ ቤ                         (5.3) 
where, ܩଵ and ܩଶdefines the total number of samples that belong to Group 1 and 
Group 2, respectively, and ݁௜ሺ௚ሻand ௝݁ሺ௚ሻdefines the gene expression of gene g in the 
ith and jth sample, respectively. Here, β evaluates the actual difference between 
two prognostic groups from a macro-level, and the higher the β of a gene, the less 
chance the gene will be selected in our prognostic gene signature, and vice-versa.  
 Therefore, to assess the overall prognostic significance of any gene g in the 
integrated dataset, their VC can be evaluated as the weighted combination of α, and 
β, i.e,    
                             ܸܥሺ௚ሻ= ሺ߬ଵ כ ߙሺ௚ሻሻ ൅ ሺ߬ଶ כ Ⱦሺ௚ሻሻ                             (5.4) 
where,ߙሺ௚ሻandȾሺ௚ሻ, represents the Correlation-factor and Penalised-factor for 
gene g, respectively, and ߬ଵ and ߬ଶ represents the weight associated with ߙ and Ⱦ, 
respectively . For the current setting, we assigned ߬ ଵ equals 1 and ߬ ଶ equals -1.0011, 
and these were chosen from our experimental analysis (i.e., by performing 
multivariate logistic regression analysis (see Section 5.3.3 for details)). The higher 
the VC score of a gene, the more chance of being selected in our prognostic gene 
signature, and vice-versa. Finally, to extract a set of robust genes based on their VC 
score, we constructed the Robust Virtual Chromosome.    
5.3.2 Robust Virtual Chromosome 
Our aim was to identify a set of robust genes with high VC scores in order to form 
our prognostic gene signature. For this purpose, we performed the following 
operations:  
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x First, we sorted the VC in descending order and then assigned a rank based 
on their VC values. The top gene shows the highest rank based on the 
highest VC value and the bottom gene shows the lowest rank based on the 
lowest VC value, i.e., 
Sorted VC =ሼܸܥ௡ሽ ;  ͳ ൑ ݊ ൑ ߮        (5.5) 
    s.t  ܸܥଵ ൒ ܸܥଶ ൒ ܸܥଷ ൒ ڮ൒ ܸܥఝ 
where, ܸܥ௡ defines the VC value for any gene that has been given nth rank, 
and ߮ defines the total number of genes in the integrated dataset. In the 
sorted VC list, the top genes through to the bottom genes reflect the highly 
associated to the least associated differentially expressed genes in regards 
to breast cancer prognosis.   
  
x Next, while moving down the sorted VC list, we define the robustness score 
(ܴ) in order to identify how far the genes can be selected to form our 
prognostic gene signature. In other words, the robustness score for any set 
of genes defines the weighted sum of the genes VC, with their weight 
evaluated as an inverse square root of the number of genes [151]. 
Specifically, the robustness score for any mth rank gene (݃௠) is: 
          ܴሺ௚೘ሻ ൌ ܴ௠ ൌ  ଵξ௠ሺσ ܸܥ௡௠௡ୀଵ ሻ          (5.6) 
The robustness score in the VC list first increases as it moves down, and 
then at a certain point achieves a maximum robustness score, and thereafter 
starts decreasing. Figure 5.1 illustrates the robustness score mechanism. 
The prime reason to generate a robustness score for the sorted VC list is to 
identify a set of top ranked robust genes that maximises the robustness 
score. Therefore, by using equation (5.6), the robustness score for each gene 
in the sorted VC list can be evaluated.   
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Figure 5.1: Robustness score overview. Here, ܸܥఝ represents the VC for any ߮th 
ranked gene. The robustness score in the list increases first until a certain point and 
then achieves a maximum robustness score, and thereafter begins to decrease.   
         
x Finally, to extract the robust genes, we identified the maximum robustness 
score in the sorted VC list. Therefore, the top gene until the gene whose 
robustness score was maximum, formed our prognostic gene signature, i.e., 
       ܴ௠௔௫ ൌ ଵஸ௠ஸఝ ܴ௠                                    (5.7)
        and, Our Prognostic Gene Signature = ሼ݃௡ሽ     (5.8)
         s.t     ܴሺ௚೙ሻ ൌ ܴ௡ ;  ܴଵ ൑ ܴ௡ ൑ ܴ௠௔௫  
   
5.3.3 Risk Score Estimation using Logistic Regression Model 
The multivariate logistic regression model was constructed (which used clinical 
data and microarray data) in an attempt to robustly discover the predictors of 
prognosis risk for breast cancer patients.      
 For each sample in the integrated dataset, we first generated the gene 
expression mean of our prognostic gene signature and referred to this as the 
mScore. Next, for patient samples with a missing ER or PR status, the dichotomised 
ER gene (ESR1) and PR gene (PgR) mRNA (positive and negative) value were 
considered. We used the following influential variables in our multivariate logistic 
regression model, as mentioned in Table 5.2. 
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Table 5.2: Variables used in our multivariate logistic regression model. 
Variable     Characteristics Code 
ଵܺ Tumor Grade (I-II) 
(III)  
0 
1 
            
 
ܺଶ 
                                              
 
Tumor Size (cm) 
(<2) 
(2-3) 
(≥4) 
0 
0.55 
1 
 
ܺଷ 
 
ER (Estrogen Receptor) (-) 
(+) 
-1 
1 
 
ܺସ 
 
PR (Progesterone Receptor) (-) 
(+) 
-1 
1 
 
ܺହ 
 
HER2 (Human Epidermal Growth Factor Receptor 2) (-) 
(+) 
-1 
1 
ܺ଺ mScore                                        
(Mean of our Prognostic Gene Signature) 
(0 
to1) 
NA 
 
By using the variables shown in Table 5.2, the multivariate logistic regression 
model was constructed using the backward selection approach to form the Risk 
Score (RS) formula. The standard way to represent the multivariate logistic 
regression equation is:   
ܮ݋݃݅ݐሺܲሻ ൌ ߚ଴ ൅ߚଵ ଵܺ ൅ߚଶܺଶ ൅ ڮ൅ ߚ௡ܺ௡      (5.9) 
where,ܮ݋݃݅ݐሺܲሻ ൌ ሾܲȀሺͳ െ ܲ)], P is the estimated probability of breast cancer 
prognosis, ߚ଴defines the constant, and ߚ௡defines the regression coefficient for the 
nth variable (i.e., ܺ௡variable). Here, ܺ௡is a promoting factor ifߚ௡ ൐ Ͳ, and ܺ௡is 
a supressing factor ifߚ௡ ൏ Ͳ. A model with ܺ௡that has a p-value less than or equal 
to 0.05 was considered to be statistically significant.      
 The Receiver Operating Characteristic (ROC) curves were used to assess 
the performance of the prediction model and determine an optimal cut-off point of 
߳ that give maximum sensitivity and specificity. Therefore, a sample can be 
classified as a good/poor prognosis if their RS is lesser/greater than the chosen cut-
off point of ߳from equation (5.9). The full algorithm workflow is shown in Figure 
5.2.       
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Figure 5.2: IPRE algorithm workflow. 
            
  
5.4 Results and Discussion   
We conducted experiments on the integrated dataset of 2,692 samples (see Section 
5.2.2). The samples with repetitions or a missing metastasis or recurrence rate were 
excluded. 2,268 samples remained, consisting of 897 poor prognosis breast cancer 
patients (metastasis or recurrence rate within five years) and 1,371 good prognosis 
breast cancer patients (metastasis or recurrence rate with more than five years). We 
named this integrated dataset the 2,268 dataset for illustrative purposes during our 
experiment.          
 Since the 2,268 dataset contains an unequal number of samples in two 
prognosis groups, this can make the algorithm biased towards the group with higher 
number of samples. Therefore, to reduce the bias in the 2,268 dataset, we balanced 
both good and poor prognosis patient samples, i.e, 897 poor prognosis breast cancer 
patients and 897 good prognosis breast cancer patients, with a total of 1,794 
samples. We called this integrated dataset the 1,794 dataset for illustrative purposes 
during our experiment.        
 By applying our IPRE algorithm on the 1,794 dataset, we identified 79 
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breast cancer prognostic genes (log-rank test, p-value < 2e-16) that formed our 
prognostic gene signature (see Appendix C). The mScore (mean score of the gene 
signature) was then generated for each sample in the 1,794 dataset (see Section 
5.3.3).           
 The ‘survival’ package of the R-project [163] has been used to generate a 
multivariate logistic regression analysis on the 1,794 dataset with the variables ER, 
PR, HER2, tumor size, tumor grade, and mScore. As discussed earlier, we 
considered and selected variables that had a p ≤ 0.05 from our multivariate model 
and further used this for the risk score estimation to classify samples as either good 
or poor prognosis based on their score. Table 5.3 lists the results of the variables 
(as mentioned in Table 5.2) from our multivariate analysis.    
Table 5.3: Multivariate analysis of the variables in the 1,794 dataset. 
Variable Characteristics ߚ z p Selected 
ଵܺ Grade -0.06176 -0.674 0.50 No 
ܺଶ Size -0.34534 -3.029 0.002 Yes 
ܺଷ ER -0.19854 -4.441 8.95E-06 Yes 
ܺସ PR -0.21123 -4.356 1.33E-05 Yes 
ܺହ HER2 0.08819 1.761 0.08 No 
ܺ଺ mScore -1.13115 -12.918 2.00E-16 Yes 
 Constant -0.99475    
                            
From Table 5.3, the tumor grade and the HER2 status variable were not selected as 
their p >0.05. Therefore, tumor size, ER, PR, and the mScore were selected (being 
statistically significant) in our multivariate logistic regression model, and the Risk 
Score (RS) formula generated from our model used for predicting the prognosis of 
breast cancer patients is represented as  
ܴܵ ൌ െͲǤͻͻͶ͹ͷ െ ͲǤ͵Ͷͷ͵Ͷܺଶ െ ͲǤͳͻͺͷͶܺଷ െ ͲǤʹͳͳʹ͵ܺସ െ ͳǤͳ͵ͳͳͷܺ଺           
  (5.10)   
With equation (5.10), the risk score can be estimated for any sample that can 
classify breast cancer patients into either a good or poor prognosis using the chosen 
cut-off point of߳. From our experiments (see Section 5.4.1), we identified ߳ equals 
-1.480, which determines a sample as a poor prognosis if their RS is greater than 
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or equal to -1.480. However, a sample can be classified as a good prognosis if their 
RS is less than -1.480, i.e., 
If RS ≥ -1.480        
  Then poor-prognosis (or high risk patients to breast cancer  
  metastasis/recurrence)  
Else If RS < -1.480         
  Then good-prognosis (or low risk patients to breast cancer  
  metastasis/recurrence)      
  
The classification results on the 1,794 dataset, the 2,268 dataset and the two testing 
datasets, in addition to a comparison with other popular existing prognosis based 
algorithms, are detailed in the following sub-sections. 
5.4.1. Classification Results on Integrated Training Datasets  
We first performed the experiments on an integrated training dataset, i.e., the 2,268 
dataset, and then on the 1,794 dataset. The experiments were initially performed on 
a constructed risk score formula (equation (5.10)) with different cut-off points in 
order to choose the robust cut-off point than can characterise the two prognosis 
breast cancer patient groups with high accuracy, sensitivity and specificity. We 
define sensitivity as the ability of the algorithm to identify the poor prognosis 
patients as poor-prognosis, specificity as the ability of the algorithm to identify the 
good prognosis patients as good-prognosis, and accuracy as the ability of the 
algorithm to accurately identify the patients as either good or poor prognosis 
patients. Our aim was not just to achieve high accuracy while ignoring sensitivity 
or specificity, but to achieve high sensitivity, specificity and accuracy. It is to be 
noted that we are more interested in achieving high specificity in order to spare the 
good prognosis patients with aggressive treatments. At the same time, we are 
interested in achieving high sensitivity in order to guide the poor prognosis patients 
with the advanced treatment options available to them.           
 Table 5.4 shows the classification results of our IPRE algorithm with 
different cut-off points in the 1,794 dataset and 2,268 dataset, respectively. Table 
5.4 shows that a cut-off point of -1.480 (in both the datasets) achieves a high F-
value (see equation (2.18) for details), sensitivity, specificity and accuracy, 
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amongst others, and therefore -1.480 is chosen as a cut-off point in our risk score 
formula. Specifically, on the 1,794 dataset, the IPRE algorithm achieves 73% F-
value, 77% accuracy, 63% sensitivity and 91% specificity. On the other hand, for 
the 2,268 dataset, the IPRE algorithm achieves 59% F-value, 66% accuracy, 60% 
sensitivity, and 71% specificity. These results are reported in Table 5.4 (highlighted 
as bold) with their boxplots shown in Figure 5.3. Clearly, the 1,794 dataset that has 
an equal proportion of two prognosis groups shows much better results than the 
2,268 dataset.  
Table 5.4: Prognosis based average classification results of the IPRE algorithm in (a) the 
1,794 dataset, and (b) the 2,268 dataset, with different cut-off points. 
 Cut-off TN FP TP FN SE                 
(95% CI) 
SP                 
(95% CI) 
ACC              
(95% CI) 
F               
(95% CI) 
 
 
 
 
 
 
 
 
 
 
(a) 1,794 
Dataset 
-0.6 
 
897 
 
0 
 
214 
 
683 
 
0.239 
(0.21 to 0.27) 
1 
(1 to 1) 
0.619 
(0.6 to 0.64) 
0.385 
(0.35 to 0.42) 
-1 892 
 
5 
 
343 
 
554 
 
0.382 
(0.35 to 0.41) 
0.994 
(0.99 to 1) 
0.688 
(0.67 to 0.71) 
0.551 
(0.52 to 0.59) 
-1.2 878 
 
19 
 
456 
 
441 
 
0.508 
(0.48 to 0.54) 
0.979 
(0.97 to 0.99) 
0.744 
(0.72 to 0.76) 
0.665 
(0.63 to 0.7) 
-1.4 834 
 
63 
 
530 
 
367 
 
0.591 
(0.56 to 0.62) 
0.930 
(0.91 to 0.95) 
0.760 
(0.74 to 0.78) 
0.711 
(0.68 to 0.74) 
-1.48 815 
 
82 
 
567 
 
330 
 
0.632 
(0.6 to 0.66) 
0.909 
(0.89 to 0.93) 
0.770 
(0.75 to 0.79) 
0.734 
(0.7 to 0.76) 
-1.6 764 
 
133 
 
573 
 
324 
 
0.639 
(0.61 to 0.67) 
0.852 
(0.83 to 0.88) 
0.745 
(0.73 to 0.77) 
0.715 
(0.68 to 0.75) 
-1.8 672 
 
225 
 
616 
 
281 
 
0.687 
(0.66 to 0.72) 
0.749 
(0.72 to 0.78) 
0.718 
(0.7 to 0.74) 
0.709 
(0.68 to 0.74) 
-2 569 
 
328 
 
653 
 
244 
 
0.728 
(0.7 to 0.76) 
0.634 
(0.6 to 0.67) 
0.681 
(0.66 to 0.7) 
0.695 
(0.67 to 0.73) 
-2.2 453 
 
444 
 
709 
 
188 
 
0.790 
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Here, TP defines true positive (poor prognosis patients predicted as poor prognosis), TN defines 
true negative (good prognosis patients predicted as good prognosis), FP defines false positive (good 
prognosis patients predicted as poor prognosis), FN defines false negative (poor prognosis patients 
predicted as good prognosis), ACC defines the accuracy of the algorithm, SE defines sensitivity, SP 
defines specificity, F defines the F-value, and 95% CI defines 95% confidence intervals. A cut-off 
point of -1.480 (highlighted as bold) gives better results in terms of high SE, SP and ACC, compared 
with other cut-off points.                   
 
    
Figure 5.3: The boxplot of the IPRE algorithm for two prognosis groups, i.e., poor-
prognosis and good-prognosis in the 1,794 dataset and the 2,268 dataset. The left figure 
represents the boxplot for the 1,794 dataset and the right figure represents the boxplot for 
the 2,268 dataset. This box plots represents the first quartile (i.e., the lower solid edge of 
the box), median (i.e., the middle solid horizontal line inside the box), third quartile (i.e., 
the upper solid edge of the box), and minimum and maximum (i.e., the lower and upper 
solid horizontal lines, respectively). The minimum and maximum represent a distance of 
1.5 times the interquartile range (IQR) from the lower quartile and upper quartile, 
respectively. Here, the x-axis represents the two prognosis groups, the y-axis represents 
the risk scores, and the dotted horizontal line represents our cut-off point, i.e., -1.480.  It 
can be clearly seen the two prognosis groups are separated in both datasets.   
      
The overall performance of the model was assessed by drawing Receiver Operating 
Characteristic (ROC) curve at different thresholds and by evaluating the area under 
the ROC curve (AUC). The larger the area under the ROC curve of an algorithm, 
the more effective the algorithm is. A model with an AUC of 0.5 is similar to 
flipping a coin. The ROC curve of an IPRE algorithm in the 1,794 dataset and the 
2,268 dataset is shown in Figure 5.4.   
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Figure 5.4: ROC curves of the IPRE algorithm in the 1,794 dataset and the 2,268 dataset. 
Clearly, this validates the better 1,794 dataset compared to the 2,268 dataset. 
  
The performance of the IPRE algorithm is good in the 1,794 dataset with an AUC 
of 0.770, whereas the algorithm performs average on the 2,268 dataset with an AUC 
of 0.688. This demonstrates that the 1,794 dataset was less biased than the 2,268 
dataset, and therefore, used to extract our prognostic gene signature and risk score 
formula (equation (5.10)) to classify the good and poor prognosis patient groups in 
the testing datasets.       
 Further, we compared our IPRE algorithm (which consists of clinical 
variables and a gene signature) with IPRE (G) (that consists of a gene signature) 
and IPRE (C) (that consists of clinical label) on the 1,794 dataset and the 2,268 
dataset, respectively. The operations were similar to IPRE for the training and the 
construction of the risk-score formula for IPRE (G) and IPRE (C), respectively. 
Figure 5.5 shows the classification results of the IPRE, IPRE (G), and IPRE (C) 
algorithm. From these results it clearly shows the IPRE algorithm, which consists 
of both a genetic and clinical component, outperforms IPRE (G), i.e., only 
consisting of the genetic component, and outperforms IPRE (C), i.e., only 
consisting of the clinical component. Also, IPRE (G) shows better results than IPRE 
(C), which demonstrates the effectiveness of our gene signature. 
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Figure 5.5: Classification results of the IPRE (C), IPRE (G), and IPRE algorithm on the 
1,794 and 2,268 dataset.        
      
5.4.2 Classification Results on Testing Datasets     
To assess the performance of our model with a chosen cut-off point of -1.480 (see 
equation (5.10)) constructed with the IPRE algorithm, two testing datasets were 
used, i.e., (a) the Desmedt dataset (GSE7390) [55], and (b) the Vijver dataset [206]. 
Comparisons with seven other existing prognosis based algorithms along with 
IPRE (G) and IPRE (C) were also performed to demonstrate the IPRE algorithm 
was more effective. The algorithms were the 70-gene signature [206], the 21-gene 
signature [157], the 76-gene signature [216], the Genomic Grade Index (GGI) 
[192], the Invasiveness Gene Signature (IGS) [131], the 112-gene signature [224], 
and the Interactome-Transcriptome Integration (ITI) [75]. Table 5.5 and Figure 5.6 
shows the classification results of the IPRE algorithm along with IPRE (G), IPRE 
(C), and seven other existing algorithms in the testing dataset of the Desmedt and 
the Vijver, respectively. Furthermore, the IPRE algorithm boxplots for the Desmedt 
and the Vijver dataset are shown in Figure 5.7. This clearly illustrates the separation 
between the two prognosis groups.   
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Table 5.5: Prognosis based classification results of the IPRE, IPRE (G), IPRE (C), and 
seven other existing algorithms in the testing dataset of (a) the Desmedt, and (b) the Vijver.    
                Algorithm N TN FP TP FN SE           
(95% CI) 
SP                      
(95% CI) 
ACC                  
(95% CI) 
 
 
 
           
 
 
 
(a) 
Desmedt 
dataset 
GGI 190 86 66 28 10 0.737 
(0.60 to 0.88) 
0.566 
(0.49 to 0.64) 
0.600  
(0.53 to 0.67) 
70 g 190 42 110 34 4 0.895 
(0.80 to 0.99) 
0.276 
(0.21 to 0.35) 
0.400  
(0.33 to 0.47) 
76 g 190 80 72 23 15 0.605 
(0.45 to 0.76) 
0.526 
(0.45 to 0.61) 
0.542  
(0.47 to 0.61) 
112 g 190 64 88 34 4 0.895 
(0.80 to 0.99) 
0.421 
(0.34 to 0.50) 
0.516  
(0.45 to 0.59) 
IGS 190 90 62 21 17 0.553 
(0.39 to 0.71) 
0.592 
(0.51 to 0.67) 
0.584  
(0.51 to 0.65) 
21 g 190 25 127 38 0 1 
(1.00 to 1.00) 
0.164 
(0.11 to 0.22) 
0.332  
(0.27 to 0.40) 
ITI 190 124 28 12 26 0.316 
(0.17 to 0.46) 
0.816 
(0.75 to 0.88) 
0.716  
(0.65 to 0.78) 
IPRE 
(C) 
190 104 48 9 29 0.237 
(0.10 to 0.37) 
0.684 
(0.61 to 0.76) 
0.595  
(0.53 to 0.67) 
 IPRE 
(G) 
190 128 24 19 19 0.500 
(0.34 to 0.66) 
0.842 
(0.78 to 0.90) 
0.774  
(0.71 to 0.83) 
 IPRE 190 133 19 23 15 0.605 
(0.45 to 0.76) 
0.875 
(0.82 to 0.93) 
0.821                 
(0.77 to 0.88) 
          
 
 
 
 
 
 
(b) 
Vijver 
dataset 
GGI 150 68 38 28 16 0.636 
(0.49 to 0.78) 
0.642 
(0.55 to 0.73) 
0.640  
(0.56 to 0.72) 
70 g 150 51 55 39 5 0.886 
(0.79 to 0.98) 
0.481 
(0.39 to 0.58) 
0.600 
(0.52 to 0.68) 
76 g 150 65 41 28 16 0.636 
(0.49 to 0.78) 
0.613 
(0.52 to 0.71) 
0.620  
(0.54 to 0.70) 
112 g 150 42 64 33 11 0.750 
(0.62 to 0.88) 
0.396 
(0.30 to 0.49) 
0.500  
(0.42 to 0.58) 
IGS 150 38 68 40 4 0.909 
(0.82 to 0.99) 
0.358 
(0.27 to 0.45) 
0.520  
(0.44 to 0.60) 
21 g 150 2 104 44 0 1 
(1.00 to 1.00) 
0.019                     
(-0.01 to 0.04) 
0.307 
(0.23 to 0.38) 
ITI 150 78 28 10 34 0.227 
(0.10 to 0.35) 
0.736 
(0.65 to 0.82) 
0.587 
(0.51 to 0.67) 
IPRE 
(C) 
150 76 30 8 36 0.182 
(0.07 to 0.30) 
0.717 
(0.63 to 0.80) 
0.560  
(0.48 to 0.64) 
 IPRE 
(G) 
150 94 12 25 19 0.568 
(0.42 to 0.71) 
0.887 
(0.83 to 0.95) 
0.793  
(0.73 to 0.86) 
 IPRE 150 101 5 29 15 0.659 
(0.52 to 0.80) 
0.953 
(0.91 to 0.99) 
0.867  
(0.81 to 0.92) 
 
Due to space restrictions, we represent the Genomic Grade Index as GGI, the 70-gene signature as 
70 g, the 76-gene signature as 76 g, the 112-gene signature as 112 g, the Invasiveness Gene 
Signature as IGS, the 21-gene signature as 21 g, Interactome-Transcriptome Integration as ITI. From 
the table, the IPRE algorithm achieved superior performance amongst others (as highlighted in bold) 
in the Desmedt dataset and the Vijver dataset.        
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Figure 5.6: Classification results of the IPRE, IPRE (G), IPRE (C), and seven other existing 
algorithms on the Desmedt and the Vijver dataset.    
  
    
Figure 5.7: The boxplot of the IPRE algorithm for two prognosis groups, i.e., poor-
prognosis and good-prognosis. The left figure represents the boxplot for the Desmedt 
dataset and the right figure represents the boxplot for the Vijver dataset. Here, the x-axis 
represents the two prognosis groups, the y-axis represents the risk scores, and the dotted 
horizontal line represents our chosen cut-off point, i.e., -1.480.  It can be clearly seen the 
two prognosis groups are separated in both datasets.    
  
Table 5.5 and Figure 5.6 shows the IPRE and IPRE (G) algorithms achieved 
superior results compared to IPRE (C) and other existing popular prognosis based 
algorithms. Specifically, on the Desmedt dataset, the IPRE and IPRE (G) 
algorithms were able to achieve a prognosis classification accuracy of 82% 
(specificity of 88%) and 77% (specificity of 84 %), respectively. This was 
significantly higher than the classification accuracies of IPRE (C), i.e., 60% 
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(specificity of 68 %), and other existing algorithms, i.e., 60% (specificity of 57 %) 
for GGI, 40% (specificity of 28%) for 70 g, 54% (specificity of 53%) for 76 g, 52% 
(specificity of 42%) for 112 g, 58% (specificity of 59%) for IGS, 33% (specificity 
of 16%) for 21 g, and 72% (specificity of 82%) for ITI. Similar results were 
achieved from the Vijver dataset which shows the IPRE and IPRE (G) algorithms 
were able to achieve a prognosis classification accuracy of 87% (specificity of 
95%) and 80% (specificity of 89%), respectively. This was much higher than the 
classification accuracies of IPRE (C), and other existing algorithms (see Table 5.5). 
 From the two testing datasets, the IPRE algorithm achieved the highest 
accuracy and performed better than any of the others, including IPRE (G), IPRE 
(C) and other existing algorithms. It should be noted that if comparing the existing 
algorithms in the Desmedt dataset, ITI showed the second best results (in terms of 
accuracy) and GGI ranked third. On the other hand, in the Vijver dataset, GGI 
ranked second and ITI ranked fifth. This points to the fact the classification 
accuracy of existing algorithms heavily depends on the choice of their training 
dataset selection. Therefore, it can be true to say that existing algorithms do not 
show consistent performance across distinct microarray datasets as these 
algorithms are biased towards the datasets used for generating gene signatures. 
However, by increasing the training compendia to a large number of samples with 
multiple microarray platforms, the algorithm’s dependency on the datasets or 
microarray platforms can be greatly reduced. This was demonstrated by the IPRE 
algorithm as we incorporated multiple training datasets with a very large number 
of samples across multiple microarray platforms. Therefore, these results 
concluded that the IPRE algorithm was stable and robust against any testing dataset 
(or their microarray platform) in order to categorise the good prognosis (low risk) 
versus poor prognosis (high risk) breast cancer patients.   
 Further, a logistic regression model was constructed (which used clinical 
variables and a gene signature) for each existing algorithm in a similar way as 
constructed for the IPRE algorithm (see Section 5.3.3). The purpose of this was to 
fairly evaluate and compare the performance of existing algorithms by removing 
any differences that came with clinical variables or their gene signatures. For 
simplicity, we still denote the existing algorithms as IGS, 21g, 112g, 70g, 76g, GGI, 
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and ITI. Figure 5.8 shows the classification performance of IPRE and other existing 
algorithms constructed using the logistic regression model with considered clinical 
variables and their respective gene signatures. This figure demonstrates the IPRE 
algorithm achieved higher specificity and accuracy which outperformed existing 
algorithms. For each of the existing algorithms, these experiments concluded that 
integrating clinical variables and gene signatures (see Figure 5.8) showed better 
classification performances than only considering gene signatures (see Figure 5.6). 
Furthermore, these experiments conducted using different angles showed the 
effectiveness of the proposed algorithm in classifying the two prognosis groups. 
 
 
Figure 5.8: Classification results of IPRE and seven other existing algorithms constructed 
with a logistic regression model (with integrated clinical variables and their gene signature) 
on the Desmedt and Vijver dataset.        
   
Venet et al. [210] compared 47 breast cancer gene signatures to the signatures made 
by random genes and claimed that most random gene expression signatures are 
significantly associated with the breast cancer outcome. Their study showed that 
almost 60% of existing gene signatures were not significantly better outcome 
predictors than the random gene signatures that contain 1,000 gene signatures of 
identical size, while nearly 23% of them were worst predictors. Therefore, we 
constructed 1,000 random gene signatures of identical size to compare the IPRE 
algorithm against random gene signatures. To fairly evaluate the IPRE algorithm, 
we incorporated the clinical variables with the random gene signatures and called 
it RAND.          
 Figure 5.9 reveals the IPRE algorithm showed a significantly stronger 
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association with the distant metastasis free survival (DMFS) outcome than the 
median of the random gene signatures (RAND) in the Desmedt dataset and the 
Vijver dataset, respectively. The classification results of the RAND and IPRE 
algorithms in the Desmedt dataset and the Vijver dataset is shown in Table 5.6. 
These results clearly show the IPRE algorithm significantly outperformed RAND. 
 
Figure 5.9: Bar plot representing the p-value of the distant metastasis free survival (DMFS) 
outcome for RAND and IPRE in the Desmedt and Vijver dataset, respectively. Here, the 
p-value of RAND represents the median p-value generated from the random gene 
signatures.           
  
Table 5.6: Prognosis based classification results of the RAND and IPRE algorithms in the 
testing dataset of (a) the Desmedt, and (b) the Vijver. 
                Algorithm  N TN FP 
 
TP FN SE                     
(95% CI) 
SP                      
(95% CI) 
ACC                  
(95% CI) 
 
(a) 
Desmedt 
dataset 
RAND 190 128 24 23 15 0.605 
(0.45 to 0.76) 
0.842   
(0.78 to 0.90) 
0.795                 
(0.74 to 0.85) 
IPRE 190 133 19 23 15 0.605 
(0.45 to 0.76) 
0.875 
(0.82 to 0.93) 
0.821                 
(0.77 to 0.88) 
 
(b) Vijver 
dataset 
RAND 150 91 15 26 16 0.619 
(0.47 to 0.77) 
0.858 
(0.79 to 0.92) 
0.791                 
(0.73 to 0.86) 
IPRE 150 101 5 29 15 0.659 
(0.52 to 0.80) 
0.953 
(0.91 to 0.99) 
0.867                 
(0.81 to 0.92) 
          
To get the overall picture of performance comparison of IPRE and other existing 
algorithms, as discussed, we calculated hazard ratios (ratio of hazard rates) using 
all combinations of DMFS end-points and cohorts in Desmedt dataset. This is 
shown in Table 5.7. Their related survival analysis is also discussed below (see 
Figure 5.10). Our analysis concluded that the IPRE algorithm was a significantly 
better outcome predictor than the random gene signatures of identical size. 
However, the random gene signatures showed a significantly better outcome than 
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the other published gene signatures used in our study. These results further validate 
the findings of Venet et al. [210] who suggest most existing gene signatures are not 
significantly better outcome predictors than the random gene signatures of identical 
size.      
Table 5.7: Hazard ratios for comparison of the distant metastasis free survival (DMFS) 
association of IPRE and other algorithms in the Desmedt dataset.  
 
Here, HR stands for Hazard Ratio and 95% CI represents 95% confidence intervals. The lesser the 
HR, the stronger the survival association of the algorithm is. Many existing published gene 
signatures and the random gene signatures of identical size are not better outcome predictors than 
IPRE.    
     
Next, a Kaplan-Meier survival analysis was performed on the Desmedt dataset by 
using the ‘survival’ package of the R-project [163]. Figure 5.10 shows the survival 
curves of the IPRE algorithm and seven other existing algorithms using the DMFS 
rate. The log-rank statistical test gave a p-value of 5.32e-09 for the IPRE algorithm, 
which was statistically significant (i.e., p-value ൑ 0.05) and indicated the best 
separation between the two prognosis groups (i.e., good prognosis or low risk to 
distant metastasis, and poor prognosis or high risk to distant metastasis) as 
compared with other existing algorithms. It should be noted the 70 g and IGS 
algorithms were incapable of separating the patients into significant prognostic 
groups (p-value > 0.05). These results supported our previous conclusions that the 
IPRE algorithm was robust enough to separate the patients into two significant 
prognosis groups.   
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Figure 5.10: Kaplan-Meier survival graphs for good and poor prognosis groups in the 
Desmedt dataset for the IPRE algorithm and seven other existing algorithms. A log-rank 
test was performed to assess the p-value and to signify the lower the p-value, the better the 
separation between the two prognosis groups. From this figure, the IPRE algorithm was 
able to achieve the lowest p-value and performed the best at separating the two prognosis 
groups.          
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5.4.3 Our Prognostic Gene Signature Stability with Existing 
Gene Signatures 
We performed stability analysis for assessing the overlap between existing gene 
signatures and our prognostic gene signature. Table 5.8 shows the number of 
overlapped genes from our prognostic gene signature compared with other existing 
signatures.       
Table 5.8: The number (percentage) of genes in our prognostic gene signature that matches 
existing gene signatures. 
Existing Gene 
Signatures 
 
Matched genes of our prognostic gene signature 
 ( in number (percentage) ) 
Bar representing 
matched genes 
ITI 16 (21%)    
76 g 3 (4%)    
70 g 2 (3%)    
LRT 2 (3%)    
IGS   1 (1.3%)    
GGI 0  
21 g 0  
The last column represents the bar graph of our matched genes (in percentage) with other gene 
signatures. Here, the ITI gene signature shows the maximum overlap (21%) amongst other 
representative gene signatures.   
          
Our prognostic gene signature shows the overlap with existing gene signatures 
within the range of 1-21%. We discovered that gene signatures extracted from the 
multiple training datasets, such as ITI, performed better and showed a greater 
overlap with our gene signature, i.e., 21%. This overlap was significantly greater 
compared to other gene signatures generated from a lower number of training 
samples. This demonstrates the effectiveness of incorporating a larger number of 
patient samples in a training dataset with multiple microarray platforms to enhance 
the performance of the algorithm across a wide range of testing datasets.    
5.4.4 Biological Analysis of Our Prognostic Gene Signature 
The biological analysis of our prognostic gene signature was performed using GO 
analysis and pathway analysis. For each gene in our prognostic gene signature, GO 
analysis was performed using the enriched biological process GO terms [11], and 
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the pathway analysis was performed using the KEGG pathways [114] (see Section 
4.4.3 for details).        
 Table 5.9 and 5.10 represents the enriched GO terms and the enriched 
KEGG pathways for our prognostic gene signature, respectively.     
Table 5.9: Enriched biological process GO terms for the genes in our prognostic gene 
signature. 
GO Description p-value 
GO:0050920 Regulation of chemotaxis 4.74E-05 
GO:0002541 Activation of plasma proteins involved in acute inflammatory response 5.20E-05 
GO:0050778 Positive regulation of immune response 6.71E-05 
GO:0006958 Complement activation, classical pathway 3.54E-04 
GO:0051605 Protein maturation by peptide bond cleavage 7.67E-04 
GO:0006954 Inflammatory response 9.13E-04 
GO:0009611 Response to wounding 9.19E-04 
GO:0032103 Positive regulation of response to external stimulus 1.88E-06 
GO:0043627 Response to estrogen stimulus 3.54E-04 
GO:0050867 Positive regulation of cell activation 1.50E-04 
GO:0008283 Cell proliferation 1.88E-06 
GO:0009991 Response to extracellular stimulus 1.05E-04 
GO:0010647 Positive regulation of cell communication 1.32E-04 
GO:0042981 Regulation of apoptosis 2.08E-05 
GO:0010941 Regulation of cell death 5.20E-05 
GO:0006355 Regulation of transcription, DNA-dependent 1.50E-04 
GO:0042325 Regulation of phosphorylation 1.05E-04 
          
Table 5.10: Enriched pathway classes for the genes in our prognostic gene signature. 
Pathway description p-value 
Cell adhesion molecules (CAMs) 4.49E-04 
Cell Cycle 5.74E-04 
Integrin signalling pathway 2.08E-05 
ECM-receptor interaction 1.88E-06 
Axon guidance 5.74E-04 
Signaling by PDGF 4.49E-04 
Focal adhesion 1.88E-06 
Signaling in immune system 3.53E-05 
T cell activation 1.50E-04 
Metabolism of lipids and lipoproteins 1.50E-04 
ATM signaling 3.54E-04 
Inflammation mediated by chemokine and cytokine signaling pathway 2.08E-05 
TGF-beta signaling 5.20E-05 
Pathways in cancer 4.49E-04 
Apoptosis 1.08E-06 
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From Table 5.9, it can be seen that several enriched GO terms are associated with 
the processes that were seen to be disrupted in the cancers, such as regulation of 
apoptosis, regulation of transcription, cell proliferation, positive regulation of cell 
activation, and positive regulation of immune response, etc. Furthermore, Table 
5.10 shows the pathways of our prognostic gene signature were related to the 
cancers, such as apoptosis, cell cycle, integrin signalling pathway, T cell activation, 
ATM signalling, and pathways in cancer, etc. These results demonstrate that our 
prognostic gene signature consists of biologically significant genes biologically 
associated with the cancers. Figure 5.11 further illustrates the biological meaning 
of our prognostic gene signature by showing the KEGG Cell Cycle pathway and 
the genes in our gene signature (as highlighted in red) that appear in this pathway. 
It was observed that many genes in our prognostic gene signature were associated 
with the KEGG Cell Cycle pathway.        
 We also observed that various genes in our prognostic gene signature were 
previously recognised as oncogenes, such as, CD74, GATA3, CD24, C1S, whose 
altered expression pattern were associated with different prognosis states or with 
various types of cancers [141, 146, 147, 148]. However, for other genes not 
previously reported as oncogenes, they may be the innovative oncogenes that 
promote breast cancer or its aggressiveness. These facts conclude that our 
prognostic gene signature is biologically meaningful and relates to breast cancer 
prognosis.   
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Figure 5.11: The KEGG pathway of a Cell Cycle. Here, the box highlighted red represents 
the genes in our gene signature. This figure was generated using the KEGG mapper 
[http://www.genome.jp/kegg/tool/map_pathway1.html].     
              
5.5 Summary   
We proposed a prognosis based classification algorithm to categorise breast cancer 
patients as high versus low risk. We developed a virtual chromosome to extract our 
prognostic gene signature that consists of 79 differentially expressed genes. This 
study particularly focussed on achieving high specificity, at the same time as 
achieving high sensitivity. For this, a multivariate logistic regression model was 
then used to correlate both the microarray data (our prognostic gene signature) and 
the clinical data (tumor size, ER, PR) to generate the risk score estimation formula. 
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A -1.480 cut-off point was chosen to distinguish two prognosis groups of breast 
cancer patients.         
 The classification results showed the IPRE algorithm was significant in 
achieving high specificity (and also high sensitivity) compared with other existing 
algorithms (see Section 5.4), which was the initial aim of our study so low risk 
patients could avoid unnecessary or aggressive therapies. In general, the IPRE 
algorithm achieves the following properties.   
x High Performance: achieves high classification performance in terms 
of high accuracy (and high specificity) for classifying the two prognosis 
groups. 
x Dataset Independence: achieves good results in the independent 
testing datasets (i.e., the dataset that was not used in the training 
dataset). This signifies the independency of the IPRE algorithm for any 
testing datasets or for any microarray platforms. 
x Better Classification: able to outperform the accuracy of seven other 
popular representative prognosis based algorithms. 
x Biological Significance: biological meaning of the IPRE algorithm 
based prognostic gene signature is significant and related to the cancers. 
This concludes that the IPRE algorithm was robust and effective in classifying the 
two prognosis groups without depending on any other factors. The above 
discussions and results suggest the proposed algorithm has the potential to guide 
physicians at the early decision stage of breast cancer prognosis.  
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Chapter 6  
 
Treatment Response Prediction for 
Breast Cancer Patients 
 
6.1 Introduction 
Advances in biotechnology and genomics have gradually discovered that breast 
cancers are biologically heterogeneous diseases with regards to different responses 
to chemotherapy and their clinical behavior is correlated with different molecular 
characteristics [133]. However, an in-depth understanding of the mechanisms 
underlying response to chemotherapy is critical for the development of effective 
biomarkers (or gene signatures) for selecting the appropriate therapeutic options 
available for patients. In previous years, a lot of progress has been made in 
identifying diagnostic or prognostic gene signatures for breast cancers, while gene 
signatures for predicting the response to standard chemotherapy regimens, called 
predictive gene signatures, has shown to be a far more complex problem [207].  
 A number of studies [37, 48, 49, 146, 159] have been developed in the past 
few years identifying gene signatures that have predicted the outcome of 
chemotherapy among breast cancer patients, with promising results. However, 
these studies developed the predictive gene signatures by considering a limited 
number of patient samples in the training cohort, which resulted in the low 
performance of their gene signatures predicting the treatment response in multiple 
validation (independent) cohorts. In addition, most studies with validation sets 
tested their signatures in a population treated with the same chemotherapy regimen 
(compared with training set), while some studies considered the validation sets 
treated differently. Furthermore, it has been shown their gene signatures were not 
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indicative of a gene’s role in the biological mechanisms underlying a drug’s 
response. Extracting the biological significance from whole genome molecular 
profiling remains a critical challenge [133].  Therefore, predictive gene signatures 
with improved performances over multiple validation cohorts and deeper biological 
insights into drug action related mechanisms are essential factors for translating 
them into clinical applications [49]. While this remains elusive, it is the potential 
aim of this current study.       
 Neoadjuvant (preoperative) chemotherapy is used to directly assess the 
binary tumor’s response to therapy, including complete eradication of all invasive 
cancer with no regional lymph nodes involved, which is called pathologic complete 
response (pCR). This response to chemotherapy has been correlated with excellent 
long-term cancer relapse-free survival [98]. The presence of residual invasive 
cancer, called a non-pathologic complete response (npCR), is correlated with poor 
short-term relapse-free survival. An accurate prediction of a neoadjuvant 
chemotherapy response can improve the survival rate of breast cancer patients for 
those achieving pCR, or reciprocally can spare the patients this aggressive therapy 
and the associated high-costs involved, while achieving npCR.             
 Cox et al. [45] showed several different combinations of chemotherapeutic 
agents (anthracycline (doxorubicin, epirubicin) – taxane (docetaxel, paclitaxel), 
doxorubicin/cyclophosphamide, taxane, and their combinations) are effective in the 
neoadjuvant setting. Also, adequately dosed multi-agent chemotherapy appears to 
be more successful than single-agent chemotherapy, and currently the combination 
of anthracyclines and taxanes might lead to a promising treatment approach 
benefiting patients with metastatic disease [70]. Therefore, one of the aims of the 
current study is to develop a general predictive gene signature that will accurately 
predict a pCR to standard chemotherapeutic regimens, including anthracyclines-
taxanes based combinations either between them or with other agents (fluorouracil, 
cyclophosphamide, gemcitabine, and capecitabine).     
 In this chapter, we propose a novel computational chemotherapy 
responsiveness prediction algorithm, called prediction of chemotherapy regimens 
treatment outcomes (ܥ݄݁݉݋), to predict the samples as either pCR or npCR in 
their neoadjuvant settings. First, from the training cohort of chemotherapy response 
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based breast cancer patient samples, a 10-fold cross-validation was performed to 
extract the predictive gene signatures to avoid over-fitting, i.e., to extract the 
predictive genes not influenced by the peculiarities of the underlying data set and 
therefore well applicable to other data [10]. It has been unclear how the 
performance of the prediction algorithm may vary considering the many different 
classification techniques. We therefore examined this question for eight different 
popular classification techniques, including TreeBoost [184], k-nearest neighbour 
(kNN), decision tree (DT), support vector machines (SVM), diagonal linear 
discriminant analysis (DLDA), the logistic regression model (LR), Majority-
Voting (MV), and Threshold. Altogether, 8 different classification techniques were 
developed for this algorithm. Further, we considered the multiple independent 
validation sets to evaluate the algorithm performance, and considered two 
performance measures to demonstrate the independency for the validation sets and 
for the performance measures. Next, we evaluated the performance of the proposed 
algorithm compared with existing prediction algorithms for chemotherapy 
response.          
 The evaluation of the proposed algorithm on published multiple microarray 
sets clearly demonstrates the robust predictive performance of our algorithm and 
how it outperformed existing algorithms in regards to any classification technique. 
Furthermore, the predictive gene signature of our algorithm reflects the underlying 
mechanisms of chemotherapy’s response with significantly greater biological 
interpretations. We detail here our ܥ݄݁݉݋ algorithm and report statistical 
validation, along with the results from breast cancer patients for the prediction of a 
chemotherapy response as either pCR or npCR. Biological validation of the 
ܥ݄݁݉݋ algorithm based gene signature will thus be defined.       
 The rest of this chapter is structured as follows. The proposed ܥ݄݁݉݋ 
algorithm is defined in Section 6.2. The training and testing sets used in this study 
along with their classification results and biological validation are presented in 
Section 6.3. Finally, we conclude this chapter in Section 6.4.  
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6.2 Methods   
6.2.1 Chemotherapy Response Prediction Algorithm         
The aim of the proposed algorithm is to assess whether neoadjuvant breast cancer 
patients will respond to standard chemotherapy regimens, and was used as the 
primary endpoint in this study. To generalize, we consider this problem as the 
binary class prediction problem i.e. positive and negative. However, the proposed 
algorithm can be extended to n number of classes.      
 Based on the binary class prediction problem regarding the outcomes of 
chemotherapy regimens as either a positive class or pCR, or negative class or npCR, 
we proposed three scoring metrics for each gene in the microarray gene expression 
dataset as: 
ܵ௕௘௧௪௘௘௡ሺ௚ሻ ൌ  ଵȁ௡ȁ σ
σ ቚ௘೔
ሺ೒ሻି௘೔ᇲ
ሺ೒ሻቚห೙
ᇲห
೔ᇲసభ
ȁ௡ᇲȁ
ȁ௡ȁ
௜ୀଵ ǡ  
ܵ௪௜௧௛௜௡ሺ௣஼ோሻሺ௚ሻ ൌ  ଵȁ௡ȁ σ
σ ቚ௘೔
ሺ೒ሻି௘ೕ
ሺ೒ሻቚȁ೙ȁೕస೔శభ
ȁ௡ȁି௜
ȁ௡ȁିଵ
௜ୀଵ ǡሺ͸Ǥͳሻ  
ܵ௪௜௧௛௜௡ሺ௡௣஼ோሻሺ௚ሻ ൌ  ଵȁ௡ᇲȁ σ
σ ฬ௘೔ᇲ
ሺ೒ሻି௘ೕᇲ
ሺ೒ሻฬห೙
ᇲห
ೕᇲస೔ᇲశభ
ȁ௡ᇲȁି௜ᇲ
ห௡ᇲหିଵ
௜ᇲୀଵ   
where,     
݊ = {samples in pCR class},  
݊ᇱ = {samples in npCR class}, 
݅,  ݆ stands for ݅th and ݆th samples in݊, 
݅ᇱ, ݆ᇱ stands for ݅th and ݆th samples in݊ᇱ, 
ȁȈȁstands for the number of set elements, and ݁௜ሺ௚ሻ stands for the gene ݃ expression 
profile in ith sample. Here, ܵ௕௘௧௪௘௘௡ሺ௚ሻ  represents the between pCR-npCR 
effectiveness score for gene ݃  which reflects the actual inter difference of these two 
classes. ܵ௪௜௧௛௜௡ሺ௣஼ோሻሺ௚ሻ  represents the within pCR effectiveness score for gene ݃ 
which reflects the actual intra difference of the pCR class, and ܵ௪௜௧௛௜௡ሺ௡௣஼ோሻሺ௚ሻ  
represents the within npCR effectiveness score for gene ݃ which reflects the actual 
intra difference of the npCR class.       
 To evaluate the relative differential expression (DE) strength of each gene 
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݃ between the two classes, we extend the previously defined three scoring metrics 
to generate DE scores as follows: 
ܵ஽ாሺ௣஼ோሻሺ௚ሻ ൌ  ௦௜௚௡௔௟௡௢௜௦௘ሺ௣஼ோሻ ൌ 
ௌ್೐೟ೢ೐೐೙
ሺ೒ሻ
ௌೢ೔೟೓೔೙ሺ೛಴ೃሻ
ሺ೒ሻ   ǡ    
ܵ஽ாሺ௡௣஼ோሻሺ௚ሻ ൌ  ௦௜௚௡௔௟௡௢௜௦௘ሺ௡௣஼ோሻ ൌ
ௌ್೐೟ೢ೐೐೙
ሺ೒ሻ
ௌೢ೔೟೓೔೙ሺ೙೛಴ೃሻ
ሺ೒ሻ                  (6.2) 
where, ܵ஽ாሺ௣஼ோሻሺ௚ሻ  and ܵ஽ாሺ௡௣஼ோሻሺ௚ሻ  stands for the DE scores for gene ݃, which 
respectively measures the relative differential strength of gene g between classes 
with respect to the noise in the form of intra difference within the pCR class and 
the npCR class, respectively. With this measure (6.2), the higher the noise for 
gene݃, i.e., ܵ௪௜௧௛௜௡ሺ௣஼ோሻሺ௚ሻ  andܵ௪௜௧௛௜௡ሺ௡௣஼ோሻሺ௚ሻ , the lesser the DE scores will be, and 
therefore, lower odds to have differential strength between the two classes and 
higher odds for differential strength within the classes.              
 Now, these two DE scores are integrated by the measure called ܥ݄݁݉݋ 
(equation (6.3)) to assess the overall DE strength of any gene ݃ between the classes, 
and in turn, to remove genes that have a higher DE strength within a class than 
between the classes. To do this, we first define the ܥ݄݁݉݋ measure of each 
gene݃,ܥ݄݁݉݋ሺ௚ሻ as follows:             
ܥ݄݁݉݋ሺ௚ሻ ൌ ߮௣஼ோ ቀܵ஽ாሺ௣஼ோሻሺ௚ሻ ቁ ൅߮௡௣஼ோ ቀܵ஽ாሺ௡௣஼ோሻሺ௚ሻ ቁ     (6.3) 
where, ߮௣஼ோ and ߮௡௣஼ோ are the weights associated with the DE scores of ܵ஽ாሺ௣஼ோሻ 
andܵ஽ாሺ௡௣஼ோሻ, respectively, and can be evaluated as: 
߮௣஼ோ ൌ ௡௡ା௡ᇲ  ǡ ߮௡௣஼ோ ൌ
௡ᇲ
௡ା௡ᇲ  
The higher the ܥ݄݁݉݋ of a gene݃, the higher the DE strength between the two 
classes.  Whether gene ݃ is having higher DE strength within or between classes is 
determined as follows:   
If  ܵ஽ாሺ௣஼ோሻሺ௚ሻ ൒ ͳ and ܵ஽ாሺ௡௣஼ோሻሺ௚ሻ ൒ ͳ   
      then gene ݃ has a higher DE strength between classes;                   
else   
      gene ݃ has higher DE strength within a class.  
  
138 
 
If gene ݃is having higher DE strength within a class than between classes, it is 
removed/filtered from the dataset. This gives the resulting set of genes (with their 
scores derived from ܥ݄݁݉݋measure) a higher DE strength between the two 
classes. In general, this process can reduce the number of genes up to 1/3rd of the 
original number of genes, which depends on the number of samples in the dataset. 
For gene݃, the higher the number of samples, the stronger or more effective it can 
evaluate the DE strength between the two classes.    
 With the above defined ܥ݄݁݉݋measure of a gene between two classes, 
we can use any of the existing clustering algorithms to cluster the resulting set of 
genes in the dataset, and then later on generate the set of genes or gene signature 
with predictive strength for a two class problem. In our algorithm, we used a 
hierarchical clustering algorithm with a normal euclidean distance and performed 
it using the GEPAS (Gene Expression Pattern Analysis Suite) Sotarray Server 
(http://www.transcriptome.ens.fr/cgi-bin/gepas/sotarray) [97]. The normal 
euclidean distance between any two genes ݃and ݇in a dataset is evaluated as 
follows: 
 ݀ሺ௚ǡ௞ሻ ൌ  หܥ݄݁݉݋ሺ௚ሻ െܥ݄݁݉݋ሺ௞ሻห      (6.4) 
where, ݀ሺ௚ǡ௞ሻdefines the euclidean distance between gene ݃and݇. The 
hierarchical clustering algorithm generates a set of clusters asܥଵǡ ܥଶǡ ǥ ǡ ܥ௡ (s.t 
ܥଵ ് ܥଶ ് ڮ ് ܥ௡and ܥଵ ് ׎ǡ ܥଶ ് ׎ǥ ǡ ܥ௡ ് ׎) that contain genes with more 
similar genes clustered together but evaluated from their distance measure. This 
can possibly reduce the impact of less similar genes over more similar genes. The 
combination of the best features or genes with similar high ܥ݄݁݉݋ scores in a 
cluster was determined by employing a homogeneity measure (ܪ), as follows:    
ܪ஼೙ ൌ  ଵȁ஼೙ȁ σ หܥ݄݁݉݋
ሺ௚ሻ െ ߤሺܥ௡ሻห௚א஼೙        (6.5) 
where, 
ߤሺܥ௡ሻ ൌ  ଵȁ஼೙ȁ σ ܥ݄݁݉݋
ሺ௚ሻ௚א஼೙ , 
ܪ஼೙stands for the homogeneity measure of a clusterܥ௡, and ȁܥ௡ȁ is the number of 
genes in clusterܥ௡. With this measure (6.5), the homogeneity score for each cluster 
can be evaluated. The higher the homogeneity score of a cluster, the higher the 
ܥ݄݁݉݋ scores will be similar to the genes in a cluster. The basic idea to generate 
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a homogeneity score is to select those cluster/s that have, on average, consistently 
high ܥ݄݁݉݋ scores across all genes in a cluster. In order to do this, we performed 
a two-step operation as follows:       
Step 1: Rank-ordered the homogeneity score of the clusters in descending order as: 
Rank-ordered 
        ܪ ൌ  ൛ܪ஼೘ൟ ;  ͳ ൑ ݉ ൑ ݊                             (6.6) 
                                    s.t ܪ஼భ ൒ ܪ஼మ ൒ ڮ ൒ ܪ஼೙  
where, ܪ஼೘ stands for the homogeneity score for any ݉୲୦ranked cluster 
and ݊  is the total number of clusters in the dataset. From this step, the cluster 
with first rank to the cluster with last rank reflects the high homogeneous 
cluster to the least homogeneous cluster. For simplicity we still denote the 
ordered clusters asܥଵǡ ܥଶǡ ǥ ǡ ܥ௡,   
Step 2: From the rank-ordered cluster list of Step 1, we select the top ݐhomogenous 
clusters, where,  
ݐ ൌ ൝
௡
ଶ ǡ ݊
௡ିଵ
ଶ ǡ ݊
       (6.7) 
Therefore, the predictive gene signature (ܲீ ௌ) for a two-class problem is 
formed by integrating the genes in each of the selected top ݐ clusters. It 
consists of N number of genes, i.e., 
ܲீ ௌ =ܥଵ ׫ܥଶ ׫ ǥ׫ ܥ௧         (6.8) 
The two-step operation maintains a balance between selecting more clusters with a 
high homogeneity score that have genes with a higher predictive strength and 
reducing the impact of possibly noisy information appearing in the form of a low 
homogeneity score in clusters with genes that have a lower predictive strength, and 
therefore removed.            
 Based on the above scoring metrics and the two-step operation, we named 
this prediction algorithm Prediction of Chemotherapy regimens Treatment outcome 
(ܥ݄݁݉݋). The pseudo-code is shown in Figure 6.1.  
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Initialize:  ߬ ൌ ׎        //߬ is the temporary list of selected genes 
   ܴு ൌ ׎       //ܴு is the rank-ordered clusters of H scores   
   ܲீ ௌ ൌ ׎      //ܲீ ௌ is a set of predicted gene signature   
//۾࡯ࢎࢋ࢓࢕ metrics evaluation 
For any gene g in the dataset D 
{ 
 evaluateܵ஽ாሺ௣஼ோሻሺ௚ሻ , and ܵ஽ாሺ௡௣஼ோሻሺ௚ሻ  
 if ܵ஽ாሺ௣஼ோሻሺ௚ሻ ൒ ͳ and ܵ஽ாሺ௡௣஼ோሻሺ௚ሻ ൒ ͳ   
 then generate ܥ݄݁݉݋ሺ௚ሻ 
 and  ߬ ൌ ߬ ׫  ሼ݃ሽ 
 else 
 removed/filtered from the dataset D              
} 
//Step 1: From ࣎ generate the clusters and rank-ordered their homogeneity 
score in descending order 
For any clusterܥ௡ (n=1, 2,…, n) 
{ 
 generate ܪ஼೙  
 ܴு = {ܥ௡} 
 sort ܴு  
} 
//Step 2: Select the top ࢚homogenous clusters 
extract top t homogenous clusters  
For any k cluster (k =1, 2,…, t) 
{ 
ܲீ ௌ = ܲீ ௌ ׫ ሼܥ௞ሽ     //ሼܥ௞ሽ  is the list of genes in ݇௧௛ cluster 
} 
Return ܲீ ௌ 
Figure 6.1: Pseudo-code of the ܲܥ݄݁݉݋ܶݔ algorithm. 
 
6.2.2 Classification Techniques 
The gene signature constructed from the ܥ݄݁݉݋ algorithm is then used to 
predict the sample as one of the binary outcomes of pCR or npCR by first evaluating 
their gene signature score (ܩ) as follows: 
ܩሺݏሻ ൌ σ ݁௦ሺ௚ሻ ȁܺȁൗ௚א௑                    (6.9) 
Where, ܺ = {genes of the ܥ݄݁݉݋  gene signature}. 
ȁȈȁstands for the number of set elements, ܩሺݏሻ is the gene signature score of sample 
s, and݁௦ሺ௚ሻ is the expression of gene ݃ in sample s. With this measure (6.9), each 
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sample s can be transformed intoܩ.      
 The ܩ generated for each sample in a dataset was then used by the different 
classification techniques to perform the prediction task. In fact, we incorporated 
eight classification techniques to evaluate the algorithm’s independency on 
classification techniques, including k nearest neighbour with k = 3, support vector 
machine with linear kernel, the logistic regression model, diagonal linear 
discriminant analysis, the decision-tree, TreeBoost, Majority Voting, and 
Threshold (see Section 6.3.3 for details).     
 As many of the existing related algorithms (see Section 6.3.3) were based 
on these classification techniques, and this was the prime basis for the selection of 
these popular classification techniques.  
6.2.3 Estimation of Predictive Performance 
The ܥ݄݁݉݋ gene signature with classification techniques was used for the 
chemotherapy response prediction of samples in the validation sets. However, as 
microarray datasets usually contain an unequal ratio of pCR and npCR samples, 
accuracy is not a good criterion to measure the performance of an algorithm in the 
validation sets. Rather, we used a performance measure called MCC for the 
comparison of different algorithms (see Section 4.3.5 for more details).  
 To demonstrate the algorithm is not dependent on MCC, we considered 
another measure called the Diagnostic Odds Ratio (DOR) [79]. The DOR is a ratio 
of the odds of positivity with pCR relative to the odds of positivity without pCR, 
and evaluated as: 
  ൌ  ሺ୘୔כ୘୒ሻାఈሺ୊୒כ୊୔ሻାఈ      (6.10) 
Here, TP represents the number of true positives, TN represents the number of true 
negatives, FP represents the number of false positives, and FN represents the 
number of false negatives. In equation (6.10), if any of the four terms is 0 then DOR 
equals 0 or is undefined. Therefore, ߙ was added in both the numerator and 
denominator for all cases to avoid any overestimation, where ߙis a constant which 
is small enough not to affect the DOR. From our experimental observation, we 
choseߙ ൌ ͳͲିଵ.  
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 In general, the value of DOR is within the range [0,λ). The higher the DOR, 
the better the performance of an algorithm. A DOR value of 1 reflects random 
prediction and 0 reflects false prediction. The DOR performance measure combines 
the strength of sensitivity and specificity into a single measure, and should be 
considered a preferred method for reporting the test performance [139]. 
 These two performance measures, the MCC and DOR, evaluate the overall 
performance of an algorithm for predicting the binary treatment response. 
   
6.3 Results and Discussion 
The response to neoadjuvant chemotherapy was measured as a binary response: 
pathologic complete response with no lymph-node involved (pCR) or non-
pathologic complete response with residual disease (npCR). The performance of 
the proposed algorithm was evaluated on real breast cancer microarray samples and 
the comparisons with other existing algorithms were performed in the meta-
analysis settings.  
6.3.1 Datasets 
All data was publicly available from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) [18]. The normalised 
microarray datasets were downloaded as published by the original studies and 
selected on the basis of the following criteria: availability of pre-treatment breast 
cancer patient samples, neo-adjuvant chemotherapy regimen, and their treatment 
response in terms of pCR, i.e., pathologic compete response (no residual cancer 
without any lymph-node involved) and npCR, i.e., non-pathologic complete 
response (residual cancer). Except for this, no other inclusion criteria was 
considered, as shown in Figure 6.2.  
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Figure 6.2: Flow diagram showing the selection of datasets used to perform and evaluate 
our algorithm. 
 
Multiple training cohorts (GSE20271, GSE21974, GSE21997, GSE22093, 
GSE22226, GSE28844, GSE29561, GSE32646, GSE34138, and GSE8465) were 
considered to identify the predictive gene signatures of our algorithm that can 
characterise the samples as either pCR or npCR (Table 6.1). Together, the training 
cohort consisted of 1,217 pre-treatment breast cancer patient gene expression 
profiles with standard multi-agent neoadjuvant chemotherapy containing 
anthracyclines, taxanes or their combinations with other agents. The samples with 
repetitions or a missing binary treatment response (pCR or npCR) were excluded. 
1,165 samples remained, consisting of 251 patients with pCR and 914 patients with 
npCR. Multiple validation cohorts (GSE20194, GSE4779, GSE22358, GSE6861, 
and GSE25055) were independently studied to test whether or not the predictive 
gene signature of our algorithm generated from the training cohort was predictive 
of pCR (Table 6.1). All together, the validation cohorts comprised five independent 
pre-treatment microarray gene expression datasets with multiple neoadjuvant 
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chemotherapy treatment regimens, such as T/FAC (paclitaxel/docetaxel, 5-
flourouracil, doxorubicin, cyclophosphamide), FEC (5-flourouracil, epirubicin, 
cyclophosphamide), TX (docetaxel, capecitabine), ET (epirubicin, paclitaxel), and 
AT (doxorubicin/epirubicin, paclitaxel). The detailed characteristics of each dataset 
is shown in Table 6.1.    
Table 6.1: Training and validation cohort of breast cancer patients treated with neoadjuvant 
chemotherapy regimens.   
Geo 
accession 
Platform Patients 
No. 
Mean age 
(range) 
ER, PR, HER status Neoadj. 
Chemo. 
regimen 
Response 
rate,  
pCR/ npCR 
Training cohort   ER     
(+/-) 
PR  
(+/-) 
HER 
(+/-) 
GSE20271 GPL96 178 50.92        
(26-74) 
98/79 83/94 26/151 T/FAC 26/152 
GSE21974 GPL6480 57 -  18/14 17/15 8/24 EC/T 18/39 
GSE21997 GPL7504 31 51.87        
(27-77) 
21/10 22/9 10/21 TA 5/26 
GSE22093 GPL96 103 49.01        
(30-78) 
42/56 - 0/103 FAC 28/69 
GSE16716 GPL96 278 51.98        
(26-79) 
164/ 
114 
121/  
157 
59/219 T/FAC 56/222 
GSE22226 GPL1708, 
GPL4133 
150 47.92        
(29-66) 
79/63 64/76 43/88 AC or 
AC/T 
36/108 
GSE28844 GPL570 61 54.49        
(29-74) 
- - - AC/T 4/28 
GSE29561 GPL96 22 - - - - ET 10/12 
GSE32646 GPL570 115 51.49        
(27-73) 
71/44 45/70 34/81 T/FEC 27/88 
GSE34138 GPL6884 178 - 119/ 57 79/94 0/178 AC 28/139 
GSE8465 GPL887 44 - 22/21 20/23 12/26 AG  13/31 
     Validation cohort 
GSE20194 GPL96 278 51.99        
(26-79) 
164/ 
114 
121/  
157 
59/219 T/FAC 56/222 
GSE4779 GPL1352 102 - 37/65 25/77 - FEC 39/63 
GSE22358 GPL5325 158 - 82/71 55/98 34/120 TX 30/92 
GSE6861 GPL1352 161 49.41        
(26-70) 
37/124 25/124 - FEC, ET  
66/95 
GSE25055 GPL96 508 49.81        
(24-75) 
297/  
205 
243/ 
258 
6/485 AT  
99/389 
Total:        
16 publicly 
available 
11 distinct 
platforms  
2424 51.98        
(24-79) 
1251/ 
1037 
920/  
1252 
291/  
1715 
7 drugs 
combin-
ation 
541/1775 
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; 
+=positive; -=negative; T, Taxane (paclitaxel or docetaxel); F, 5-flourouracil; A, doxorubicin; E, epirubicin; C, 
cyclophosphamide; G, Gemictabine; X, Capecitabine; pCR, pathologic complete response (disease-free); npCR, non-
pathologic complete response (residual disease).      
   
As mentioned in Section 4.2.1 and Section 5.2.2, larger-scale computational studies 
with more patient samples are required to best perform the various tasks, such as 
diagnosis or prognosis, given all available information. In order to achieve this goal 
for treatment prediction, first, the data normalisation (see equation (4.1)) was done 
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as defined in Section 4.2.1.       
 Next, to increase the dataset size, a common list of genes (see Section 4.2.1 
for more details) from the distinct microarray platforms was then extracted, which 
consisted of 8,960 genes. The training cohorts were then directly integrated. This 
enabled the gene signature to be independent of the microarray datasets or their 
platform types.    
6.3.2 10-fold Cross-Validation to construct ۾࡯ࢎࢋ࢓࢕܂ܠ gene 
signature  
To construct the ܥ݄݁݉݋ gene signature for predicting the pCR or npCR class 
while avoiding over-fitting, a 10-fold cross-validation (CV) was performed by 
stratifying the training cohort (see Section 6.3.1) and forming training/testing sets 
while considering the clinical status of the samples. In other words, the stratification 
was done to balance the pCR/npCR outcome between each of the 10-fold CV. Each 
time the 9-fold was combined to form the training set and the remaining fold was 
treated as a testing set. This process was repeated until each fold was used as the 
testing set, thus leading to 10 randomly selected training sets with their respective 
testing sets. The preservation of the binary outcome class in each set enabled higher 
training and testing set homogeneity, while avoiding clinical and molecular bias.
 For each training set, predictive gene signatures were constructed with the 
ܥ݄݁݉݋  algorithm, yielding 10 predictive gene signature lists. Next, the genes 
appearing in all of the 10 lists were identified, therefore forming our ܥ݄݁݉݋ 
gene signature. The size of each predictive gene signature list is shown in Table 
6.2. The final ܥ݄݁݉݋ gene signature is provided in Appendix D, which consists 
of 74 predictive genes.        
 The response or resistance to chemotherapy almost likely depends on the 
interplay of multiple genes, therefore it is likely the gene signature that consists of 
multiple genes will achieve high performances in predicting the response to 
chemotherapy, thus resulting in reliable predictive tests [88].   
 
  
146 
 
Table 6.2: Size of ten predictive gene signature lists generated from each training set in a 
10-fold CV. 
Training/ Testing 
set 
No. of genes (evaluated from 
training set) 
ଵܶ 1326 
ଶܶ 1476 
ଷܶ 1756 
ସܶ 2223 
ହܶ 1525 
଺ܶ 1651 
଻ܶ 1784 
଼ܶ  1680 
ଽܶ 2077 
ଵܶ଴ 2137 
Here, ௡ܶ denotes the ݊୲୦ training set. 
 
6.3.3 Prediction performance  
To assess the performance of the gene signature constructed with the ܥ݄݁݉݋ 
algorithm, we compared it with previously established algorithms, such as the 
OptDis algorithm [49], the Dense algorithm [48], the MAQC-II studies [159], the 
p53 algorithm [146], and the Five-gene signature (5gs) algorithm [37]. The 
performance was measured on the five benchmark validation sets, i.e., GSE20194 
was represented as validation set 1 (VD1), GSE4779 was represented as validation 
set 2 (VD2), GSE22358 was represented as validation set 3 (VD3), GSE6861 was 
represented as validation set 4 (VD4), and GSE25055 was represented as validation 
set 5 (VD5) (see Table 6.1).        
 For the ܥ݄݁݉݋ algorithm, the TreeBoost classification technique 
performed well amongst other classification techniques (see Figure 6.4), and is 
therefore the optimal classifier selected for the ܥ݄݁݉݋  algorithm to perform 
binary class predictions. For existing algorithm based gene signatures, the 
classification technique from their respective studies was used to perform 
prediction tasks. For the OptDis algorithm, the three-nearest neighbour classifier 
(3NN) under ܮଵ distance was used [49]. For the Dense algorithm, the support vector 
machine approach with linear kernel (LinearSVM) was implemented [48]. For 
MAQC-II studies, the simpler linear methods, such as the logistic regression (LR) 
model, generally performed well and was therefore used for prediction [159]. For 
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the p53 algorithm, the diagonal linear discriminant analysis (DLDA) linear 
regression model was selected for prediction [146]. For the Five-gene signature 
algorithm, the decision-tree (DT) was built to perform the prediction [37]. The 
comparison results with their performance measures (in terms of sensitivity, 
specificity, accuracy, MCC and DOR) on five validation sets are detailed in Table 
6.3. In Table 6.3, the ܥ݄݁݉݋ algorithm is shown to achieve higher MCC and 
DOR on the five validation sets.        
 As the MCC and DOR of the ܥ݄݁݉݋ algorithm from the five validation 
sets was not as high as we expected, it was still significant compared with other 
existing algorithms or with the random classifier where MCC equals 0 or DOR 
equals 1. Specifically, from the five validation sets, the ܥ݄݁݉݋ algorithm 
showed the MCC performance in the range of 0.228 to 0.419, with an overall mean 
of 0.318, which was comparatively higher than the overall MCC mean of other 
existing algorithms, i.e., 0.067 (with a range of -0.105 to 0.177) for OptDis, 0.011 
(with a range of -0.151 to -0.196) for Dense, -0.015 (with a range of -0.130 to 0.107) 
for MAQC-II, -0.041 (with a range of -0.319 to 0.085) for p53, and 0.064 (with a 
range of -0.027 to 0.20) for 5gs. This shows the performance of the ܥ݄݁݉݋ 
algorithm based gene signature was vastly superior to previously established 
algorithms. Similar conclusions were derived while considering the DOR 
performance measure. This showed the effectiveness of the ܥ݄݁݉݋ algorithm 
in predicting the binary treatment outcome of pCR or npCR for varied 
chemotherapy regimens, while considering the two performance measures of MCC 
and DOR in multiple validation sets. 
Table 6.3: A multiple performance measures based comparison for the ܲܥ݄݁݉݋ܶݔ gene 
signature and other algorithm based gene signatures on the five validation sets.  
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
  
 
ܥ݄݁݉݋ 
VD1 230 43 83 5 99 0.896 0.456 0.548 0.294 7.210 
VD2 102 24 39 15 24 0.615 0.619 0.618 0.228 2.600 
VD3 122 18 73 12 19 0.600 0.793 0.746 0.369 5.763 
VD4 161 43 60 23 35 0.652 0.632 0.640 0.279 3.205 
VD5 488 89 242 10 147 0.899 0.622 0.678 0.419 14.65 
 Mean: 0.732 0.624 0.646 0.318 6.686 
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
 
 
VD1 230 3 163 45 19 0.063 0.896 0.722 -0.058 0.572 
VD2 102 37 9 2 54 0.949 0.143 0.451 0.143 3.083 
VD3 122 27 25 3 67 0.900 0.272 0.426 0.176 3.358 
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OptDis VD4 161 56 8 10 87 0.848 0.084 0.398 -0.105 0.515 
VD5 488 63 227 36 162 0.636 0.584 0.594 0.177 2.452 
 Mean: 0.679 0.396 0.518 0.067 1.996 
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
 
 
Dense 
VD1 230 39 35 9 147 0.813 0.192 0.322 0.005 1.032 
VD2 102 18 46 21 17 0.462 0.730 0.627 0.196 2.319 
VD3 122 16 56 14 36 0.533 0.609 0.590 0.124 1.778 
VD4 161 36 32 30 63 0.545 0.337 0.422 -0.119 0.610 
VD5 488 3 328 96 61 0.030 0.843 0.678 -0.151 0.168 
 Mean: 0.477 0.542 0.528 0.011 1.181 
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
 
 
MAQC-II 
VD1 230 7 169 41 13 0.146 0.929 0.765 0.107 2.220 
VD2 102 10 42 29 21 0.256 0.667 0.510 -0.081 0.690 
VD3 122 0 86 30 6 0.000 0.935 0.705 -0.130 0.000 
VD4 161 38 36 28 59 0.576 0.379 0.460 -0.046 0.828 
VD5 488 47 240 52 149 0.475 0.617 0.588 0.075 1.456 
 Mean: 0.291 0.705 0.606 -0.015 1.039 
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
 
 
p53 
VD1 230 0 182 48 0 0.000 1.000 0.791 0.000 1.000 
VD2 102 22 33 17 30 0.564 0.524 0.539 0.085 1.424 
VD3 122 0 63 30 29 0.000 0.685 0.516 -0.319 0.000 
VD4 161 49 29 17 66 0.742 0.305 0.484 0.052 1.266 
VD5 488 0 388 99 1 0.000 0.997 0.795 -0.023 0.001 
 Mean: 0.261 0.702 0.625 -0.041 0.738 
 Dataset N TP TN FN FP SE SP ACC MCC DOR 
 
 
5gs 
VD1 230 23 119 25 63 0.479 0.654 0.617 0.112 1.738 
VD2 102 26 21 13 42 0.667 0.333 0.461 0.000 1.000 
VD3 122 11 76 19 16 0.367 0.826 0.713 0.200 2.750 
VD4 161 54 20 12 75 0.818 0.211 0.460 0.035 1.200 
VD5 488 39 223 60 166 0.394 0.573 0.537 -0.027 0.873 
  Mean: 0.545 0.519 0.558 0.064 1.512 
Here, N defines the total number of samples, TP defines true positive, TN defines true negative, FN 
defines false negative, FP defines false positive, SE defines sensitivity, SP defines specificity, ACC 
defines accuracy, MCC defines Matthews coefficient correlation, DOR defines the diagnostic odds 
ratio, and Mean represents the mean of the respective performance measure from the five validation 
sets.           
  
Since Table 6.3 shows the algorithms that used the classification techniques as 
reported in their original respective studies, this may result in biased performance 
comparison results between the algorithms as they considered different 
classification techniques. Therefore, to perform fair comparisons we examined 
each algorithm with previously mentioned multiple classification techniques, 
including TreeBoost [184], 3NN [49], DT [37], LinearSVM [48], DLDA [146], and 
LR [159]. Further, we also examined the algorithms with two other widely used 
classification techniques, i.e., Majority-Voting (MV) [82] and Threshold (see 
Appendix E for details). Overall 8 classification techniques were used for each of 
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the 6 algorithms, resulting in a total of 48 models, with comparisons performed in 
five validation sets. Figure 6.3 represents these performance based comparison 
results for each classification technique with different algorithms on the five 
validation sets, while Figure 6.4 shows their respective average performance 
measures from the five validation sets.        
 It can be seen from Figure 6.4 the ܥ݄݁݉݋ algorithm achieved an overall 
higher MCC and DOR performance measure for each classification technique, and 
outperformed all other algorithms on the basis of average performance measures. 
This demonstrates the independency of the ܥ݄݁݉݋ algorithm for varied 
classification techniques while achieving higher classification performances. In 
other words, the ܥ݄݁݉݋ algorithm is not biased to any particular classification 
technique and suggests that it captures a more informative gene signature for 
chemotherapy response prediction.        
 In general, the TreeBoost, DT, and MV classification techniques were 
consistently among the best for ܥ݄݁݉݋ and other existing algorithms. 
Interestingly, LinearSVM, Threshold, and LR were often among the worst-
performing classification techniques. However, it is possible that with further fine-
tuning of the parameters of these classifiers, the prediction performance may 
improve.             
 For the ܥ݄݁݉݋  algorithm, if computational costs are a concern, then 
DT or MV can serve the optimal classification technique. However, if the 
performance of predicting the binary chemotherapy response is of primary concern 
(the initial aim of our study) then TreeBoost serves as the best classification 
technique.            
 For further analysis, we compared the average best and single best 
classification technique for each algorithm from five validation sets. Here, the 
average best classification technique for an algorithm refers to the classification 
technique that performed the best in the respective validation set and then the 
average is taken from each of the five validation sets. The single best classification 
technique for an algorithm refers to the classification technique that performed best 
in one of the five validation sets. Figure 6.5 shows the ܥ݄݁݉݋  algorithm 
achieved the best MCC and DOR performance measures from the average best 
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classification technique and also from the single best classification technique. In 
contrast, the other existing algorithms showed less MCC and DOR performance 
measures.       
(A) 
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 (B) 
 
Figure 6.3: (A) MCC performance measures of the ܲܥ݄݁݉݋ܶݔ algorithm and five other 
existing algorithms on five validation sets, and (B) their respective DOR performance 
measures. Here, Avg represents the average performance measures from five validation 
sets. Overall, ܲܥ݄݁݉݋ܶݔ algorithm achieved high MCC and DOR performance measures 
and outperformed five other existing algorithms for predicting the chemotherapy response. 
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Figure 6.4: The bar plots of the average performance measures of (A) MCC, and (B) DOR 
for the ܲܥ݄݁݉݋ܶݔ algorithm and other existing algorithms under different classification 
techniques. Here, the x-axis represents the classification techniques for each algorithm.   
              
      
   
Figure 6.5: The bar plots of the average best and single best performance measures of (A) 
MCC, and (B) DOR for the ܲܥ݄݁݉݋ܶݔ algorithm and other existing algorithms. Here, the 
Avg denotes the average best classification technique for an algorithm, whereas the Best 
denotes the single best classification technique for an algorithm. 
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From the above analyses conducted using different angles, we demonstrated the 
prediction strength of the proposed algorithm by showing its effectiveness in 
predicting the binary chemotherapy response from multiple validation sets. The 
proposed algorithm outperformed the other five existing algorithms with 
consideration given to all eight of the classification techniques.    
6.3.4 Chemotherapy response rate in molecular subtypes of 
breast cancer 
The Oxford meta-analysis showed the long-term advantage of chemotherapy 
includes preventing breast cancer relapse and improving overall survival [2]. While 
chemotherapy on average improves the long-term survival, conflicting evidence 
indicates the effectiveness rate may differ among patient groups characterised by 
the three major molecular subtypes, including triple-negative breast cancer 
(TNBC), Luminal A (LumA), and human epidermal growth factor receptor 2 
(HER2). As nearly 30% of the Luminal B tumors are HER2 positive [192], patients 
with these tumors were included in the HER2 subtype in the current study. Further, 
due to the lesser sizes in subtypes, no sub-categorization was possible to perform. 
We believe this classification (based on three molecular subtypes) is practical, 
informative, clinically useful, and possesses discriminative strength between 
subtypes.           
 To support the above statement, we performed a Kaplan-Meier survival 
analysis using the ‘survival’ package of the R-project [163]. The survival curves 
with the relapse free survival (RFS) rate were constructed for the three molecular 
subtypes and was performed on the VD5 set (GSE25055) due to the larger number 
of patients in each molecular subtypes involved in the set. From Figure 6.6, it can 
be seen the three subtypes showed significantly different survival curves (with p-
value <0.001) that reflects their rate of aggressiveness. Specifically, the TNBC 
subtype showed the worst RFS rates and is considered the most aggressive form of 
breast cancer compared to others, while the LumA subtype showed the most 
favorable RFS rates and is considered as the least aggressive form of breast cancer. 
This analysis further supports the other studies [33, 34, 53, 156] that have shown 
the TNBC and HER2 subtypes have poorer clinical, pathological and molecular 
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prognoses.         
  
 
Figure 6.6: Kaplan-Meier curves for the relapse free survival rate for the three molecular 
subtypes of breast cancer. A p-value of <0.05 was considered statistically significant. 
       
Since chemotherapy is considered the most aggressive treatment available for 
breast cancers, it can affect cancerous cells as well as normal cells. Therefore, the 
less aggressive subtypes of breast cancer should be spared from chemotherapy. 
 To investigate the pCR and npCR rates to chemotherapy between each 
subtype, we further performed survival analysis of the patients to include those with 
TNBC, with pCR and npCR; those with HER2, with pCR and npCR; and LumA, 
with pCR and npCR. Figure 6.7 shows patients in the pCR groups had better RFS 
outcomes than corresponding patients in the npCR groups. This effect was observed 
as statistically significant relative to RFS for patients with TNBC subtypes and 
those with HER2 subtypes. However, for the LumA subtype, this effect was not 
observed as statistically significant. Specifically, patients with the LumA subtype, 
HER2 subtype, and TNBC subtype showed non-significant lesser separated (p-
value = 0.436), significant wider separated (p-value = 0.013), and significant best 
separated (p-value = 7.74e-07), pCR and npCR curves, respectively. These results 
were consistent with our previously mentioned results that reflected patients with 
the TNBC subtype showed the most effective pCR rates from chemotherapy, 
followed by the HER2 subtype. However, for the LumA subtype, these results 
reflect their non-responsiveness to chemotherapy. This analysis also confirms 
previous reports that pCR is associated with a more favorable prognosis in some 
molecular subtypes [67]. The message from this study and previous studies is that 
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subtypes can possibly impact chemotherapy outcomes, suggesting that decisions 
for selecting an appropriate chemotherapy regimen based on molecular subtypes 
could be possible, and therefore should be considered with all possible aspects prior 
to neo-adjuvant chemotherapy.      
   
 
Figure 6.7: (A) Kaplan-Meier curves for the relapse free survival rate for the three 
molecular subtypes of breast cancer and each characterised by pCR and npCR groups, and 
(B) their corresponding number of patients with their p-values.   
  
Chemotherapy continues to show its potential in improving outcomes and still plays 
a leading role in breast cancer treatment. A recent meta-analysis by Laporte et al. 
[124] conducted on more than 20,000 patients with a follow-up period of 5 years 
in most cases, showed the chemotherapy regimens effectiveness in terms of RFS. 
Results indicated that from the subgroup characterised by the three molecular 
subtypes, there was a clear benefit in patients with pCR. By looking at other 
subgroups, we analysed patients with lymph node-negative, stage 1-3, grade 3, 
estrogen receptor (ER) negative with TNBC or HER2 subtype, and found that all 
benefited significantly from the neo-adjuvant chemotherapy regimens (Figure 6.8).  
 Furthermore, if we look over the age subgroups in Figure 6.8, it clearly 
shows no significant difference for chemotherapy effectiveness between younger 
women and older women, as suggested by Swain [198]. The message here is that if 
effectiveness of chemotherapy regimens is evaluating, then age alone should not be 
considered the primary factor nor should it matter. However, in combination with 
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other subgroups, such as younger patients with TNBC subtype compared to older 
patients with TNBC subtype, age may play a significant factor. 
 
Figure 6.8: Forest plot meta-analysis for RFS by subgroup. The Cox-proportional hazard 
model was used to estimate the HR and 95% CI for RFS between the subgroups adjusted 
for age, lymph node status, stage, grade, ER, HER2, and subtypes.  
  
Overall, on the basis of receptor status, we analysed that ER negative was effective 
in achieving pCR rates to chemotherapy, while on the basis of molecular subtypes 
the TNBC  subtype achieved higher pCR rates to chemotherapy. While results such 
as these are encouraging, more studies are needed to assess the effectiveness of 
chemotherapy on breast cancer categorised by their subgroups in the adjuvant 
setting.            
 Finally, we performed a ܥ݄݁݉݋ algorithm based gene signature score 
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(ܩ) variability analysis among three different subtypes with their respective pCR 
and npCR groups. Figure 6.9 clearly shows the variability between the ܩscores of 
the pCR and npCR groups for each subtype. Since the ܩscores were consistently 
higher in each subtype for the pCR group, this reflects that patients with higher 
ܩscores were associated with the pCR group and reciprocally for the npCR group. 
By identifying an optimal threshold T value (in our study, T = 0.506), the samples 
can preliminarily be predicted as either pCR or npCR. However, this should not be 
selcted as the best criteria for the prediction task as other classification techniques 
outperformed this threshold based classification technique (see Section 6.3.3). 
Furthermore, we closely observed the median ܩscore for pCR was higher for the 
TNBC subtype amongst others, thus showing the strength of TNBC for achieving 
higher pCR rates for chemotherapy than non-TNBC subtypes, i.e, HER2 and 
LumA. Also, it can be seen the TNBC and HER2 subtypes showed similar higher 
ܩscores for the pCR groups and this showed their effectiveness for chemotherapy 
compared with the LumA subtype that achieved lower ܩscores with a non 
statistical significant difference between their pCR and npCR groups.     
 
Figure 6.9: Box plot for the ܲܥ݄݁݉݋ܶݔ algorithm based ܩ scores in the three different 
subtypes, including LumA, HER2, and TNBC, each categorised with their respective pCR 
and npCR rates. This box plot represents the first quartile (i.e., the lower solid edge of the 
box), median (i.e., the middle solid horizontal line inside the box), third quartile (i.e., the 
upper solid edge of the box), and minimum and maximum (i.e., the lower and upper dashed 
horizontal lines, respectively). The minimum and maximum represent a distance of 1.5 
times the interquartile range (IQR) from the lower quartile and upper quartile, respectively. 
If any of the points are a distance greater than 1.5 times the IQR, these are plotted 
individually (i.e., the hollow circles).      
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6.3.5 Reproducibility of the ܥ݄݁݉݋ gene signature 
We performed a reproducibility analysis of gene signatures obtained with the 
ܥ݄݁݉݋algorithm and other existing algorithms, and evaluated the number of 
overlapping genes. There was an overlap of nearly 2-11% between the genes in the 
ܥ݄݁݉݋gene signature and the gene signatures of other existing algorithms, 
which is greater than the overlap of gene signatures between these existing 
algorithms (1-4%). These relatively small gene overlaps support the current 
concept that prediction of anticancer drug outcomes is a highly complex 
phenomenon triggered by several interacting molecular mechanisms that can be 
switched on and off and can be temporarily active at the same time. However, this 
overlap could probably be improved by using a larger training compendium.
 Overall, the higher reproducibility of our ܥ݄݁݉݋gene signature may 
contribute to improved stability in terms of consistently achieving high predictive 
performances over multiple validation sets. 
6.3.6 Biological analysis 
We performed GO analysis and pathway analysis to assess the biological 
significance of our gene signature involved with the responsiveness for 
chemotherapy regimens. For each gene in our gene signature, GO analysis was 
performed using the enriched biological process GO terms [11] (see Section 4.4.3 
for details). Figure 6.10 lists some of the enriched biological processes with their 
p-values. We believe the set of 74 genes in our gene signature may have an 
influential role in the activity patterns of taxane-anthracycline based chemotherapy 
regimens.                 
 Anthracyclines are anticancer compounds that work by blocking an enzyme 
called topo isomerase 2 which participates in DNA replication. The most widely 
used anthracyclines are Doxorubicin and Epirubicin, and are gold-standard agents 
for chemotherapy. These drugs work in all phases of the cell cycle. Anthracyclines 
show their anticancer activity through activation of adaptive anticancer immune 
responses [73] by making a type of cancer cell death that is “immunogenic” [132]. 
Some existing studies, such as Ma et al. [136] and Zitvogel et al. [233], have shown 
that therapeutic effectiveness of anthracyclines relies on anticancer immune 
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responses triggered by dying cancer cells. From our ܥ݄݁݉݋gene signature of 
74 genes, we found that NMI, OAS3, CXCL9, IFI16, GBP1, and CXCL10 genes 
were crucial for anticancer immune responses. Ideally, anthracyclines alone or in 
appropriate combination with other agents (in particular cyclophosphamide, 
gemcitabine, and 5-flourouracil) could achieve beneficial effects by inhibiting 
anticancer immune responses to cause cancer cell death. Bénéteau et al. [21] 
showed that cancer cell death could be induced by combining glycolysis inhibition 
with DNA-damaging agents.        
 Taxanes are the type of drugs that restrain cell growth by inhibiting mitosis 
(cell division) and they also interfere with microtubules, which are components of 
the cytoskeleton and contain cellular structures that correctly segregate their 
chromosomes during cell division. Therefore, these are called a mitotic inhibitor or 
antimicrotubule agent. Taxane agents include Paclitaxel (Taxol) and Docetaxel 
(Taxotere). Jordon et al. [111] observed that after taxane treatment, some 
characteristics of apoptosis, such as morphologic features and DNA fragmentation 
patterns, occurred in tumor cells. Further, other existing studies by Kavallaris [116] 
and Gascoigne et al. [77] showed the therapeutic effectiveness of taxanes as 
antimitotic or antimicrotubule agents. The core mechanism of action of taxane 
drugs is disruption of microtubule function which works by binding to beta-tubulin 
and suppressing the spindle microtubule dynamics, leading to cell cycle arrest 
during the M phase (G2/M) of the mitotic cell cycle followed by apoptosis 
(programmed cell death). From our gene signature, the KIF2C, ZWINT, TPX2, 
CDC20, CEP55, PTTG1, UBE2C genes were associated with the organisation of 
actin filaments and also the M phase of the mitotic cell cycle, which were believed 
to be the crucial target biological processes for the antimitotic or antimicrotubule 
agents to cause cancer cell death. Further, the neoadjuvant combinations of taxanes 
and anthracyclines produced a higher pCR rate for improved disease-free survival 
[150].          
 In addition, many other genes in our ܥ݄݁݉݋gene signature enriched in 
various other biological processes (see Figure 6.10), such as DNA Replication, 
Recombination, and Repair, Drug Metabolism, and Cell Death and Survival, which 
are expected biological responses from many anticancer drugs [49]. 
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Figure 6.10: Some of the enriched biological process GO functions associated with 
chemotherapy responsiveness for the 74 genes of the ܲܥ݄݁݉݋ܶݔgene signature. The x-
axis represents the logarithm of p-values calculated by the Fisher exact test, with a 
threshold for statistical significance of p=0.05 represented by the thick vertical red line. 
  
Finally, we performed a pathway analysis to uncover the mechanisms underlying 
pCR for chemotherapy regimens. Figure 6.11 lists the signaling pathways 
reproducible from the ܥ݄݁݉݋gene signature and five other algorithm based 
gene signatures (see Section 6.3.3) generated by using the Ingenuity Pathway 
Analysis Software (IPA) (http://www.ingenuity.com/). Figure 6.11 shows the many 
significantly enriched pathways identified for the ܥ݄݁݉݋gene signature that 
includes chemokine signaling, insulin receptor signaling, ATM signaling, estrogen 
receptor signalling, and PI3K\AKT signaling, etc. These pathways are associated 
with a chemotherapy response, while other existing algorithms showed no or very 
few significant pathways associated with a chemotherapy response.        
 As previously stated (see Section 6.3.4), the breast cancer subtypes showed 
variable effects on the chemotherapy response, with TNBC showing the most 
favourable outcomes, followed by HER2. In other words, the ER status played a 
significant role in achieving pCR rates to chemotherapy, with different response 
rates to cytotoxic treatments, and ER positive cancers generally less sensitive to 
chemotherapy compared with ER negative cancers [140]. Therefore, as expected, 
the genes in our gene signature were strongly enriched with estrogen receptor 
signaling and androgen signaling pathways.  Lehman et al. [125] concluded that 
patients with a TNBC (or ER negative) subtype should be treated with anticancer 
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agents that engage DNA damage signaling response pathways (see Figure 6.11).     
 Several other pathways were also related to the responsiveness of 
chemotherapy. For example, the PI3K/AKT signaling pathway that promoted 
breast cancer cell survival due to the PI3K inhibitor, and the AKT mutant that 
inhibited AKT activity while increasing apoptosis caused by chemotherapy [44] 
resulted in greater effectiveness for chemotherapy. Zha et al. [227] suggested that 
the Insulin receptor pathway is implicated in resistance to chemotherapy and is an 
attractive target for anticancer therapy. Many other studies also suggest links 
between Insulin receptor signaling and the estrogen receptor signaling pathway 
[197, 228] and their response to anticancer agents. The chemokine signaling 
pathway has played a critical role in the immune response in guiding immune cells 
to regions of secondary lymphoid organs and guiding inflammation sites [1]. Bierly 
et al. [22] suggested that targeting the chemokine signaling pathway may be a 
promising chemotherapy treatment for opposing cancer progression and fighting 
against metastasis. Previous experiments have shown that expression of the CXCL8 
chemokine has been used as a marker in assessing patient response to 
chemotherapy, with high levels of their expression correlating with a poor response 
to chemotherapy [158].         
  
 
Figure 6.11: Signaling pathways associated with chemotherapy responsiveness for the 74 
genes of the ܲܥ݄݁݉݋ܶݔgene signature and other existing algorithm gene signatures. The 
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y-axis represents the logarithm of p-values calculated by the Fisher exact test, with a 
threshold for statistical significance of p=0.05 represented by the thick horizontal red line.
     
Figure 6.10 and 6.11 clearly show the biology of the ܥ݄݁݉݋gene signature is 
significant and strongly related to mechanisms targeting a chemotherapy response.
         
6.4 Summary   
Treatment decision making is clinically essential for breast cancer patients given 
the potential long-term side effects of neoadjuvant chemotherapy. This study was 
primarily focused on constructing gene signature patterns to predict the two classes 
of response (pCR and npCR) for commonly used neoadjuvant chemotherapy 
regimens among breast cancer patients which provide opportunities to better use 
these drugs to reduce time, cost, effort, and mental stress involved with treatment. 
The proposed ܥ݄݁݉݋ algorithm demonstrated its effectiveness by predicting 
the binary responsiveness on five validation sets that outperformed five other 
existing related algorithms developed with eight classification techniques for each 
algorithm and evaluated by considering two performance measures. This clearly 
showed the strength of the ܥ݄݁݉݋ algorithm. The biological processes and 
associated pathways for genes in the ܥ݄݁݉݋ gene signature suggests their 
significantly enriched biological roles are associated with a chemotherapy 
response. We propose our results have immediate clinical translation as they 
provide an essential platform and insight for future clinical investigations.   
 From this study, we conclude there is significant potential for gene 
expression profiles to assist the selection of treatment among neoadjuvant breast 
cancer patients. While results such as these are encouraging, further study is needed 
to assess the impact of such drugs among other cancer types with increased 
coverage of samples.         
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Chapter 7  
 
Prediction of Estrogen Receptor 
Status and Treatment Outcomes for 
Breast Cancer Patients 
 
7.1 Introduction 
To perform the various prediction tasks for breast cancer, Chuang et al. [42] 
indicates that a cancer originates from driver genes that rapidly alter the expressions 
in genes which interact with a driver gene. Therefore, it is good to consider the 
network based approach because it shows higher reproducibility across different 
cohorts compared with a non-network based approach, and shows higher accuracy 
in performing prediction tasks. Various network based approaches have been 
developed for performing different prediction tasks [42, 75].       
 Although network based approaches are effective in performing prediction 
tasks they have one major issue, i.e., existing protein interaction datasets contain 
many false-positive interactions (interactions shown in the experimental dataset but 
never occurring biologically), which may cause a bias in these interaction datasets 
discovering biological knowledge [172]. In other words, the identification of 
reliable interactions from the experimental protein interaction datasets is one of the 
most challenging tasks that is yet to be resolved (see Section 3.1 for more details). 
While some studies showed the network based approach is effective, other studies 
have shown non-network based approaches are effective in performing the 
prediction tasks. There is no general consensus on which approach is the most 
effective over the other, and this is one of the potential aims of the current study, 
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which is to discover the better approach for performing different prediction tasks. 
 In this chapter, we propose a novel computational predictive algorithm, 
called the Integrated Predictive Algorithm (IPA) for performing multiple prediction 
tasks, including predicting the estrogen receptor based binary subclass and 
predicting the chemotherapy response (neoadjuvantly) based binary subclass. First, 
from the training cohort, 2-fold cross-validation was performed to extract the 
predictive gene signatures to avoid over-fitting, and then different classification 
techniques were incorporated for an algorithm to predict the binary subclasses. The 
reason we considered multiple classification techniques was because the 
performance of the prediction algorithm may vary with different classification 
techniques. The techniques we considered included TreeBoost; decision tree (DT); 
support vector machine with Linear kernel, Sigmoid kernel, and RBF kernel (SVM-
L, SVM-S, and SVM-RBF); diagonal linear discriminant analysis (DLDA); and the 
logistic regression model (LR) [184]. Next, we considered the multiple 
performance measures to further demonstrate the independency of the algorithm 
for the performance measures. Further, the proposed algorithm was constructed 
using the network based information, called the network based IPA algorithm (N-
IPA), to perform the comparison between the network based and non-network 
based approach. The performances of the proposed algorithm was evaluated and 
compared with the Ttest algorithm constructed for performing the binary prediction 
tasks.          
 The evaluation of the proposed algorithm demonstrates their robust and 
stable performances across different cohorts of patients. The proposed algorithm 
also outperformed the Ttest algorithm with consideration given to any classification 
technique.         
 The rest of the chapter is organised as follows. The proposed algorithm is 
defined in Section 7.2. The training and validation cohorts used in this study, 
statistical validation with patient prediction results, and biological validation are 
presented in Section 7.3. Finally, we conclude this chapter in Section 7.4. 
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7.2 Methods   
7.2.1 Integrated Predictive Algorithm 
The aim of the proposed algorithm is to construct a gene signature that can predict 
the binary subclass of estrogen receptors and the neoadjuvant breast cancer patient 
response to standard chemotherapy regimens. In other words, this problem can be 
considered a binary class prediction problem, i.e., predicting estrogen receptor 
positive (ER+) and estrogen receptor negative (ER-), or predicting a pathological 
complete response (with no residual cancer or lymph-node involved) (pCR) and a 
non-pathological complete response (residual cancer) (npCR).  
 The ER- subtype is considered an aggressive form of breast cancer 
compared with the ER+ subtype [145, 212]. Also, patients with the ER- subtype 
achieved higher pCR rates to standard chemotherapy regimens (treated 
neoadjuvantly) compared with their counterpart ER+ subtype (see Section 6.3.4 for 
more details). Therefore, based on the above ideas, to predict the binary subclass, 
we proposed two scoring metrics for each gene in the gene expression dataset (see 
Table 7.1) as: 
ߜ௚ ൌ ߤ௣஼ோǡாோିሺ௚ሻ െߤ௣஼ோǡாோାሺ௚ሻ  
ߪ௚ ൌ ߤ௡௣஼ோǡாோାሺ௚ሻ െߤ௡௣஼ோǡாோିሺ௚ሻ        (7.1) 
                        where,ߤ௣஼ோǡாோିሺ௚ሻ ൌ σ
௘೔
ሺ೒ሻ
ே௜א௣஼ோǡாோି  ;        
݁௜ሺ௚ሻ defines expression of gene g in ith sample, N defines the total number of 
samples which belong to pCR and ER-. The prime idea for the equation (7.1) is to 
identify the differential expression (DE) pattern of the estrogen receptor subclass 
with consideration given to the chemotherapy response based subclass. Here, 
Ɂrepresents the estrogen receptor based differential expression effectiveness score 
with respect to pCR, and ɐrepresents the estrogen receptor based differential 
expression effectiveness score with respect to npCR.    
 However, as defined above, we are interested in identifying the genes with 
their positive or negative Ɂ and ɐ based two-scoring metric. In other words,  
If (Ɂ ൐ Ͳ andɐ ൐ Ͳ) or (Ɂ ൏ Ͳ andɐ ൏ Ͳ) 
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then gene ݃ has DE strength between subclasses and 
remains in the dataset;                   
else   
         gene ݃ is removed/filtered from the dataset.  
Table 7.1: Illustration of the microarray gene expression dataset incorporated in this study. 
Chemotherapy response (pCR: 1, npCR: 0) 1 1 0  
 
 
 
 
… 
0 
Estrogen Receptor status (ER+: 1, ER-: 0) 1 0 1 1 
 ܵଵ ܵଶ ܵଷ ܵ௠ 
݃ଵ ݔଵଵ ݔଵଶ ݔଵଷ ݔଵ௠ 
݃ଶ ݔଶଵ ݔଶଶ ݔଶଷ ݔଶ௠ 
݃ଷ ݔଷଵ ݔଷଶ ݔଷଷ ݔଷ௠ 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
݃௡ ݔ௡ଵ ݔ௡ଶ ݔ௡ଷ ݔ௡௠ 
Here, ݃௡ defines the ݊௧௛ gene, ܵ௠ defines the ݉௧௛ sample, and ݔ௡௠ defines the gene expression of 
the ݊௧௛gene in the ݉௧௛ sample. 
          
  
The remaining number of genes from the above step with their two-scoring metrics 
of Ɂ and ɐ were then retained to form the discriminative score. The discriminative 
score or S measure can be formed by integrating the Ɂ and ɐscoring metrics that 
can evaluate the overall DE strength of any gene ݃ between ER+ and ER- with 
respect to a binary chemotherapy response. The equation (7.2) provides the details 
for calculating the S measure for a gene ݃ (ܵሺ௚ሻሻ. 
ܵሺ௚ሻ ൌ 
ۖە
۔
ۖۓ
ͳ
ߠͳ
Ɂሺ݃ሻ ൅  ͳߠʹ ɐ
ሺ݃ሻǢ ߠͳ  ് ͲǢ ߠʹ  ് Ͳ
ͳ
ߠͳ
Ɂሺ݃ሻ ൅ ɐሺ݃ሻǢ ߠͳ  ് ͲǢ ߠʹ ൌ Ͳ
Ɂሺ݃ሻ ൅  ͳߠʹ ɐ
ሺ݃ሻǢ  ߠͳ ൌ ͲǢ ߠʹ  ് Ͳ
      (7.2) 
Here, ߠଵ and ߠଶare incorporated to penalise Ɂ andɐ, respectively, and represents 
the number of samples in ER+ and ER- groups, respectively. With this equation 
(7.2), each gene in a dataset is assigned an S measure. Since the values of ߠଵ and 
ߠଶ vary in different cases, the calculation of ܵሺ௚ሻ varies accordingly. The higher 
theܵሺ௚ሻ, the higher the DE strength between the two binary classes of estrogen 
receptor with consideration given to their binary chemotherapy response. 
Therefore, based on the S measure, the significant genes were then identified with 
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a p-value <0.05 (using log-rank test), and were extracted. These extracted genes 
form the gene signature.       
 Based on the two scoring metrics and the S measure, we named this 
proposed algorithm the Integrated Predictive Algorithm for predicting estrogen 
receptor and chemotherapy response based binary subclasses (IPA). The pseudo-
code is shown in Figure 7.1.     
 
    Initialise:  ߬ ൌ ׎               //߬ is the temporary list of selected genes 
                       ܲீ ௌ ൌ ׎           //ܲீ ௌ is the set of predicted gene signature   
 
//Two scoring metrics and S measure evaluation  
For any gene g in dataset D 
{ 
        Evaluate ߜ andߪ 
        if (ߜ ൐ Ͳ andߪ ൐ Ͳ) or (ߜ ൏ Ͳ andߪ ൏ Ͳ) 
              then generate ܵ measure of gene g 
              and  ߬ ൌ ߬ ׫ ሼ݃ሽ 
       else 
              removed/filtered from dataset D  
} 
 
//identifying significant genes to form the IPA gene signature 
For each gene k contained in ߬ 
{ 
       generate p-value using log-rank test 
       if p<0.05 
              ܲீ ௌ = ܲீ ௌ ׫ ሼ݇ሽ 
       else 
             removed/filtered from߬         
}  
return ܲீ ௌ 
Figure 7.1: Pseudo-code of the IPA algorithm 
 
7.2.1.1  Network based IPA Algorithm  
Given n genes and m edges or interactions, the interaction network is defined by G 
= (V, E), where ȁܸȁ ൌ n and ȁܧȁ ൌm. The S measure (see equation (7.2)) was then 
generated for each gene ݃ in the interaction network, as generated in the IPA 
algorithm. Therefore, each interaction y between genes (݃,݇) was then assigned a 
merged S measure (߮) from their interacting genes, which is simply the average of 
the S measure between genes݃ and݇. The generated ߮ measure for each gene 
interaction was then used to identify the significant gene interactions with a p-value 
<0.05 (using log-rank test), and were extracted. The genes that participated in these 
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extracted significant gene interactions form the gene signature. This algorithm is 
named the network-based integrated predictive algorithm (N-IPA). 
7.2.2 Classification techniques and performance evaluation 
The IPA gene signature is then used to perform the prediction tasks for the samples 
by evaluating their gene signature score (G) as mentioned in Section 6.2.2. 
 Using equation (6.9), each sample s can be transformed intoܩ, which can 
be used by any of the existing classification techniques to perform the binary 
prediction task. For this study, we considered seven widely used classification 
techniques, including the decision tree (DT); TreeBoost; support vector machine 
with Linear kernel, Sigmoid kernel, and RBF kernel (SVM-L, SVM-S, SVM-
RBF); the logistic regression (LR) model; and diagonal linear discriminant analysis 
(DLDA) (see Section 6.3.3 for details), to evaluate the predictive strength and to 
show the independency of the algorithm on the classification techniques (see 
Section 7.3.3).                
 To evaluate the overall performance or the predictive strength of an 
algorithm, or to demonstrate the algorithm independency on the performance 
measure, three performance measures were considered, including the Accuracy, F-
measure, and the area under the ROC curve (AUC) measure, which was evaluated 
from the receiver-operating characteristic (ROC) curve (see Section 2.3.1.1 and 
equation (2.18) for more details).      
    
7.3 Results           
7.3.1 Datasets                
We retrieved two publicly available breast cancer microarray gene expression 
datasets (GSE20194 and GSE22226) from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) [18]. The downloaded 
microarray datasets were normalised as published by the original studies. These 
datasets were selected based on the availability of estrogen receptor labels, i.e., 
ER+ or ER-, and the chemotherapy treatment response labels (treated 
neoadjuvantly), i.e., pCR (pathological complete response with no residual cancer) 
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or npCR (non-pathological complete response with residual cancer). The detailed 
characteristics of each microarray dataset is shown in Table 7.2. 
Table 7.2: Microarray datasets used in this study. 
GEO 
accession Platform Samples ER (+/-) 
Tumor Grade  
(G1/G2/G3) 
Average Age 
in years 
(range) 
Neoadj. 
Chemo. 
regimen 
Response rate 
(pCR/npCR) 
GSE20194 GPL96 278 164/114 13/104/150 51.9 (26-79) TFAC 56/222 
GSE22226 GPL1708 130 65/58 7/52/69 48.17 (28-65) AC or AC/T 32/92 
Abbreviations: ER, estrogen receptor; p=positive; n=negative; TFAC, paclitaxel (T), 5-flourouracil (F), doxorubicin (A) 
and cyclophosphamide (C); AC, doxorubicin (A) and cyclophosphamide (C); AC/T, AC plus taxane (T); pCR, pathologic 
complete response (disease-free); npCR, non-pathologic complete response (residual disease). 
 
The samples were limited in size if considering the individual dataset with their 
binary ER label or their binary chemotherapy response label. Therefore, we 
integrated the two microarray datasets, as shown in Table 7.2. To integrate the data, 
data normalisation (see equation (4.1)) was done first as defined in Section 4.2.1.  
 Next, a common list of genes (see Section 4.2.1 for more details) from the 
two microarray datasets was then extracted, which consisted of 8,960 genes. The 
datasets were then directly integrated. This enabled the gene signature to be 
independent of microarray datasets or their platform types.      
 From the integrated dataset, the samples with repetitions, missing ER status 
labels, or missing chemotherapy response labels were excluded. 395 samples 
remained that consisted of 225 ER+ patient samples and 170 ER- patient samples, 
and 87 pCR patient samples and 308 npCR patient samples, respectively.  
7.3.1.1 Network dataset 
In this study, we incorporated six PPI datasets (see Section 4.2.2 for more details) 
in order to increase the interactions coverage that were limited considering the 
single protein interaction dataset. The gene interaction network was then formed 
with genes in the integrated microarray dataset (see Section 7.3.1) from multiple 
PPI datasets by considering the Universal Protein Resource Database [203]. Once 
constructed, the self-interactions and the duplicate edges were then removed as they 
did not have any biological meaning. The resulted gene interaction network 
contained 75,553 gene interactions involving 7,706 genes. 
  
170 
 
7.3.2 Two-split dataset to form IPA and N-IPA gene signature 
The integrated dataset was split into two different cohorts according to their ER 
status labels and chemotherapy response labels that contained 197 and 198 samples, 
respectively, in order to form the IPA and N-IPA gene signature. We named these 
two distinct cohorts as the forward cohort (FWC) and the backward cohort (BWC). 
Two analyses were then performed by applying the IPA algorithm. First, the FWC 
cohort was used as a training set to extract the gene signature, while the BWC 
cohort was used as a validation set to evaluate the algorithm performance. Next, we 
swapped the cohorts previously used as training and validation.   
 The genes were then extracted which appeared in both the training set based 
gene signature lists, and were used to form the IPA gene signature that consisted of 
18 genes. A similar process was repeated to form the N-IPA gene signature that 
consisted of 106 genes.  
7.3.3 Prediction performance 
The performance of our method IPA, N-IPA was evaluated along with their 
comparison with the gene signature generated using a t-test (denoted as Ttest). To 
perform the binary prediction tasks, the algorithms were applied on both the FWC 
cohort and the BWC cohort.               
 First, we performed the binary prediction task of predicting the ER+ or ER- 
subclass of a sample. For the IPA gene signature, the N-IPA gene signature and the 
Ttest gene signature, the TreeBoost and SVM-RBF classification technique 
performed well amongst the other classification techniques. However, performing 
the binary prediction task with SVM was a more computationally time-consuming 
task. Therefore, TreeBoost can be chosen as an optimal classifier (being less-time 
consuming) to build the model compared with SVM, and also showed better 
prediction performance than SVM-RBF. Figure 7.2 shows the IPA algorithm 
achieved the overall best performance measures of Accuracy, F-measure, and 
AUC. In contrast, the network based IPA algorithm (N-IPA) achieved lower 
performance measures, and further, the Ttest achieved worst performance 
measures. In addition, if comparing the algorithms given the different classification 
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technique, the IPA algorithm achieved nearly the best performance measures, 
followed by N-IPA and Ttest. 
 
 
 
 
Figure 7.2: Line charts show the performance measures of Accuracy, F-measure, and AUC 
in the FWC and BWC cohort for the different prediction algorithms that predict ER+/ER- 
binary subclass. Here, the Avg for an algorithm denotes the overall average performance 
calculated as averaging the performance measure from all the different classification 
techniques. 
 
Next, we performed the binary prediction task of predicting the pCR or npCR 
treatment response of a sample. As mentioned previously, the TreeBoost 
classification technique also performed well amongst other classification 
techniques in each of the algorithms. Figure 7.3 shows the IPA algorithm still 
achieved ov erall best performance measures, followed by N-IPA and Ttest. 
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However, in this case, if considering the individual classification technique, the 
IPA and the N-IPA algorithm performed almost similar. Also, if considering the 
overall performance measures, the IPA algorithm achieved marginally better 
performance measures and their difference was statistically non-significant (p-
value>0.05).              
 
 
 
Figure 7.3: Line charts show the performance measures of Accuracy, F-measure, and AUC 
in the FWC and BWC cohort for the different prediction algorithms that predict pCR/npCR 
binary subclass. 
 
The treatment response prediction of chemotherapy has been shown as a complex 
endpoint to predict [185] due to the differences that come with the known 
heterogeneity within the same subclass of cancers or the variation in drug 
metabolism, dosage, and schedules between each patient [159] (see Section 6.3.4). 
Also, constructing the gene signatures for the prediction of response to 
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chemotherapy has shown to be a more complex problem than predicting the 
subtypes of cancer [172]. Therefore, the prediction of treatment response is a more 
challenging task than to predict the ER+/ER- breast cancer subclass, and this 
complexity can be overcome by incorporating an interactions network into the gene 
expressions [11, 49]. Also, from the above experiments, we concluded that 
considering the network-based information improved the prediction performance 
measures for performing the treatment prediction task, compared with performing 
the prediction task of ER+ or ER- (see Figure 7.2 and Figure 7.3).  
 However, as discussed in Chapter 3 and 4, the protein interactions identified 
from the experiments usually contain false-positive interactions, and as a 
consequence, the discovered biological knowledge from the interaction networks 
may be biased. The reliable interactions incorporated with gene expressions can 
significantly lead to improved predictive performance results with improved 
biological meaning associated with the genes in the gene signature (see Section 
4.4).          
 In the N-IPA algorithm, we directly incorporated the interaction network 
with the gene expression information without considering the reliability of the 
interactions. This may lead to biased results and may possibly be one of the 
potential reasons that the N-IPA algorithm showed lesser overall performance 
measures than the IPA algorithm for predicting the ER+/ER- subclass and the 
pCR/npCR subclass, respectively. However, if considering the reliability metrics 
(see Chapter 3 and 4 for details), then possibly the performance measures may be 
improved, which lead to further investigations.      
   As the TreeBoost classification technique achieved the best performance 
measures for each of the algorithms, we selected the best classification technique 
to perform the predictive task for further analysis. Figure 7.4 shows the IPA 
algorithm outperformed the other algorithms on average (as well as individual 
cohort) performances while conducting the prediction task of ER+/ER- with 
consideration given to the best classification technique of TreeBoost. Similar 
results were achieved in Figure 7.5 when performing the prediction task of 
pCR/npCR with consideration given to the best classification technique of 
TreeBoost. From Figure 7.5, it can be seen that performance measures of IPA and 
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N-IPA were close together and were consistent with the previously mentioned 
results as discussed above (Figure 7.3).  
 
 
Figure 7.4: Bar charts show the performance measures of Accuracy, F-measure, and AUC 
for the different prediction algorithms using the best classification technique of TreeBoost 
that predicts the ER+/ER- binary subclass. Here, the Avg for an algorithm denotes the 
overall average performance measure, calculated as averaging the performance measure 
from the FWC and BWC. 
 
 
Figure 7.5: Bar charts show the performance measures of Accuracy, F-measure, and AUC 
for the different prediction algorithms using the best classification technique of TreeBoost 
that predicts the pCR/npCR binary subclass. 
 
In summary, the IPA algorithm based gene signature showed the best predictive 
performances and higher stability between different cohorts in performing the 
prediction of binary subclass with demonstrated their independency to the multiple 
classification technique, and therefore, can be more clinically applicable to patients 
from other independent cohorts. 
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7.3.4 Reproducibility of predictive gene signatures 
We performed the reproducibility analysis of gene signatures derived from the IPA, 
the N-IPA, and the Ttest algorithm, and this was performed by calculating the 
number of overlapping genes between them. There was an overlap of 12 genes 
(16.7-66.7%) between the IPA gene signature and the other gene signatures. This 
overlap was greater than the overlap of gene signatures between the N-IPA and the 
Ttest (2-9%). This reproducibility may contribute to the higher stability that 
achieved better predictive performances from the different cohorts compared with 
the N-IPA and the Ttest algorithms 
7.3.5 Biological analysis of predictive gene signatures 
The biological analysis of the gene signatures was performed considering GO 
analysis by using the Ingenuity Pathway Analysis Software (IPA) 
(http://www.ingenuity.com/). For each gene in the gene signature, GO analysis was 
performed using the enriched biological process GO terms [11].   
 Figure 7.6 lists the enriched biological processes associated with the gene 
signatures along with their p-values. Figure 7.6 shows many significantly enriched 
biological processes for the N-IPA gene signature, including Cell Signaling, 
Apoptosis, DNA Replication, Recombination, and Repair, and Drug Metabolism, 
etc., which are the expected target biological processes that relate to the treatment 
response for various anticancer drugs [49] and with the estrogen receptor subclass 
(see Section 6.3.6 for more details).      
 Further, it can be observed that the N-IPA gene signature was more 
biologically enriched compared to its counterpart IPA gene signature (see Figure 
7.6). This biological analysis showed the network based gene signatures were more 
significantly associated with the phenotype of interest, and the biological meaning 
of their gene signatures were meaningful and strongly related with the enriched 
biological processes associated with the estrogen receptor subclass or the 
chemotherapy response subclass.       
 As mentioned previously, incorporating reliability metrics into the 
interaction network may further enhance the performance results (see Section 3.3 
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and 4.4 for more details), which may also significantly improve the association of 
their gene signatures with the enriched biological processes.   
 
 
Figure 7.6: Enriched biological process based GO functions for the IPA, N-IPA, and Ttest 
algorithm based gene signatures. Here, Ttest-ER+/ER- stands for the Ttest algorithm based 
gene signature for predicting the binary estrogen receptor subclass, and Ttest-pCR/npCR 
stands for the Ttest algorithm based gene signature for predicting the binary chemotherapy 
response subclass. The y-axis shows the logarithm of p-values evaluated from the Fisher 
exact test, with a threshold for statistical significance of p-value=0.05 represented by the 
thin horizontal red line. 
 
7.4 Summary  
In this study, we derived the gene signatures from our proposed algorithm, IPA and 
their network-based variant, N-IPA from a different cohort of breast cancer 
patients, which demonstrated the effectiveness of the proposed algorithm in 
predicting the binary estrogen receptor subclass and predicting the binary 
chemotherapy treatment response subclass with consideration of multiple 
classification techniques. Further, we also demonstrated the effectiveness of 
considering network-based information in performing the binary prediction task.  
 From our statistical and biological analyses, we suggest that our proposed 
algorithm, IPA, may serve as a better clinical predictor in performing prediction 
tasks. While the initial conclusions such as these are motivating, further detailed 
study is needed with an increased coverage of samples.   
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Chapter 8  
 
Conclusions 
 
The research presented in this thesis consists of four parts. The first part focuses on 
the interaction reliability issue, the second part focuses on the breast cancer 
diagnosis issue, the third part focuses on the breast cancer prognosis issue, while 
the fourth part focuses on the breast cancer treatment prediction issue. Several new 
research problems and solutions have been identified in this context. 
 We have explored existing approaches for breast cancer diagnosis, 
prognosis, and treatment outcome prediction that have been unable to provide the 
expected satisfactory results, such as the inability to accurately characterise ER+ or 
ER- breast cancers. Also, most existing approaches are based on a small number of 
microarray data based samples, and for the approaches that consider network based 
information, they do not consider the reliability of interactions that can detect an 
unreliable (or biologically invalid) interaction from the interaction dataset, and as 
a consequence unsatisfactory results.      
 In this thesis, we have addressed the above issues and proposed five novel 
algorithms to effectively identify the reliable interactions from the protein 
interaction network, effectively identify the ER+ or ER- breast cancer patients, 
effectively characterise the good prognosis or poor prognosis breast cancer patients, 
effectively predicts a good response or poor response to chemotherapy for breast 
cancer patients, and effectively performs multiple tasks, including characterising 
ER+/ER- breast cancer patients and predicting a good/poor response to 
chemotherapy. Further, this chapter summarises the main findings and provides 
necessary recommendations in this research area and also provides details for our 
future work.        
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8.1 Review of Main Findings  
We proposed five novel algorithms: the SR algorithm (Chapter 3), the RRHGE 
algorithm (Chapter 4), the IPRE algorithm (Chapter 5), the PChemoTx algorithm 
(Chapter 6), and the IPA algorithm (Chapter 7). These algorithms are briefly 
explained below. 
x The SR algorithm is based on semantic methodology which considers all 
the external and internal interactions between any two interacting proteins 
in order to detect potential unreliable or false-positive interactions from the 
protein interaction network. The Semantic Reliability (SR) algorithm 
derives the semantic property of protein-protein interactions from the 
FunCat terms (as defined in Section 3.2). The reliability assessment of 
protein interaction data from the SR algorithm is based on two new semantic 
reliability metrics; Semantic Interaction Reliability 1 (R1) and Semantic 
Interaction Reliability 2 (R2).      
 We compared our proposed reliability approach with other existing 
reliability approaches IG2, IRAP, and PVM, with experimental results 
showing that the proposed reliability approach provides outstanding results. 
This result signifies that a semantic based reliability approach, such as our 
SR approach which considers each interaction semantically, is a much more 
promising approach than the topological based approaches, such as IG2, 
IRAP, and PVM. This validates the effectiveness of our SR reliability 
approach. 
x The RRHGE algorithm is based on reliable gene expression metrics to 
measure and extract reliable gene interactions from gene interaction 
networks in terms of real biological processes, and incorporate the extracted 
reliable gene interactions into our proposed algorithm; the robust reliability 
based hub gene expression algorithm (RRHGE).The RRHGE algorithm uses 
hub gene topology to identify significant genes for classifying ER+ and ER- 
breast cancer samples effectively.     
 The evaluation of our proposed approach and the experimental 
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comparisons with other existing approaches, such as GGI, 70g, 76g, ITI, 
and HRGE, demonstrated that RRHGE significantly increased the 
classification performance by accurately characterizing a high number of 
ER+ and ER- samples without depending on any specific dataset or any 
other factors. Further, in addition to the statistical evaluations, thorough 
biological evaluations were also conducted using GO and pathway analysis 
to show the effectiveness and stability of the proposed algorithm.  
x The IPRE algorithm is based on a Virtual Chromosome (VC) consisting of 
two components (Correlation-factor and Penalised-factor), which are used 
to extract our prognostic gene signature. The extracted Integrated Prognosis 
Risk Estimation (IPRE) algorithm based gene signature is then incorporated 
into a multivariate logistic regression model along with clinical variables 
for generating the risk score formula that can classify the good prognosis or 
poor prognosis breast cancer patient samples effectively.   
 We demonstrated that when using the training dataset that consists 
of an equal number of two prognosis groups, it achieved a high 
classification performance in comparison to the training dataset that 
consisted of an unequal ratio of the two prognosis groups. This study 
particularly focussed on achieving high specificity, at the same time as 
achieving high sensitivity. The evaluation of our proposed algorithm, called 
IPRE and the experimental comparisons with other prognosis based 
classifiers, such as GGI, 70g, 76g, 112g, IGS, 21g, and ITI, demonstrated 
the IPRE algorithm outperforms other classifiers by achieving a high 
classification accuracy. Furthermore, the gene signature for the proposed 
algorithm is biologically meaningful and relates to breast cancer prognosis.   
x The PChemoTx algorithm is based on three scoring metrics and a two-step 
operation to effectively predict the two classes of response (pCR and npCR) 
for commonly used neoadjuvant chemotherapy regimens among breast 
cancer patients. We named this prediction algorithm Prediction of 
Chemotherapy regimens Treatment outcome (ܥ݄݁݉݋) which provides 
better opportunities to use these drugs to reduce time, cost, effort, and 
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mental stress involved with treatment.    
 The evaluation of our proposed algorithm and the experimental 
comparisons with other existing related algorithms, such as OptDis, p53, 
5gs, Dense, and MAQC-II, clearly demonstrated the robust predictive 
performance of our algorithm and how it outperformed other existing 
algorithms with considering any classification technique and multiple 
performance measures. Furthermore, the gene signature of our proposed 
algorithm reflects the underlying mechanisms of chemotherapy’s response 
with significantly greater biological interpretations.  
x The IPA algorithm is based on two scoring metrics and a discriminative 
score (or S measure) to effectively perform multiple tasks, including 
predicting ER+ or ER- breast cancer patients, or predicting pCR or npCR 
for neoadjuvant chemotherapy regimens among breast cancer patients. We 
named this proposed algorithm Integrated Predictive Algorithm (IPA) 
which predicts estrogen receptor and chemotherapy response based binary 
subclasses.        
 The evaluation of the proposed algorithm demonstrates its robust 
and stable performance across different cohorts of patients. It also 
outperformed the Ttest algorithm with consideration given to any 
classification technique. Further, the proposed algorithm was constructed 
using network based information, called the network based IPA algorithm 
(N-IPA), to perform the comparison between the network based and non-
network based approach. Also, the biological analysis showed the 
biological meaning of our proposed algorithm based gene signatures were 
meaningful and strongly related with the enriched biological processes 
associated with the estrogen receptor subclass or the chemotherapy 
response subclass.     
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8.2 Recommendations and Future work   
Although the proposed algorithms have addressed the interaction reliability issue, 
the breast cancer diagnosis issue, the breast cancer prognosis issue, and the breast 
cancer treatment prediction issue to a certain extent, there is further research that 
needs to be undertaken to explore these issues even further and extend the methods 
and experimental findings presented in this thesis. These includes: 
x Similarity Calculations: In the SR algorithm, the semantic similarity 
between two functions in the R2 reliability measure could also be calculated 
using other available methods. This is worth investigating along with the 
impact of other function similarity calculations on the effectiveness of the 
reliability assessment method. Another possible avenue for future work is 
to apply our SR method to protein interactions of other species, such as mice 
and humans, while improving the method by combining functional 
semantic information with other kinds of information, such as the 
interaction topological structure information.  
x Reliability Metrics: We observed that if gene interactions in the network are 
reliable, then classification performance will significantly increase when 
compared to cases where the reliability criterion is not considered. As a 
matter of fact, this provides us with a possible research direction to improve 
the reliability metrics in the RRHGE algorithm by incorporating highly 
biologically-related information. In addition, it is worthwhile investigating 
how the classification performance behaves if we integrate other data types, 
such as the DNA copy number variation. Furthermore, in the IPRE 
algorithm, the PChemoTx algorithm, and the IPA algorithm, we considered 
microarray gene expression data and not incorporated any interaction 
network based reliability metrics that could improve their respective 
performances to a significant extent. This will likely be part of our future 
work. 
x Treatment Outcome Prediction: One possible limitation of the PChemoTx 
algorithm is to restrict it with the hierarchical clustering algorithm to 
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generate the clusters that are later used to extract the gene signature. 
However, there is no analysis performed that shows the impact of other 
clustering algorithms on formation of the clusters. This is worthwhile 
investigating in our future work along with the impact of other clustering 
algorithms on the performance of our algorithm. Furthermore, it would be 
interesting to investigate how the performance metrics of the PChemoTx 
algorithm will behave in the adjuvant setting. 
x Other Cancers: Although, in this thesis our research focus is on breast 
cancer, our algorithms could be applied to diagnose, prognose, or to predict 
the treatment outcome for other types of cancer. This depends on the two 
prime factors, including the availability of related microarray gene 
expression data incorporated with clinical data, and the molecular subtypes 
which have been clearly defined. 
x Web-based Software Suites:  While anyone who implements the proposed 
algorithms in this thesis needs to be familiar with programming language to 
use them for their own research, the  development of stand-alone software 
or web-based software suites that implements the proposed algorithms 
makes it possible for doctors, biologists, or bioinformaticians to easily 
perform the various tasks.             
While this thesis provides a thorough report of our research in interaction 
reliability, breast cancer diagnosis, breast cancer prognosis, and in breast cancer 
treatment prediction approaches, there are still interesting and promising issues that 
remain to be explored. The ever-increasing volume of microarray gene expression 
data and interaction networks presents an opportunity to perform various biological 
tasks, such as the diagnosis or prognosis of breast cancer, but it also presents a 
challenge in utilising the available data in the best possible manner.         
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Appendix A 
 
 
Commercially Available gene Signatures 
 
 
Table A.1: Commercially available (or in developmental phase) gene signatures for the 
diagnosis/prognosis of breast cancer. 
Gene 
signature 
Test Details Diagnostic Prognostic Output 
 
70-gene 
signature 
[208] 
x Test Name: MammaPrint®  
x Manufacturer: Agendia BV   
x Analytical Platform: Microarray 
x Tissue Sample requirement: 
Fresh-frozen tumor 
x FDA Approved: Yes  
x Availability: Europe and USA 
x Level of Evidence: III  
 
Yes 
 
Yes 
 
Two metastasis risk 
categories of tumors, 
i.e., low-risk tumors 
and high-risk tumors. 
 
 
3-gene 
signature 
[138] 
x Test Name: Theros/ MGI  
x Manufacturer: Biotheranostics 
x Analytical Platform: qRT-PCR  
x Tissue Sample requirement: 
Paraffin-embedded tumor 
x FDA Approved: No  
x Availability: USA 
x Level of Evidence: III  
 
No 
 
Yes 
 
 
HOXB13:IL17BR 
expression ratio 
classify ER+ patients 
into 2 recurrence risk 
categories, i.e., low-
risk and high-risk. 
 
 
 
76-gene 
signature 
[216] 
x Test Name: (In Development 
phase) 
x Manufacturer: Johnson & 
Johnson 
x Analytical Platform: Microarray 
x Tissue Sample requirement: 
Fresh-frozen tumor 
x FDA Approved: No  
x Availability: - 
x Level of Evidence: III 
 
Yes 
 
Yes Relapse Score 
(positive or negative) 
predicts the risk of 
distant metastasis into 
poor-prognosis 
(positive-score) or 
good-prognosis 
(negative-score), and 
the Gene Expression 
Score identifies ER+ 
or ER- subgroup. 
 
 
97-gene 
signature 
[192] 
x Test Name: MapQuant DX™ 
x Manufacturer: Ipsogen 
x Analytical Platform: qRT-PCR  
x Tissue Sample requirement: 
Frozen/Paraffin-embedded tumor 
x FDA Approved: No  
 
Yes 
 
Yes 
 
Genomic Grade 
Index or GGI 
categorises the Grade 
2 tumors into two 
grades, i.e., GGI low-
grade or GGI high-
grade. 
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x Availability: Europe 
x Level of Evidence: III 
 
21-gene 
signature 
[157] 
x Test Name: Oncotype DX™ 
x Manufacturer: Genomic Health 
Inc. 
x Analytical Platform: qRT-PCR  
x Tissue Sample requirement: 
Paraffin-embedded tumor 
x FDA Approved: No  
x Availability: Europe and USA 
x Level of Evidence: II 
 
No 
 
Yes 
 
 
Recurrence Score or 
RS (in the range 0-
100) predicts the risk 
of distant recurrence 
into low-risk (if 
RS<18) , 
intermediate-risk 
(18≤RS<31), and 
high-risk (RS>31). 
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Appendix B 
 
RRHGE Gene Signature 
 
 
Table B.1: RRHGE gene signature consists of 471 genes, i.e., 326 genes for the ER+ 
subtype and 145 genes for the ER- subtype.     
  
ER+ gene signature 
Gene ENTREZ 
GENE ID 
Gene Title 
ABCB8 11194 ATP-binding cassette, sub-family B (MDR/TAP), member 
8 
ACIN1 22985 apoptotic chromatin condensation inducer 1 
ADRB2 154 adrenergic, beta-2-, receptor, surface 
AES 166 amino-terminal enhancer of split 
AGR2 10551 anterior gradient homolog 2 (Xenopus laevis) 
ANP32A 8125 acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member A 
AP1M2 10053 adaptor-related protein complex 1, mu 2 subunit 
APEH 327 N-acylaminoacyl-peptide hydrolase 
APPL1 26060 adaptor protein, phosphotyrosine interaction, PH domain 
and leucine zipper containing 1 
APPL2 55198 adaptor protein, phosphotyrosine interaction, PH domain 
and leucine zipper containing 2 
AR 367 androgen receptor 
ARAF 369 v-raf murine sarcoma 3611 viral oncogene homolog 
ARHGEF15 22899 Rho guanine nucleotide exchange factor (GEF) 15 
ARL15 54622 ADP-ribosylation factor-like 15 
ARL2 402 ADP-ribosylation factor-like 2 
ARL2BP 23568 ADP-ribosylation factor-like 2 binding protein 
ARL3 403 ADP-ribosylation factor-like 3 
ARL4D 379 ADP-ribosylation factor-like 4D 
ARMC7 79637 armadillo repeat containing 7 
ARR3 407 arrestin 3, retinal (X-arrestin) 
ASB13 79754 ankyrin repeat and SOCS box-containing 13 
ATG12 9140 ATG12 autophagy related 12 homolog (S. cerevisiae) 
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ATG4B 23192 ATG4 autophagy related 4 homolog B (S. cerevisiae) 
ATN1 1822 atrophin 1 
ATP6V1G1 9550 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 
AXIN1 8312 axin 1 
BAD 572 BCL2-associated agonist of cell death 
BAIAP2 10458 BAI1-associated protein 2 
BAK1 578 BCL2-antagonist/killer 1 
BAX 581 BCL2-associated X protein 
BBC3 27113 BCL2 binding component 3 
BCL2 596 B-cell CLL/lymphoma 2 
BCL2L1 598 BCL2-like 1 
BCL2L11 10018 BCL2-like 11 (apoptosis facilitator) 
BCL2L2 599 BCL2-like 2 
BECN1 8678 beclin 1, autophagy related 
BIK 638 BCL2-interacting killer (apoptosis-inducing) 
BIRC7 79444 baculoviral IAP repeat-containing 7 
BRAP 8315 BRCA1 associated protein 
BRCA1 672 breast cancer 1, early onset 
BSG 682 basigin (Ok blood group) 
BTRC 8945 beta-transducin repeat containing 
C1orf35 79169 chromosome 1 open reading frame 35 
C2orf44 80304 chromosome 2 open reading frame 44 
CA12 771 carbonic anhydrase XII 
CAB39 51719 calcium binding protein 39 
CABIN1 23523 calcineurin binding protein 1 
CALCOCO2 10241 calcium binding and coiled-coil domain 2 
CASP7 840 caspase 7, apoptosis-related cysteine peptidase 
CBL 867 Cas-Br-M (murine) ecotropic retroviral transforming 
sequence 
CCDC106 29903 coiled-coil domain containing 106 
CCDC33 80125 coiled-coil domain containing 33 
CCDC85B 11007 coiled-coil domain containing 85B 
CCND1 595 cyclin D1 
CCNT1 904 cyclin T1 
CCNT2 905 cyclin T2 
CD81 975 CD81 molecule 
CDC42 998 cell division cycle 42 (GTP binding protein, 25kDa) 
CDC42EP2 10435 CDC42 effector protein (Rho GTPase binding) 2 
CDK2 1017 cyclin-dependent kinase 2 
CDK9 1025 cyclin-dependent kinase 9 
CELSR1 9620 cadherin, EGF LAG seven-pass G-type receptor 1 
(flamingo homolog, Drosophila) 
CEP63 80254 centrosomal protein 63kDa 
CEP76 79959 centrosomal protein 76kDa 
CETN3 1070 centrin, EF-hand protein, 3 
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CHMP4A 29082 chromatin modifying protein 4A 
CHP 11261 calcium binding protein P22 
CLTC 1213 clathrin, heavy chain (Hc) 
CNNM3 26505 cyclin M3 
COBRA1 25920 cofactor of BRCA1 
COIL 8161 coilin 
COL3A1 1281 collagen, type III, alpha 1 
COPS4 51138 COP9 constitutive photomorphogenic homolog subunit 4 
(Arabidopsis) 
COPS6 10980 COP9 constitutive photomorphogenic homolog subunit 6 
(Arabidopsis) 
CPSF6 11052 cleavage and polyadenylation specific factor 6, 68kDa 
DAG1 1605 dystroglycan 1 (dystrophin-associated glycoprotein 1) 
DAXX 1616 death-domain associated protein 
DCP1A 55802 DCP1 decapping enzyme homolog A (S. cerevisiae) 
DHX58 79132 DEXH (Asp-Glu-X-His) box polypeptide 58 
DIABLO 56616 diablo homolog (Drosophila) 
DNALI1 7802 dynein, axonemal, light intermediate chain 1 
DNM1 1759 dynamin 1 
DRG2 1819 developmentally regulated GTP binding protein 2 
DTX2 113878 deltex homolog 2 (Drosophila) 
DUSP12 11266 dual specificity phosphatase 12 
E2F2 1870 E2F transcription factor 2 
EDC3 80153 enhancer of mRNA decapping 3 homolog (S. cerevisiae) 
EEF1A1 1915 eukaryotic translation elongation factor 1 alpha 1 
EIF2B1 1967 eukaryotic translation initiation factor 2B, subunit 1 alpha, 
26kDa 
EIF4EBP3 8637 Eukaryotic Translation Initiation Factor 4E Binding Protein 
3 
ERBB3 2065 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian) 
FAM134A 79137 family with sequence similarity 134, member A 
FAM46C 54855 family with sequence similarity 46, member C 
FAM82A2 55177 family with sequence similarity 82, member A2 
FAM86C 55199 family with sequence similarity 86, member C 
FAU 2197 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) 
ubiquitously expressed 
FBXO34 55030 F-box protein 34 
FBXW2 26190 F-box and WD repeat domain containing 2 
FKBP6 8468 FK506 binding protein 6, 36kDa 
FOS 2353 FBJ murine osteosarcoma viral oncogene homolog 
GABARAPL
2 
11345 GABA(A) receptor-associated protein-like 2 
GADD45GIP
1 
90480 growth arrest and DNA-damage-inducible, gamma 
interacting protein 1 
GAPDH 2597 glyceraldehyde-3-phosphate dehydrogenase 
GEMIN7 79760 gem (nuclear organelle) associated protein 7 
GLRX3 10539 glutaredoxin 3 
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GLUL 2752 glutamate-ammonia ligase 
GNB2 2783 guanine nucleotide binding protein (G protein), beta 
polypeptide 2 
GOLSYN 55638 GOLSYN A Protein 
GRK6 2870 G protein-coupled receptor kinase 6 
GSK3B 2932 glycogen synthase kinase 3 beta 
HBXIP 10542 hepatitis B virus x interacting protein 
HDAC3 8841 histone deacetylase 3 
HEXIM1 10614 hexamethylene bis-acetamide inducible 1 
HIF1AN 55662 hypoxia inducible factor 1, alpha subunit inhibitor 
HIP1 3092 huntingtin interacting protein 1 
HMOX2 3163 heme oxygenase (decycling) 2 
HNRNPM 4670 heterogeneous nuclear ribonucleoprotein M 
HSD17B14 51171 hydroxysteroid (17-beta) dehydrogenase 14 
HSP90AB1 3326 heat shock protein 90kDa alpha (cytosolic), class B 
member 1 
HSPB1 3315 heat shock 27kDa protein 1 
HSPBP1 23640 HSPA (heat shock 70kDa) binding protein, cytoplasmic 
cochaperone 1 
HTRA2 27429 HtrA serine peptidase 2 
HUWE1 10075 HECT, UBA and WWE domain containing 1 
IGF1R 3480 insulin-like growth factor 1 receptor 
IGF2R 3482 insulin-like growth factor 2 receptor 
IK 3550 IK cytokine, down-regulator of HLA II 
IKBKAP 8518 inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase complex-associated protein 
IKBKE 9641 inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase epsilon 
INO80B 83444 INO80 complex subunit B 
INVS 27130 inversin 
IQGAP1 8826 IQ motif containing GTPase activating protein 1 
IRS1 3667 insulin receptor substrate 1 
ISYNA1 51477 inositol-3-phosphate synthase 1 
ITGB3BP 23421 integrin beta 3 binding protein (beta3-endonexin) 
KIAA0174 9798 KIAA0174 
KIAA1279 26128 KIAA1279 
KIDINS220 57498 kinase D-interacting substrate, 220kDa 
KIF15 56992 kinesin family member 15 
KIF22 3835 kinesin family member 22 
KLC1 3831 kinesin light chain 1 
KLC2 64837 kinesin light chain 2 
KLHL12 59349 kelch-like 12 (Drosophila) 
KLHL2 11275 kelch-like 2, Mayven (Drosophila) 
LAMC1 3915 laminin, gamma 1 (formerly LAMB2) 
LIG4 3981 ligase IV, DNA, ATP-dependent 
LIMK1 3984 LIM domain kinase 1 
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LRPAP1 4043 low density lipoprotein receptor-related protein associated 
protein 1 
LRPPRC 10128 leucine-rich PPR-motif containing 
Magmas 51025 mitochondria associated protein involved in granulocyte 
macrophage colony stimulating factor signal transduction 
MAP2K2 5605 mitogen-activated protein kinase kinase 2 
MAP3K1 4214 mitogen-activated protein kinase kinase kinase 1 
MAPK8 5599 mitogen-activated protein kinase 8 
MAPKSP1 8649 MAPK scaffold protein 1 
MAPT 4137 microtubule-associated protein tau 
MBIP 51562 MAP3K12 binding inhibitory protein 1 
MCL1 4170 myeloid cell leukemia sequence 1 (BCL2-related) 
MDM2 4193 Mdm2 p53 binding protein homolog (mouse) 
MDM4 4194 Mdm4 p53 binding protein homolog (mouse) 
MEA1 4201 male-enhanced antigen 1 
MED22 6837 mediator complex subunit 22 
MED27 9442 mediator complex subunit 27 
MED28 80306 mediator complex subunit 28 
MED31 51003 mediator complex subunit 31 
MOAP1 64112 modulator of apoptosis 1 
MOBKL3 25843 MOB1, Mps One Binder kinase activator-like 3 (yeast) 
MORF4L1 10933 mortality factor 4 like 1 
MRE11A 4361 MRE11 meiotic recombination 11 homolog A (S. 
cerevisiae) 
MRFAP1L1 114932 Morf4 family associated protein 1-like 1 
MRPL44 65080 mitochondrial ribosomal protein L44 
MSN 4478 moesin 
MUC1 4582 mucin 1, cell surface associated 
MYCBP 26292 c-myc binding protein 
MYL6 4637 myosin, light chain 6, alkali, smooth muscle and non-
muscle 
NBN 4683 nibrin 
NCOA1 8648 nuclear receptor coactivator 1 
NCOA2 10499 nuclear receptor coactivator 2 
NCOA4 8031 nuclear receptor coactivator 4 
NCOR1 9611 nuclear receptor corepressor 1 
NDC80 10403 NDC80 homolog, kinetochore complex component (S. 
cerevisiae) 
NDEL1 81565 nudE nuclear distribution gene E homolog (A. nidulans)-
like 1 
NDUFB8 4714 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 
19kDa 
NDUFV2 4729 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 
NEDD4 4734 neural precursor cell expressed, developmentally down-
regulated 4 
NFKBIA 4792 nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha 
NHEJ1 79840 nonhomologous end-joining factor 1 
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NME3 4832 non-metastatic cells 3, protein expressed in 
NOC4L 79050 nucleolar complex associated 4 homolog (S. cerevisiae) 
NPDC1 56654 neural proliferation, differentiation and control, 1 
NUDT18 79873 nudix (nucleoside diphosphate linked moiety X)-type motif 
18 
NUDT21 11051 nudix (nucleoside diphosphate linked moiety X)-type motif 
21 
NUP54 53371 nucleoporin 54kDa 
OGFOD2 79676 2-oxoglutarate and iron-dependent oxygenase domain 
containing 2 
ORC2L 4999 origin recognition complex, subunit 2 
ORC4L 5000 origin recognition complex, subunit 4 
ORC5L 5001 origin recognition complex, subunit 5 
P2RY1 5028 purinergic receptor P2Y, G-protein coupled, 1 
PAFAH1B2 5049 platelet-activating factor acetylhydrolase 1b, catalytic 
subunit 2 (30kDa) 
PAK2 5062 p21 protein (Cdc42/Rac)-activated kinase 2 
PARP1 142 poly (ADP-ribose) polymerase 1 
PCBD1 5092 pterin-4 alpha-carbinolamine dehydratase/dimerization 
cofactor of hepatocyte nuclear factor 1 alpha 
PDE6D 5147 phosphodiesterase 6D, cGMP-specific, rod, delta 
PDLIM7 9260 PDZ and LIM domain 7 (enigma) 
PEX11B 8799 peroxisomal biogenesis factor 11 beta 
PEX12 5193 peroxisomal biogenesis factor 12 
PEX19 5824 peroxisomal biogenesis factor 19 
PEX5 5830 peroxisomal biogenesis factor 5 
PHF10 55274 PHD finger protein 10 
PIH1D1 55011 PIH1 domain containing 1 
PIK3R1 5295 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
PIK3R4 30849 phosphoinositide-3-kinase, regulatory subunit 4 
PJA2 9867 praja ring finger 2 
PLA2G15 23659 phospholipase A2, group XV 
PLEKHF2 79666 pleckstrin homology domain containing, family F (with 
FYVE domain) member 2 
PLXNB1 5364 plexin B1 
POLI 11201 polymerase (DNA directed) iota 
POU2F1 5451 POU class 2 homeobox 1 
PPP2CA 5515 protein phosphatase 2, catalytic subunit, alpha isozyme 
PPP2R1A 5518 protein phosphatase 2, regulatory subunit A, alpha 
PPP2R1B 5519 protein phosphatase 2, regulatory subunit A, beta 
PQBP1 10084 polyglutamine binding protein 1 
PRKAR1A 5573 protein kinase, cAMP-dependent, regulatory, type I, alpha 
(tissue specific extinguisher 1) 
PRKRA 8575 protein kinase, interferon-inducible double stranded RNA 
dependent activator 
PRPF4 9128 PRP4 pre-mRNA processing factor 4 homolog (yeast) 
PRR13 54458 proline rich 13 
PSAP 5660 prosaposin 
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PTBP2 58155 polypyrimidine tract binding protein 2 
PTPRK 5796 protein tyrosine phosphatase, receptor type, K 
PXMP3 5828 Peroxisomal Membrane Protein 3 (35kD, Zellweger 
Syndrome) 
PXN 5829 paxillin 
PYCARD 29108 PYD and CARD domain containing 
QARS 5859 glutaminyl-tRNA synthetase 
RAB11A 8766 RAB11A, member RAS oncogene family 
RAB11FIP2 22841 RAB11 family interacting protein 2 (class I) 
RAB17 64284 RAB17, member RAS oncogene family 
RAB2A 5862 RAB2A, member RAS oncogene family 
RAB3IL1 5866 RAB3A interacting protein (rabin3)-like 1 
RABGGTB 5876 Rab geranylgeranyltransferase, beta subunit 
RAD50 10111 RAD50 homolog (S. cerevisiae) 
RAD51 5888 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 
RALGPS2 55103 Ral GEF with PH domain and SH3 binding motif 2 
RANBP2 5903 RAN binding protein 2 
RANGAP1 5905 Ran GTPase activating protein 1 
RARA 5914 retinoic acid receptor, alpha 
RASSF1 11186 Ras association (RalGDS/AF-6) domain family member 1 
RBM4B 83759 RNA binding motif protein 4B 
RBPMS 11030 RNA binding protein with multiple splicing 
RCBTB2 1102 regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 2 
RDBP 7936 RD RNA binding protein 
RGS1 5996 regulator of G-protein signaling 1 
RNASE6 6039 ribonuclease, RNase A family, k6 
RND1 27289 Rho family GTPase 1 
RNF14 9604 ring finger protein 14 
ROBLD3 28956 roadblock domain containing 3 
ROGDI 79641 rogdi homolog (Drosophila) 
RPL11 6135 ribosomal protein L11 
RPS6KC1 26750 ribosomal protein S6 kinase, 52kDa, polypeptide 1 
RWDD2B 10069 RWD domain containing 2B 
RXRA 6256 retinoid X receptor, alpha 
S100A10 6281 S100 calcium binding protein A10 
SAFB 6294 scaffold attachment factor B 
SCAND1 51282 SCAN domain containing 1 
SELENBP1 8991 selenium binding protein 1 
SERPINA5 5104 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 5 
SETDB1 9869 SET domain, bifurcated 1 
SFRS1 6426 serine/arginine-rich splicing factor 1 
SIRT6 51548 sirtuin 6 
SLC9A3R1 9368 solute carrier family 9 (sodium/hydrogen exchanger), 
member 3 regulator 1 
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SMAD5 4090 SMAD family member 5 
SMARCD1 6602 SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, member 1 
SMC3 9126 structural maintenance of chromosomes 3 
SMN1 6606 survival of motor neuron 1, telomeric  
SNRPB 6628 small nuclear ribonucleoprotein polypeptides B and B1 
SOS2 6655 son of sevenless homolog 2 (Drosophila) 
SP1 6667 Sp1 transcription factor 
SP110 3431 SP110 nuclear body protein 
SPARC 6678 secreted protein, acidic, cysteine-rich (osteonectin) 
SRRM2 23524 serine/arginine repetitive matrix 2 
STAG2 10735 stromal antigen 2 
STK11 6794 serine/threonine kinase 11 
STK19 8859 serine/threonine kinase 19 
STMN4 81551 stathmin-like 4 
SYT17 51760 synaptotagmin XVII 
TAC3 6866 tachykinin 3 
TADA3L 10474 transcriptional adaptor 3 
TAF1 6872 TAF1 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 250kDa 
TAF1A 9015 TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, A, 48kDa 
TBC1D17 79735 TBC1 domain family, member 17 
TCEB1 6921 transcription elongation factor B (SIII), polypeptide 1 
(15kDa, elongin C) 
TCEB2 6923 transcription elongation factor B (SIII), polypeptide 2 
(18kDa, elongin B) 
TERF1 7013 telomeric repeat binding factor (NIMA-interacting) 1 
TFG 10342 TRK-fused gene 
TGFB1I1 7041 transforming growth factor beta 1 induced transcript 1 
TGIF1 7050 TGFB-induced factor homeobox 1 
THAP1 55145 THAP domain containing, apoptosis associated protein 1 
TIMM44 10469 translocase of inner mitochondrial membrane 44 homolog 
(yeast) 
TINF2 26277 TERF1 (TRF1)-interacting nuclear factor 2 
TOE1 114034 target of EGR1, member 1 (nuclear) 
TOLLIP 54472 toll interacting protein 
TRIM23 373 tripartite motif-containing 23 
TSC1 7248 tuberous sclerosis 1 
TSC22D1 8848 TSC22 domain family, member 1 
U2AF2 11338 U2 small nuclear RNA auxiliary factor 2 
UBA5 79876 ubiquitin-like modifier activating enzyme 5 
UBE2B 7320 ubiquitin-conjugating enzyme E2B (RAD6 homolog) 
ULK2 9706 unc-51-like kinase 2 (C. elegans) 
UNC119 9094 unc-119 homolog (C. elegans) 
VAMP4 8674 vesicle-associated membrane protein 4 
VAV3 10451 vav 3 guanine nucleotide exchange factor 
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VDR 7421 vitamin D (1,25- dihydroxyvitamin D3) receptor 
WASL 8976 Wiskott-Aldrich syndrome-like 
WDYHV1 55093 WDYHV motif containing 1 
WWP1 11059 WW domain containing E3 ubiquitin protein ligase 1 
XIAP 331 X-linked inhibitor of apoptosis 
XPA 7507 xeroderma pigmentosum, complementation group A 
XRCC4 7518 X-ray repair complementing defective repair in Chinese 
hamster cells 4 
YY1 7528 YY1 transcription factor 
ZCCHC10 54819 zinc finger, CCHC domain containing 10 
ZEB2 9839 zinc finger E-box binding homeobox 2 
ZFP36L1 677 zinc finger protein 36, C3H type-like 1 
ZFPL1 7542 zinc finger protein-like 1 
ZFYVE9 9372 zinc finger, FYVE domain containing 9 
ZMYND10 51364 zinc finger, MYND-type containing 10 
ZNF263 10127 zinc finger protein 263 
ZNF408 79797 zinc finger protein 408 
ZNF580 51157 zinc finger protein 580 
ZNF764 92595 zinc finger protein 764 
ER- gene signature 
ACTN4 81 actinin, alpha 4 
ALDH2 217 aldehyde dehydrogenase 2 family (mitochondrial) 
ANXA3 306 annexin A3 
AOF2 23028 amine oxidase (flavin containing) domain 2 
APBA1 320 amyloid beta (A4) precursor protein-binding, family A, 
member 1 
APIP 51074 APAF1 interacting protein 
APP 351 amyloid beta (A4) precursor protein 
ATP5C1 509 ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
BCR 613 breakpoint cluster region 
C10orf10 11067 chromosome 10 open reading frame 10 
C10orf88 80007 chromosome 10 open reading frame 88 
CBLB 868 Cas-Br-M (murine) ecotropic retroviral transforming 
sequence b 
CBX5 23468 chromobox homolog 5 
CCND3 896 cyclin D3 
CCT5 22948 chaperonin containing TCP1, subunit 5 (epsilon) 
CD1B 910 CD1b molecule 
CDC25B 994 cell division cycle 25 homolog B (S. pombe) 
CKAP4 10970 cytoskeleton-associated protein 4 
COPB2 9276 coatomer protein complex, subunit beta 2 (beta prime) 
CSNK2A1 1457 casein kinase 2, alpha 1 polypeptide 
CSNK2A2 1459 casein kinase 2, alpha prime polypeptide 
CSNK2B 1460 casein kinase 2, beta polypeptide 
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CTSB 1508 cathepsin B 
CUTC 51076 cutC copper transporter homolog (E. coli) 
CXCL13 10563 chemokine (C-X-C motif) ligand 13 
DDX1 1653 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 
DFFA 1676 DNA fragmentation factor, 45kDa, alpha polypeptide 
DFFB 1677 DNA fragmentation factor, 40kDa, beta polypeptide 
(caspase-activated DNase) 
DIAPH1 1729 diaphanous homolog 1 (Drosophila) 
DKC1 1736 dyskeratosis congenita 1, dyskerin 
DOCK2 1794 dedicator of cytokinesis 2 
DVL2 1856 dishevelled, dsh homolog 2 (Drosophila) 
EEF1B2 1933 eukaryotic translation elongation factor 1 beta 2 
EGLN1 54583 egl nine homolog 1 (C. elegans) 
EIF2AK2 5610 eukaryotic translation initiation factor 2-alpha kinase 2 
EIF2S1 1965 eukaryotic translation initiation factor 2, subunit 1 alpha, 
35kDa 
EIF3A 8661 eukaryotic translation initiation factor 3, subunit A 
EIF3B 8662 eukaryotic translation initiation factor 3, subunit B 
EIF4A1 1973 eukaryotic translation initiation factor 4A1 
EIF4A2 1974 eukaryotic translation initiation factor 4A2 
EIF4G2 1982 eukaryotic translation initiation factor 4 gamma, 2 
FAS 355 Fas (TNF receptor superfamily, member 6) 
FHL2 2274 four and a half LIM domains 2 
FXR1 8087 fragile X mental retardation, autosomal homolog 1 
FYB 2533 FYN binding protein 
GADD45A 1647 growth arrest and DNA-damage-inducible, alpha 
GCC1 79571 GRIP and coiled-coil domain containing 1 
GOT2 2806 glutamic-oxaloacetic transaminase 2, mitochondrial 
(aspartate aminotransferase 2) 
GPNMB 10457 glycoprotein (transmembrane) nmb 
GRAP2 9402 GRB2-related adaptor protein 2 
GREM1 26585 gremlin 1 
GTF2H1 2965 general transcription factor IIH, polypeptide 1, 62kDa 
HLA-A 3105 major histocompatibility complex, class I, A 
HMG20A 10363 high-mobility group 20A 
HNRNPUL1 11100 heterogeneous nuclear ribonucleoprotein U-like 1 
HPCAL1 3241 hippocalcin-like 1 
KARS 3735 lysyl-tRNA synthetase 
KIAA0408 9729 KIAA0408 
KIAA1128 54462 coiled-coil serine-rich protein 2 
KIT 3815 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
KPNA3 3839 karyopherin alpha 3 (importin alpha 4) 
LAPTM5 7805 lysosomal protein transmembrane 5 
LCK 3932 lymphocyte-specific protein tyrosine kinase 
LCP2 3937 lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 
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LMNA 4000 lamin A/C 
LMNB1 4001 lamin B1 
LSM6 11157 LSM6 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
LSM7 51690 LSM7 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
LTBP3 4054 latent transforming growth factor beta binding protein 3 
LUM 4060 lumican 
MAD1L1 8379 MAD1 mitotic arrest deficient-like 1 (yeast) 
MAGOH 4116 mago-nashi homolog, proliferation-associated (Drosophila) 
MAP3K5 4217 mitogen-activated protein kinase kinase kinase 5 
MARK2 2011 MAP/microtubule affinity-regulating kinase 2 
MBD1 4152 methyl-CpG binding domain protein 1 
MBD4 8930 methyl-CpG binding domain protein 4 
MCM7 4176 minichromosome maintenance complex component 7 
MCOLN1 57192 mucolipin 1 
MPZL1 9019 myelin protein zero-like 1 
MVD 4597 mevalonate (diphospho) decarboxylase 
NAE1 8883 NEDD8 activating enzyme E1 subunit 1 
NCF2 4688 neutrophil cytosolic factor 2 
NCK2 8440 NCK adaptor protein 2 
NFYB 4801 nuclear transcription factor Y, beta 
NFYC 4802 nuclear transcription factor Y, gamma 
PABPC1 26986 poly(A) binding protein, cytoplasmic 1 
PAFAH1B1 5048 platelet-activating factor acetylhydrolase 1b, regulatory 
subunit 1 (45kDa) 
PAIP1 10605 poly(A) binding protein interacting protein 1 
PJA1 64219 praja ring finger 1 
PLS3 5358 plastin 3 
PLSCR3 57048 phospholipid scramblase 3 
PRNP 5621 prion protein 
PRPF40A 55660 PRP40 pre-mRNA processing factor 40 homolog A (S. 
cerevisiae) 
PSMD11 5717 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 11 
PTCD3 55037 Pentatricopeptide repeat domain 3 
RBM7 10179 RNA binding motif protein 7 
RBM8A 9939 RNA binding motif protein 8A 
RCN2 5955 reticulocalbin 2, EF-hand calcium binding domain 
RCOR1 23186 REST corepressor 1 
RELB 5971 v-rel reticuloendotheliosis viral oncogene homolog B 
RGS2 5997 regulator of G-protein signaling 2, 24kDa 
RNF111 54778 ring finger protein 111 
RNF13 11342 ring finger protein 13 
RNF146 81847 ring finger protein 146 
RPA3 6119 replication protein A3, 14kDa 
RPL5 6125 ribosomal protein L5 
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RPS15 6209 ribosomal protein S15 
RUNX3 864 runt-related transcription factor 3 
S100A4 6275 S100 calcium binding protein A4 
SAE1 10055 SUMO1 activating enzyme subunit 1 
SERPINB9 5272 serpin peptidase inhibitor, clade B (ovalbumin), member 9 
SMAD1 4086 SMAD family member 1 
SMURF1 57154 SMAD specific E3 ubiquitin protein ligase 1 
SMURF2 64750 SMAD specific E3 ubiquitin protein ligase 2 
SNIP1 79753 Smad nuclear interacting protein 1 
SNRPE 6635 small nuclear ribonucleoprotein polypeptide E 
SORBS2 8470 sorbin and SH3 domain containing 2 
SOS1 6654 son of sevenless homolog 1 (Drosophila) 
SRGN 5552 serglycin 
SSR1 6745 signal sequence receptor, alpha 
SUMO2 6613 SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae) 
SVIL 6840 supervillin 
TBK1 29110 TANK-binding kinase 1 
TNFAIP3 7128 tumor necrosis factor, alpha-induced protein 3 
TNFAIP8 25816 tumor necrosis factor, alpha-induced protein 8 
TNFRSF1B 7133 tumor necrosis factor receptor superfamily, member 1B 
TNIP1 10318 TNFAIP3 interacting protein 1 
TRAF3 7187 TNF receptor-associated factor 3 
TRIM27 5987 tripartite motif-containing 27 
TRIM29 23650 tripartite motif-containing 29 
TSPAN6 7105 tetraspanin 6 
TTC19 54902 tetratricopeptide repeat domain 19 
TXN 7295 thioredoxin 
TYK2 7297 tyrosine kinase 2 
UBA2 10054 ubiquitin-like modifier activating enzyme 2 
UBE2J1 51465 ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, 
yeast) 
UBQLN2 29978 ubiquilin 2 
UPF1 5976 UPF1 regulator of nonsense transcripts homolog (yeast) 
UPF2 26019 UPF2 regulator of nonsense transcripts homolog (yeast) 
UPF3B 65109 UPF3 regulator of nonsense transcripts homolog B (yeast) 
WAS 7454 Wiskott-Aldrich syndrome (eczema-thrombocytopenia) 
WIPF1 7456 WAS/WASL interacting protein family, member 1 
XPO1 7514 exportin 1 (CRM1 homolog, yeast) 
YAP1 10413 Yes-associated protein 1 
YIPF3 25844 Yip1 domain family, member 3 
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Appendix C 
 
IPRE Gene Signature 
 
Table C.1: IPRE gene signature consists of 79 genes. 
Gene 
Signature 
Probe Name Entrez 
Gene ID 
Cytoband Description Correlation-
factor (α) 
Penalized-
factor (β) 
KCTD12 212188_at 115207 13q22.3 potassium channel tetramerisation 
domain containing 12 
0.4002 0.7911 
LOC93349 214791_at 93349 2q37.1 hypothetical protein BC004921 0.3880 0.7812 
C1S 208747_s_at 716 12p13 complement component 1, s 
subcomponent 
0.3846 0.7481 
SERPING1 200986_at 710 11q12-
q13.1 
serpin peptidase inhibitor, clade G 
(C1 inhibitor), member 1, 
(angioedema, hereditary) 
0.3824 0.7846 
BST2 201641_at 684 19p13.2 bone marrow stromal cell antigen 2 0.3824 0.7726 
TNFSF10 202687_s_at 8743 3q26 tumor necrosis factor (ligand) 
superfamily, member 10 
0.3824 0.7898 
HLA-DPA1 211990_at 3113 6p21.3 major histocompatibility complex, 
class II, DP alpha 1 
0.3813 0.7989 
CXCL12 203666_at 6387 10q11.1 chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1) 
0.3813 0.7707 
C3 217767_at 718 19p13.3-
p13.2 
complement component 3 0.3757 0.7561 
RNF144 204040_at 9781 2p25.2-
p25.1 
ring finger protein 144 0.3757 0.7833 
PTER 218967_s_at 9317 10p12 phosphotriesterase related 0.3757 0.7891 
MPI 202472_at 4351 15q22-
qter 
mannose phosphate isomerase 0.3746 0.7815 
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DCN 201893_x_at 1634 12q21.33 decorin 0.3724 0.7942 
ITGBL1 205422_s_at 9358 13q33 integrin, beta-like 1 (with EGF-like 
repeat domains) 
0.3712 0.7681 
SERPINF1 202283_at 5176 17p13.1 serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
0.3712 0.7836 
SH2D3A 219513_s_at 10045 19p13.3 SH2 domain containing 3A 0.3679 0.8039 
VASH1 203940_s_at 22846 14q24.3 vasohibin 1 0.3668 0.7925 
HLA-DPB1 201137_s_at 3115 6p21.3 major histocompatibility complex, 
class II, DP beta 1 
0.3645 0.8003 
ACADM 202502_at 34 1p31 acyl-Coenzyme A dehydrogenase, C-
4 to C-12 straight chain 
0.3634 0.8029 
IGFBP4 201508_at 3487 17q12-
q21.1 
insulin-like growth factor binding 
protein 4 
0.3623 0.7776 
TNS3 217853_at 64759 7p12.3 tensin 3 0.3623 0.7989 
RAI2 219440_at 10742 Xp22 retinoic acid induced 2 0.3601 0.7602 
TRIM22 213293_s_at 10346 11p15 tripartite motif-containing 22 0.3590 0.8100 
MGST2 204168_at 4258 4q28.3 microsomal glutathione S-transferase 
2 
0.3579 0.8151 
AZGP1 209309_at 563 7q22.1 alpha-2-glycoprotein 1, zinc-binding 0.3567 0.7795 
SCP2 201339_s_at 6342 1p32 sterol carrier protein 2 0.3567 0.8178 
PLCD1 205125_at 5333 3p22-
p21.3 
phospholipase C, delta 1 0.3567 0.8058 
DNAJC15 218435_at 29103 13q14.1 DnaJ (Hsp40) homolog, subfamily C, 
member 15 
0.3556 0.7838 
CFB 202357_s_at 629 6p21.3 complement factor B 0.3556 0.7754 
FN1 210495_x_at 2335 2q34 fibronectin 1 0.3545 0.8306 
ZNF33B 215022_x_at 7582 10q11.2 zinc finger protein 33B 0.3534 0.8105 
RABGAP1L 213982_s_at 9910 1q24 RAB GTPase activating protein 1-like 0.3534 0.7836 
HLA-DRA 208894_at 3122 6p21.3 major histocompatibility complex, 
class II, DR alpha 
0.3523 0.8058 
C1R 212067_s_at 715 12p13 complement component 1, r 
subcomponent 
0.3512 0.8093 
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GNG12 212294_at 55970 1p31.3 guanine nucleotide binding protein (G 
protein), gamma 12 
0.3501 0.8122 
C1orf123 203197_s_at 54987 1p32.3 chromosome 1 open reading frame 
123 
0.3501 0.8422 
SEPP1 201427_s_at 6414 5q31 selenoprotein P, plasma, 1 0.3501 0.8133 
PARP3 209940_at 10039 3p21.31-
p21.1 
poly (ADP-ribose) polymerase 
family, member 3 
0.3501 0.8094 
SELENBP1 214433_s_at 8991 1q21-q22 selenium binding protein 1 0.3489 0.8036 
PIGN 219048_at 23556 18q21.33 phosphatidylinositol glycan anchor 
biosynthesis, class N 
0.3445 0.7901 
NME5 206197_at 8382 5q31 non-metastatic cells 5, protein 
expressed in (nucleoside-diphosphate 
kinase) 
0.3445 0.7805 
COL1A2 202403_s_at 1278 7q22.1 collagen, type I, alpha 2 0.3423 0.8226 
PPAP2C 209529_at 8612 19p13 phosphatidic acid phosphatase type 
2C 
0.3423 0.8188 
PMP22 210139_s_at 5376 17p12-
p11.2 
peripheral myelin protein 22 0.3423 0.8282 
MGP 202291_s_at 4256 12p13.1-
p12.3 
matrix Gla protein 0.3400 0.8023 
COL3A1 201852_x_at 1281 2q31 collagen, type III, alpha 1 (Ehlers-
Danlos syndrome type IV, autosomal 
dominant) 
0.3378 0.8234 
MICALL2 219332_at 79778 7p22.3 MICAL-like 2 0.3378 0.8158 
APPL 218158_s_at 26060 3p21.1-
p14.3 
adaptor protein containing pH 
domain, PTB domain and leucine 
zipper motif 1 
0.3378 0.8363 
GATA3 209602_s_at 2625 10p15 GATA binding protein 3 0.3367 0.7803 
COL10A1 205941_s_at 1300 6q21-q22 collagen, type X, alpha 1(Schmid 
meta chondrodysplasia) 
0.3367 0.7900 
LUM 201744_s_at 4060 12q21.3-
q22 
lumican 0.3344 0.8116 
AGR2 209173_at 10551 7p21.3 anterior gradient 2 homolog (Xenopus 
laevis) 
0.3333 0.7684 
CDKN1B 209112_at 1027 12p13.1-
p12 
cyclin-dependent kinase inhibitor 1B 
(p27, Kip1) 
0.3333 0.8310 
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CRIP1 205081_at 1396 14q32.33 cysteine-rich protein 1 (intestinal) 0.3333 0.8013 
CTA-
246H3.1 
209138_x_at 91353 22q11.23 similar to omega protein 0.3322 0.7845 
SOX9 202935_s_at 6662 17q24.3-
q25.1 
SRY (sex determining region Y)-box 
9 (campomelic dysplasia, autosomal 
sex-reversal) 
0.3311 0.8100 
IL4R 203233_at 3566 16p11.2-
12.1 
interleukin 4 receptor 0.3311 0.8272 
KRT19 201650_at 3880 17q21.2 keratin 19 0.3300 0.8258 
CD74 209619_at 972 5q32 CD74 molecule, major 
histocompatibility complex, class II 
invariant chain 
0.3289 0.8277 
EFHD1 209343_at 80303 2q37.1 EF-hand domain family, member D1 0.3255 0.8156 
RIN2 209684_at 54453 20p11.22 Ras and Rab interactor 2 0.3255 0.8429 
CTDSP1 217844_at 58190 2q35 CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase 1 
0.3244 0.8356 
IGFBP7 201162_at 3490 4q12 insulin-like growth factor binding 
protein 7 
0.3233 0.8135 
ATP1B1 201242_s_at 481 1q24 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
0.3233 0.8208 
PSMB8 209040_s_at 5696 6p21.3 proteasome (prosome, macropain) 
subunit, beta type, 8 (large 
multifunctional peptidase 7) 
0.3233 0.8152 
ARHGDIB 201288_at 397 12p12.3 Rho GDP dissociation inhibitor (GDI) 
beta 
0.3222 0.8319 
CD24 208650_s_at 934 6q21 CD24 molecule 0.3211 0.8320 
MMP2 201069_at 4313 16q13-
q21 
matrix metallopeptidase 2 (gelatinase 
A, 72kDa gelatinase, 72kDa type IV 
collagenase) 
0.3188 0.8152 
KRT18 201596_x_at 3875 12q13 keratin 18 0.3188 0.8464 
KIAA0409 203171_s_at 23378 11p15.4 KIAA0409 0.3166 0.8541 
POSTN 210809_s_at 10631 13q13.3 periostin, osteoblast specific factor 0.3133 0.8452 
DENND2D 221081_s_at 79961 1p13.3 DENN/MADD domain containing 2D 0.3133 0.8203 
ARID5B 212614_at 84159 10q21.2 AT rich interactive domain 5B 
(MRF1-like) 
0.3099 0.8451 
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COL6A3 201438_at 1293 2q37 collagen, type VI, alpha 3 0.3077 0.8301 
RIC8A 221647_s_at 60626 11p15.5 resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
0.3066 0.8450 
DSP 200606_at 1832 6p24 desmoplakin 0.3021 0.8475 
HLA-C 208812_x_at 3107 6p21.3 major histocompatibility complex, 
class I, C 
0.2988 0.8386 
STK16 209622_at 8576 2q34-q37 serine/threonine kinase 16 0.2943 0.8430 
ZNF140 204523_at 7699 12q24.32-
q24.33 
zinc finger protein 140 0.2943 0.8655 
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Appendix D 
 
PChemoTx Gene Signature 
 
Table D.1: PChemoTx gene signature. 
Gene Description Location 
ARHGAP25 Rho GTPase activating protein 25 Cytoplasm 
CSDC2 cold shock domain containing C2, RNA binding Cytoplasm 
DNAJC17 DnaJ (Hsp40) homolog, subfamily C, member 17 Other 
MTERFD1 MTERF domain containing 1 Cytoplasm 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Cytoplasm 
RFXAP regulatory factor X-associated protein Nucleus 
SDK2 sidekick cell adhesion molecule 2 Other 
SMU1 smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) Nucleus 
AGR2 anterior gradient 2  Extracellular Space 
AMD1 adenosylmethionine decarboxylase 1 Cytoplasm 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide Plasma Membrane 
CCDC170 coiled-coil domain containing 170 Extracellular Space 
C9orf116 chromosome 9 open reading frame 116 Other 
CDC20 cell division cycle 20 Nucleus 
CDH3 cadherin 3, type 1, P-cadherin (placental) Plasma Membrane 
CEP55 centrosomal protein 55kDa Cytoplasm 
CKS1B CDC28 protein kinase regulatory subunit 1B Other 
CORO1C coronin, actin binding protein, 1C Cytoplasm 
CTPS1 CTP synthase 1 Nucleus 
CXCL10 chemokine (C-X-C motif) ligand 10 Extracellular Space 
CXCL9 chemokine (C-X-C motif) ligand 9 Extracellular Space 
DNALI1 dynein, axonemal, light intermediate chain 1 Cytoplasm 
FOXA1 forkhead box A1 Nucleus 
GABRP gamma-aminobutyric acid (GABA) A receptor, pi Plasma Membrane 
GBP1 guanylate binding protein 1, interferon-inducible Cytoplasm 
GLI3 GLI family zinc finger 3 Nucleus 
GMPS guanine monphosphate synthase Nucleus 
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GPNMB glycoprotein (transmembrane) nmb Plasma Membrane 
HECA headcase homolog (Drosophila) Other 
IFI16 interferon, gamma-inducible protein 16 Nucleus 
IFI30 interferon, gamma-inducible protein 30 Cytoplasm 
IFI44L interferon-induced protein 44-like Other 
INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa Cytoplasm 
ISG20 interferon stimulated exonuclease gene 20kDa Nucleus 
ITM2C integral membrane protein 2C Cytoplasm 
KIF2C kinesin family member 2C Nucleus 
LAPTM4B lysosomal protein transmembrane 4 beta Other 
LBR lamin B receptor Nucleus 
LDHB lactate dehydrogenase B Cytoplasm 
LRBA LPS-responsive vesicle trafficking, beach and anchor 
containing 
Cytoplasm 
MCM3 minichromosome maintenance complex component 3 Nucleus 
MELK maternal embryonic leucine zipper kinase Cytoplasm 
MLPH melanophilin Cytoplasm 
MX1 myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse) 
Cytoplasm 
NFIB nuclear factor I/B Nucleus 
NFIL3 nuclear factor, interleukin 3 regulated Nucleus 
NMI N-myc (and STAT) interactor Cytoplasm 
NXN nucleoredoxin Nucleus 
PDIA6 protein disulfide isomerase family A, member 6 Cytoplasm 
PFN2 profilin 2 Other 
PNPLA4 patatin-like phospholipase domain containing 4 Cytoplasm 
PROM1 prominin 1 Plasma Membrane 
PTTG1 pituitary tumor-transforming 1 Nucleus 
RARRES1 retinoic acid receptor responder (tazarotene induced) 1 Plasma Membrane 
RBKS ribokinase Other 
RFC4 replication factor C (activator 1) 4, 37kDa Nucleus 
RTN2 reticulon 2 Cytoplasm 
SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2 
Extracellular Space 
SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) 
Extracellular Space 
SLC44A4 solute carrier family 44, member 4 Plasma Membrane 
SLC7A8 solute carrier family 7 (amino acid transporter light chain, L 
system), member 8 
Plasma Membrane 
SNRPG small nuclear ribonucleoprotein polypeptide G Nucleus 
SUMO3 small ubiquitin-like modifier 3 Nucleus 
TEX14 testis expressed 14 Plasma Membrane 
TFF3 trefoil factor 3 (intestinal) Extracellular Space 
TMC5 transmembrane channel-like 5 Other 
TMEM45A transmembrane protein 45A Plasma Membrane 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 Nucleus 
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 Plasma Membrane 
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TPX2 TPX2, microtubule-associated Nucleus 
UBE2C ubiquitin-conjugating enzyme E2C Cytoplasm 
UQCRH ubiquinol-cytochrome c reductase hinge protein Cytoplasm 
WFS1 Wolfram syndrome 1 (wolframin) Cytoplasm 
ZWINT ZW10 interacting kinetochore protein Nucleus 
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Appendix E 
 
 
Threshold based Classification Technique 
 
The gene signature scores (ܩ) generated for each samples in the testing sets 
(constructed from the 10-fold cross-validation (CV) experiments) were then used 
by the Threshold based classification technique to perform the binary prediction 
task for the ܥ݄݁݉݋ algorithm and other existing algorithms. By varying the 
different ܩ scores based threshold T value (cut-off point), the performance of an 
algorithm can be evaluated and the optimal T value can be identified.     
 Specifically, Figure E.1 shows the average sensitivity, specificity and 
accuracy of different T values from the testing sets for the ܥ݄݁݉݋ algorithm 
based gene signature, and suggests an optimal T value of 0.506, i.e., if ܩሺݏሻ ≥ 0.506, 
then sample s is predicted as pCR, otherwise it is npCR.  
 
Figure E.1: (A) The average based threshold calibration curves of the PChemoTx algorithm 
evaluated from a 10-fold cross-validation, and identified the optimal threshold T value of 
0.506 for the threshold based classification technique, and (B) the performance measures 
of the PChemoTx algorithm in the testing sets, with a selected T value of 0.506. Here, ௡ܶ 
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denotes the ݊ ୲୦ testing set, SE (denotes sensitivity), SP (denotes specificity), ACC (denotes 
accuracy), MCC (denotes Matthews correlation coefficient), and DOR (denotes diagnostic 
odds ratio) represents the performance measures in the respective testing set. Mean 
represents the average performance measures of 10 testing sets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
